

WEBVTT

NOTE duration:"01:20:20"

NOTE language:en-us

NOTE Confidence: 0.836859365789474

00:00:00.000 --> 00:00:02.790 GAIL breast cancer CME series.

NOTE Confidence: 0.836859365789474

00:00:02.790 --> 00:00:06.320 Really excited and fortunate to have

NOTE Confidence: 0.836859365789474

00:00:06.320 --> 00:00:10.220 three phenomenal speakers in our medical

NOTE Confidence: 0.836859365789474

00:00:10.220 --> 00:00:12.855 oncology colleagues in this session.

NOTE Confidence: 0.836859365789474

00:00:12.855 --> 00:00:15.525 We're going to first start off

NOTE Confidence: 0.836859365789474

00:00:15.525 --> 00:00:17.831 with Doctor Maryam Lustberg,

NOTE Confidence: 0.836859365789474

00:00:17.831 --> 00:00:22.388 who is our incoming breast program director,

NOTE Confidence: 0.836859365789474

00:00:22.390 --> 00:00:23.338 packing her bags,

NOTE Confidence: 0.836859365789474

00:00:23.338 --> 00:00:26.184 and on our way from Ohio State to Yale

NOTE Confidence: 0.836859365789474

00:00:26.184 --> 00:00:28.448 in the in the next couple of weeks,

NOTE Confidence: 0.836859365789474

00:00:28.450 --> 00:00:30.786 she's going to be talking about a really,

NOTE Confidence: 0.836859365789474

00:00:30.790 --> 00:00:32.934 really interesting area area

NOTE Confidence: 0.836859365789474

00:00:32.934 --> 00:00:35.078 just so much excitement,

NOTE Confidence: 0.836859365789474

00:00:35.080 --> 00:00:38.216 change and controversy on when do we

NOTE Confidence: 0.836859365789474
00:00:38.216 --> 00:00:41.182 deescalate and when do we escalate
NOTE Confidence: 0.836859365789474
00:00:41.182 --> 00:00:43.238 for breast oncology therapies?
NOTE Confidence: 0.836859365789474
00:00:43.240 --> 00:00:44.868 Then we'll go to.
NOTE Confidence: 0.836859365789474
00:00:44.868 --> 00:00:46.089 Doctor Michael D.
NOTE Confidence: 0.836859365789474
00:00:46.090 --> 00:00:48.280 Geovanna is going to be discussing
NOTE Confidence: 0.836859365789474
00:00:48.280 --> 00:00:49.740 recent advances in systemic
NOTE Confidence: 0.836859365789474
00:00:49.799 --> 00:00:51.327 therapy for breast cancer,
NOTE Confidence: 0.836859365789474
00:00:51.330 --> 00:00:53.688 and you know each year whether it's at ASCO,
NOTE Confidence: 0.836859365789474
00:00:53.690 --> 00:00:55.242 ESMO or San Antonio.
NOTE Confidence: 0.836859365789474
00:00:55.242 --> 00:00:57.182 There's so many really exciting
NOTE Confidence: 0.836859365789474
00:00:57.190 --> 00:00:59.625 developments in drug therapy that
NOTE Confidence: 0.836859365789474
00:00:59.625 --> 00:01:03.247 come out and it'll be great to to
NOTE Confidence: 0.836859365789474
00:01:03.247 --> 00:01:05.569 hear about those and certainly last
NOTE Confidence: 0.836859365789474
00:01:05.569 --> 00:01:08.848 but not least is Doctor Andrea Silber
NOTE Confidence: 0.836859365789474
00:01:08.848 --> 00:01:11.310 discussing really super important topic
NOTE Confidence: 0.836859365789474

00:01:11.310 --> 00:01:14.395 of breast cancer epidemiology in 2021.

NOTE Confidence: 0.836859365789474

00:01:14.395 --> 00:01:15.765 Risk factors,

NOTE Confidence: 0.836859365789474

00:01:15.765 --> 00:01:19.190 and specifically in our vulnerable

NOTE Confidence: 0.836859365789474

00:01:19.190 --> 00:01:19.875 population.

NOTE Confidence: 0.836859365789474

00:01:19.880 --> 00:01:21.924 We're going to leave some time at

NOTE Confidence: 0.836859365789474

00:01:21.924 --> 00:01:24.258 the end to answer any questions,

NOTE Confidence: 0.836859365789474

00:01:24.260 --> 00:01:26.871 but please feel free to put in

NOTE Confidence: 0.836859365789474

00:01:26.871 --> 00:01:29.076 questions either into the chat box

NOTE Confidence: 0.836859365789474

00:01:29.076 --> 00:01:31.435 or to the question and answer box.

NOTE Confidence: 0.836859365789474

00:01:31.440 --> 00:01:33.648 It will try to answer some of those

NOTE Confidence: 0.836859365789474

00:01:33.648 --> 00:01:35.810 in real time and then at the end

NOTE Confidence: 0.836859365789474

00:01:35.810 --> 00:01:38.310 leave time for some discussion

NOTE Confidence: 0.836859365789474

00:01:38.310 --> 00:01:40.810 with our three esteemed colleagues.

NOTE Confidence: 0.836859365789474

00:01:40.810 --> 00:01:41.764 And with that,

NOTE Confidence: 0.836859365789474

00:01:41.764 --> 00:01:43.672 I'd like to turn the podium

NOTE Confidence: 0.836859365789474

00:01:43.672 --> 00:01:45.720 over to Doctor Doctor, Maryam,

NOTE Confidence: 0.836859365789474
00:01:45.720 --> 00:01:46.720 Lustberg, Deescalation,
NOTE Confidence: 0.836859365789474
00:01:46.720 --> 00:01:49.720 and escalation of breast cancer therapy.
NOTE Confidence: 0.836859365789474
00:01:49.720 --> 00:01:50.472 Current status.
NOTE Confidence: 0.836859365789474
00:01:50.472 --> 00:01:51.976 Thank you doctor Lester.
NOTE Confidence: 0.848286186923077
00:01:53.020 --> 00:01:55.988 Thank you Doctor Gosain and thank you
NOTE Confidence: 0.848286186923077
00:01:55.988 --> 00:01:58.680 to the participants for joining today.
NOTE Confidence: 0.848286186923077
00:01:58.680 --> 00:02:01.302 I'll start with sharing with you
NOTE Confidence: 0.848286186923077
00:02:01.302 --> 00:02:03.727 patient perspectives on the escalation
NOTE Confidence: 0.848286186923077
00:02:03.727 --> 00:02:06.119 of medical oncology therapies.
NOTE Confidence: 0.848286186923077
00:02:06.120 --> 00:02:09.102 This was a recent publication where
NOTE Confidence: 0.848286186923077
00:02:09.102 --> 00:02:12.116 patients and advocates were engaged on
NOTE Confidence: 0.848286186923077
00:02:12.116 --> 00:02:14.954 what they thought about the escalation
NOTE Confidence: 0.848286186923077
00:02:14.954 --> 00:02:18.617 trials and what were their some of their
NOTE Confidence: 0.848286186923077
00:02:18.617 --> 00:02:21.130 perceived barriers and facilitators.
NOTE Confidence: 0.848286186923077
00:02:21.130 --> 00:02:23.890 And in these discussions,
NOTE Confidence: 0.848286186923077

00:02:23.890 --> 00:02:26.458 it's interesting that up too close
NOTE Confidence: 0.848286186923077

00:02:26.458 --> 00:02:29.050 to half of patients expressed.
NOTE Confidence: 0.848286186923077

00:02:29.050 --> 00:02:31.375 Some unwillingness to participate in
NOTE Confidence: 0.848286186923077

00:02:31.375 --> 00:02:33.700 a deescalation medical oncology trial
NOTE Confidence: 0.848286186923077

00:02:33.765 --> 00:02:36.404 and some of it was actually centered
NOTE Confidence: 0.848286186923077

00:02:36.404 --> 00:02:38.304 around terminology they actually did
NOTE Confidence: 0.848286186923077

00:02:38.304 --> 00:02:40.768 not like the term deescalation and the
NOTE Confidence: 0.848286186923077

00:02:40.768 --> 00:02:43.480 most preferred terminology was actually
NOTE Confidence: 0.848286186923077

00:02:43.480 --> 00:02:46.430 the lowest effective chemotherapy goes.
NOTE Confidence: 0.848286186923077

00:02:46.430 --> 00:02:49.566 Listed here are some of the facilitators
NOTE Confidence: 0.848286186923077

00:02:49.566 --> 00:02:51.971 that patients expressed and a lot
NOTE Confidence: 0.848286186923077

00:02:51.971 --> 00:02:53.945 of this centered around the hope
NOTE Confidence: 0.848286186923077

00:02:53.945 --> 00:02:55.868 that deescalated therapy would
NOTE Confidence: 0.848286186923077

00:02:55.868 --> 00:02:58.403 have less physical side effects,
NOTE Confidence: 0.848286186923077

00:02:58.410 --> 00:03:00.750 less impact on day-to-day life,
NOTE Confidence: 0.848286186923077

00:03:00.750 --> 00:03:03.648 and less out of pocket expenses.

NOTE Confidence: 0.848286186923077
00:03:03.650 --> 00:03:05.828 The biggest barriers were related to
NOTE Confidence: 0.848286186923077
00:03:05.828 --> 00:03:08.369 fear that the cancer would come back,
NOTE Confidence: 0.848286186923077
00:03:08.370 --> 00:03:09.666 or that they would have decision,
NOTE Confidence: 0.848286186923077
00:03:09.670 --> 00:03:11.362 regret, and so this.
NOTE Confidence: 0.848286186923077
00:03:11.362 --> 00:03:13.900 These data highlight the importance of
NOTE Confidence: 0.848286186923077
00:03:13.972 --> 00:03:16.837 good patient and provider communication.
NOTE Confidence: 0.848286186923077
00:03:16.840 --> 00:03:19.220 Other standards continue to change,
NOTE Confidence: 0.848286186923077
00:03:19.220 --> 00:03:20.717 and breast cancer,
NOTE Confidence: 0.848286186923077
00:03:20.717 --> 00:03:23.711 and as we have mounting evidence
NOTE Confidence: 0.848286186923077
00:03:23.711 --> 00:03:26.940 for better deescalated therapies.
NOTE Confidence: 0.848286186923077
00:03:26.940 --> 00:03:30.786 Thankfully, due to ongoing clinical trials,
NOTE Confidence: 0.848286186923077
00:03:30.790 --> 00:03:33.526 so I will highlight in the next few
NOTE Confidence: 0.848286186923077
00:03:33.526 --> 00:03:36.246 slides some of the the the the the
NOTE Confidence: 0.848286186923077
00:03:36.246 --> 00:03:38.197 latest advances in the escalation
NOTE Confidence: 0.848286186923077
00:03:38.197 --> 00:03:39.889 in medical oncology.
NOTE Confidence: 0.848286186923077

00:03:39.890 --> 00:03:41.810 There are so many that I won't be
NOTE Confidence: 0.848286186923077

00:03:41.810 --> 00:03:43.930 able to highlight all of them but
NOTE Confidence: 0.848286186923077

00:03:43.930 --> 00:03:46.380 to to recap our goals and medical
NOTE Confidence: 0.848286186923077

00:03:46.380 --> 00:03:48.210 oncology and the escalation.
NOTE Confidence: 0.848286186923077

00:03:48.210 --> 00:03:50.045 The calls aren't you reduced
NOTE Confidence: 0.848286186923077

00:03:50.045 --> 00:03:51.880 chemotherapy use while still having
NOTE Confidence: 0.848286186923077

00:03:51.942 --> 00:03:53.550 the most effective regiment.
NOTE Confidence: 0.848286186923077

00:03:53.550 --> 00:03:55.482 Making regiments better tolerated,
NOTE Confidence: 0.848286186923077

00:03:55.482 --> 00:03:58.380 both acute and long term stamping
NOTE Confidence: 0.848286186923077

00:03:58.456 --> 00:04:00.928 therapies that are not shown to
NOTE Confidence: 0.848286186923077

00:04:00.928 --> 00:04:03.198 be effective in reducing costs.
NOTE Confidence: 0.848286186923077

00:04:03.200 --> 00:04:05.786 So starting with your positive disease.
NOTE Confidence: 0.848286186923077

00:04:05.790 --> 00:04:08.942 Most of you are familiar with the Taylor
NOTE Confidence: 0.848286186923077

00:04:08.942 --> 00:04:12.310 R ask RX perspective study using the
NOTE Confidence: 0.848286186923077

00:04:12.310 --> 00:04:15.920 21 gene expression assay or Oncotype DX.
NOTE Confidence: 0.848286186923077

00:04:15.920 --> 00:04:19.898 Which should that?

NOTE Confidence: 0.848286186923077
00:04:19.900 --> 00:04:23.218 Most patients with low required scores.
NOTE Confidence: 0.848286186923077
00:04:23.220 --> 00:04:25.590 There really was no improvement in
NOTE Confidence: 0.848286186923077
00:04:25.590 --> 00:04:28.035 outcomes by the addition of chemotherapy
NOTE Confidence: 0.848286186923077
00:04:28.035 --> 00:04:30.800 to standard of care and open therapy,
NOTE Confidence: 0.848286186923077
00:04:30.800 --> 00:04:33.758 and this has of course changed
NOTE Confidence: 0.848286186923077
00:04:33.758 --> 00:04:37.746 our standard of care care and has
NOTE Confidence: 0.848286186923077
00:04:37.746 --> 00:04:39.660 significantly reduced chemotherapy
NOTE Confidence: 0.848286186923077
00:04:39.660 --> 00:04:43.669 use in ER positive breast cancer.
NOTE Confidence: 0.848286186923077
00:04:43.670 --> 00:04:46.001 Going on to just kind of delving
NOTE Confidence: 0.848286186923077
00:04:46.001 --> 00:04:48.380 into the data a little bit more,
NOTE Confidence: 0.848286186923077
00:04:48.380 --> 00:04:52.055 the benefits of D escalation in the
NOTE Confidence: 0.848286186923077
00:04:52.055 --> 00:04:55.572 younger cohort where a little less clear
NOTE Confidence: 0.848286186923077
00:04:55.572 --> 00:04:59.459 based on the Taylor Taylor RX study Hall,
NOTE Confidence: 0.848286186923077
00:04:59.460 --> 00:05:04.095 and I think we can see here in those.
NOTE Confidence: 0.848286186923077
00:05:04.100 --> 00:05:07.580 In those patients who are 50 or younger
NOTE Confidence: 0.848286186923077

00:05:07.580 --> 00:05:10.927 between the required scores of 16 to 25.
NOTE Confidence: 0.848286186923077

00:05:10.930 --> 00:05:13.086 What the data was showing is that
NOTE Confidence: 0.848286186923077

00:05:13.086 --> 00:05:15.933 there was a lower at that rate do
NOTE Confidence: 0.848286186923077

00:05:15.933 --> 00:05:17.884 too with chemotherapy when it,
NOTE Confidence: 0.848286186923077

00:05:17.884 --> 00:05:19.994 when it preceded undergone therapy.
NOTE Confidence: 0.848286186923077

00:05:20.000 --> 00:05:23.640 So is this what is what is leading
NOTE Confidence: 0.848286186923077

00:05:23.640 --> 00:05:25.915 to this better outcome and this is
NOTE Confidence: 0.848286186923077

00:05:25.915 --> 00:05:27.550 continues to be widely debated.
NOTE Confidence: 0.848286186923077

00:05:27.550 --> 00:05:29.194 Is it ovarian suppression,
NOTE Confidence: 0.848286186923077

00:05:29.194 --> 00:05:30.427 effect of chemotherapy,
NOTE Confidence: 0.848286186923077

00:05:30.430 --> 00:05:33.802 or is it actually the cytotoxic
NOTE Confidence: 0.848286186923077

00:05:33.802 --> 00:05:35.488 effects of chemotherapy,
NOTE Confidence: 0.848286186923077

00:05:35.490 --> 00:05:39.158 and several models have been proposed and
NOTE Confidence: 0.86163117

00:05:39.160 --> 00:05:40.984 several perspective studies are.
NOTE Confidence: 0.86163117

00:05:40.984 --> 00:05:43.720 And to answer this question and
NOTE Confidence: 0.86163117

00:05:43.791 --> 00:05:46.027 different medical oncologists have

NOTE Confidence: 0.86163117

00:05:46.027 --> 00:05:48.842 very strong opinions about this

NOTE Confidence: 0.86163117

00:05:48.842 --> 00:05:52.238 that I'm sure you've heard about.

NOTE Confidence: 0.86163117

00:05:52.240 --> 00:05:54.040 So what about the escalation

NOTE Confidence: 0.86163117

00:05:54.040 --> 00:05:55.480 in ER positive node,

NOTE Confidence: 0.86163117

00:05:55.480 --> 00:05:58.075 positive disease and there is

NOTE Confidence: 0.86163117

00:05:58.075 --> 00:06:01.175 on your study was reported out

NOTE Confidence: 0.86163117

00:06:01.175 --> 00:06:03.635 in in the last San Antonio.

NOTE Confidence: 0.86163117

00:06:03.640 --> 00:06:07.384 And as you can see in this schema,

NOTE Confidence: 0.86163117

00:06:07.390 --> 00:06:09.724 those patients with up to three

NOTE Confidence: 0.86163117

00:06:09.724 --> 00:06:12.080 positive nodes with the crime scores

NOTE Confidence: 0.86163117

00:06:12.080 --> 00:06:14.968 of 0 to 25 were randomized to standard

NOTE Confidence: 0.86163117

00:06:15.043 --> 00:06:17.238 of care which was chemotherapy.

NOTE Confidence: 0.86163117

00:06:17.240 --> 00:06:19.700 Plus under compare P versus

NOTE Confidence: 0.86163117

00:06:19.700 --> 00:06:21.176 Anderson therapy alone.

NOTE Confidence: 0.86163117

00:06:21.180 --> 00:06:22.752 Those with high recurrence

NOTE Confidence: 0.86163117

00:06:22.752 --> 00:06:24.717 scores actually came up study.
NOTE Confidence: 0.86163117

00:06:24.720 --> 00:06:27.670 Receive standard of care chemotherapy.
NOTE Confidence: 0.86163117

00:06:27.670 --> 00:06:30.376 Close to 5000 patients were enrolled.
NOTE Confidence: 0.86163117

00:06:30.380 --> 00:06:31.820 And as you can see,
NOTE Confidence: 0.86163117

00:06:31.820 --> 00:06:34.370 there was no significant difference in
NOTE Confidence: 0.86163117

00:06:34.370 --> 00:06:36.560 invasive disease free survival with
NOTE Confidence: 0.86163117

00:06:36.560 --> 00:06:38.260 additional chemotherapy for those
NOTE Confidence: 0.86163117

00:06:38.260 --> 00:06:40.820 with requests for between zero to 25.
NOTE Confidence: 0.86163117

00:06:40.820 --> 00:06:43.424 After immediate follow up of five years,
NOTE Confidence: 0.86163117

00:06:43.430 --> 00:06:48.590 so this is obviously practice changing and.
NOTE Confidence: 0.86163117

00:06:48.590 --> 00:06:51.313 A wonderful set of data for us
NOTE Confidence: 0.86163117

00:06:51.313 --> 00:06:54.294 to reassure our patients with not
NOTE Confidence: 0.86163117

00:06:54.294 --> 00:06:56.590 positive disease with favorable
NOTE Confidence: 0.86163117

00:06:56.590 --> 00:06:58.808 features on gentleman profiling.
NOTE Confidence: 0.86163117

00:06:58.808 --> 00:07:03.080 But again, similar to the Taylor RX study,
NOTE Confidence: 0.86163117

00:07:03.080 --> 00:07:06.328 how we approach the younger cohort of

NOTE Confidence: 0.86163117

00:07:06.328 --> 00:07:09.927 patients is a little less clear in

NOTE Confidence: 0.86163117

00:07:09.927 --> 00:07:13.269 the in the study that premenopausal

NOTE Confidence: 0.86163117

00:07:13.269 --> 00:07:15.903 cohort appeared to have significant

NOTE Confidence: 0.86163117

00:07:15.903 --> 00:07:17.795 difference in outcomes when

NOTE Confidence: 0.86163117

00:07:17.795 --> 00:07:19.214 chemotherapy was used.

NOTE Confidence: 0.86163117

00:07:19.220 --> 00:07:22.532 And again whether this was due to the

NOTE Confidence: 0.86163117

00:07:22.532 --> 00:07:25.307 chemotherapy affect or to the effect

NOTE Confidence: 0.86163117

00:07:25.307 --> 00:07:27.647 of ovarian suppression from chemotherapy.

NOTE Confidence: 0.86163117

00:07:27.650 --> 00:07:29.888 These data are not going to

NOTE Confidence: 0.86163117

00:07:29.888 --> 00:07:31.380 answer that specific question.

NOTE Confidence: 0.86163117

00:07:31.380 --> 00:07:31.691 Although,

NOTE Confidence: 0.86163117

00:07:31.691 --> 00:07:32.002 interestingly,

NOTE Confidence: 0.86163117

00:07:32.002 --> 00:07:33.868 when we actually look at the

NOTE Confidence: 0.86163117

00:07:33.868 --> 00:07:35.428 type of endocrine therapy that

NOTE Confidence: 0.86163117

00:07:35.428 --> 00:07:36.893 was used in this study,

NOTE Confidence: 0.86163117

00:07:36.900 --> 00:07:39.126 only 16% and then they can therapy,
NOTE Confidence: 0.86163117

00:07:39.130 --> 00:07:40.270 arm actually had a variance.
NOTE Confidence: 0.86163117

00:07:40.270 --> 00:07:42.019 Regression therapy administered
NOTE Confidence: 0.86163117

00:07:42.019 --> 00:07:45.519 and only 3% in the chemotherapy
NOTE Confidence: 0.86163117

00:07:45.519 --> 00:07:48.434 arm had a variance oppression.
NOTE Confidence: 0.86163117

00:07:48.440 --> 00:07:50.735 Straight so so where do we go from here?
NOTE Confidence: 0.86163117

00:07:50.740 --> 00:07:52.798 How do we synthesize these data
NOTE Confidence: 0.86163117

00:07:52.798 --> 00:07:54.170 and how do we?
NOTE Confidence: 0.86163117

00:07:54.170 --> 00:07:56.792 How do we approach that younger
NOTE Confidence: 0.86163117

00:07:56.792 --> 00:07:59.240 patients with no positive disease?
NOTE Confidence: 0.86163117

00:07:59.240 --> 00:08:01.790 And I think the data are
NOTE Confidence: 0.86163117

00:08:01.790 --> 00:08:03.065 continuing to evolve,
NOTE Confidence: 0.86163117

00:08:03.070 --> 00:08:05.200 and it's important to also highlight
NOTE Confidence: 0.86163117

00:08:05.200 --> 00:08:07.058 some new data that represented
NOTE Confidence: 0.86163117

00:08:07.058 --> 00:08:09.302 also in the last time Junior
NOTE Confidence: 0.86163117

00:08:09.302 --> 00:08:11.460 breast meeting by Nadia Harbucks,

NOTE Confidence: 0.86163117

00:08:11.460 --> 00:08:13.230 Group of the ADAPT Study.

NOTE Confidence: 0.86163117

00:08:13.230 --> 00:08:17.780 And here they use dynamic K 67

NOTE Confidence: 0.86163117

00:08:17.780 --> 00:08:20.280 monitoring where those who actually

NOTE Confidence: 0.86163117

00:08:20.377 --> 00:08:23.576 had favorable K 67 numbers after three

NOTE Confidence: 0.86163117

00:08:23.576 --> 00:08:26.880 to four weeks of endocrine therapy,

NOTE Confidence: 0.86163117

00:08:26.880 --> 00:08:28.116 regardless of their age,

NOTE Confidence: 0.86163117

00:08:28.116 --> 00:08:29.970 even if they had low low

NOTE Confidence: 0.86163117

00:08:30.042 --> 00:08:31.368 nodal disease burden.

NOTE Confidence: 0.86163117

00:08:31.370 --> 00:08:34.730 Actually did fine without chemotherapy.

NOTE Confidence: 0.86163117

00:08:34.730 --> 00:08:35.342 So so.

NOTE Confidence: 0.86163117

00:08:35.342 --> 00:08:37.484 So there's this kind of adds to

NOTE Confidence: 0.86163117

00:08:37.484 --> 00:08:40.686 the body of data of if we have

NOTE Confidence: 0.86163117

00:08:40.686 --> 00:08:41.892 better biological predictors

NOTE Confidence: 0.86163117

00:08:41.965 --> 00:08:44.226 to be able to better pluck out,

NOTE Confidence: 0.86163117

00:08:44.230 --> 00:08:45.935 patients were at higher risk

NOTE Confidence: 0.86163117

00:08:45.935 --> 00:08:46.958 versus lower risk,
NOTE Confidence: 0.86163117

00:08:46.960 --> 00:08:50.140 can be better tailor our therapies
NOTE Confidence: 0.86163117

00:08:50.140 --> 00:08:52.284 in this endocrine responsive
NOTE Confidence: 0.86163117

00:08:52.284 --> 00:08:55.500 group that had this lower post
NOTE Confidence: 0.86163117

00:08:55.599 --> 00:08:58.847 Ki 67 levels after a short pre
NOTE Confidence: 0.86163117

00:08:58.847 --> 00:09:01.188 operative in therapy at the data
NOTE Confidence: 0.86163117

00:09:01.188 --> 00:09:03.400 I just showed you in the previous
NOTE Confidence: 0.86163117

00:09:03.472 --> 00:09:05.788 slide tend to do relatively well.
NOTE Confidence: 0.86163117

00:09:05.790 --> 00:09:06.741 Start a push.
NOTE Confidence: 0.86163117

00:09:06.741 --> 00:09:08.960 I I did a nice job summarizing
NOTE Confidence: 0.86163117

00:09:09.036 --> 00:09:11.328 these data as a discussion in
NOTE Confidence: 0.86163117

00:09:11.328 --> 00:09:12.856 the last thing Antonio,
NOTE Confidence: 0.86163117

00:09:12.860 --> 00:09:14.384 and as I mentioned,
NOTE Confidence: 0.86163117

00:09:14.384 --> 00:09:16.670 these data are continuing to evolve.
NOTE Confidence: 0.876628236470588

00:09:16.670 --> 00:09:19.570 What we know for sure is that we do need
NOTE Confidence: 0.876628236470588

00:09:19.651 --> 00:09:22.556 to take into account on anatomical risk,

NOTE Confidence: 0.876628236470588
00:09:22.560 --> 00:09:24.840 use some type of baseline
NOTE Confidence: 0.876628236470588
00:09:24.840 --> 00:09:26.208 gene expression profiling,
NOTE Confidence: 0.876628236470588
00:09:26.210 --> 00:09:27.730 whether it's Uncle Type DX,
NOTE Confidence: 0.876628236470588
00:09:27.730 --> 00:09:30.094 mammaprint and then whether we should
NOTE Confidence: 0.876628236470588
00:09:30.094 --> 00:09:33.283 also use some type of endocrine therapy
NOTE Confidence: 0.876628236470588
00:09:33.283 --> 00:09:35.838 response guided measurements I think.
NOTE Confidence: 0.876628236470588
00:09:35.840 --> 00:09:38.792 It remains to still be determined
NOTE Confidence: 0.876628236470588
00:09:38.792 --> 00:09:41.869 whether this is additive or superior.
NOTE Confidence: 0.876628236470588
00:09:41.870 --> 00:09:43.918 I don't think we can say for sure,
NOTE Confidence: 0.876628236470588
00:09:43.920 --> 00:09:46.808 but but the data are continuing to evolve
NOTE Confidence: 0.876628236470588
00:09:46.808 --> 00:09:48.958 pretty rapidly in the in this space,
NOTE Confidence: 0.876628236470588
00:09:48.960 --> 00:09:50.646 and I'm sure I'm giving this
NOTE Confidence: 0.876628236470588
00:09:50.646 --> 00:09:51.770 talk in two years.
NOTE Confidence: 0.876628236470588
00:09:51.770 --> 00:09:54.605 Will have additional data to share with
NOTE Confidence: 0.876628236470588
00:09:54.605 --> 00:09:57.320 you moving on to her two positive disease,
NOTE Confidence: 0.876628236470588

00:09:57.320 --> 00:09:59.742 a huge area of the escalation strategy
NOTE Confidence: 0.876628236470588

00:09:59.742 --> 00:10:02.097 has been with the use of another
NOTE Confidence: 0.876628236470588

00:10:02.097 --> 00:10:04.525 site plans since her to direct the
NOTE Confidence: 0.876628236470588

00:10:04.525 --> 00:10:06.330 therapies carried cardio toxicity risk.
NOTE Confidence: 0.876628236470588

00:10:06.330 --> 00:10:08.600 And as you enter cyclins,
NOTE Confidence: 0.876628236470588

00:10:08.600 --> 00:10:11.150 there has been continued effort
NOTE Confidence: 0.876628236470588

00:10:11.150 --> 00:10:14.719 looking at whether we can safely
NOTE Confidence: 0.876628236470588

00:10:14.719 --> 00:10:17.472 eliminate anthracyclines in in
NOTE Confidence: 0.876628236470588

00:10:17.472 --> 00:10:19.276 her two positive therapies.
NOTE Confidence: 0.876628236470588

00:10:19.280 --> 00:10:22.763 So this was one of the first studies that
NOTE Confidence: 0.876628236470588

00:10:22.763 --> 00:10:27.792 showed that where non after after cycling,
NOTE Confidence: 0.876628236470588

00:10:27.792 --> 00:10:30.960 taxane plus Carbo regimen less stressed
NOTE Confidence: 0.876628236470588

00:10:31.046 --> 00:10:33.806 him out was compared to two AC TH.
NOTE Confidence: 0.876628236470588

00:10:33.810 --> 00:10:35.994 And other numerically the numbers favor
NOTE Confidence: 0.876628236470588

00:10:35.994 --> 00:10:38.347 that the answer cycling regimen there
NOTE Confidence: 0.876628236470588

00:10:38.347 --> 00:10:40.427 was actually no statistical difference

NOTE Confidence: 0.876628236470588

00:10:40.427 --> 00:10:42.609 in outcomes between the two groups,

NOTE Confidence: 0.876628236470588

00:10:42.610 --> 00:10:46.060 but certainly higher toxicity with

NOTE Confidence: 0.876628236470588

00:10:46.060 --> 00:10:49.920 increased cardiac toxicity as well as.

NOTE Confidence: 0.876628236470588

00:10:49.920 --> 00:10:53.330 Secondary malignancies with anthracite news.

NOTE Confidence: 0.876628236470588

00:10:53.330 --> 00:10:55.635 But this numerical difference still

NOTE Confidence: 0.876628236470588

00:10:55.635 --> 00:10:57.940 was unsettling for some oncologists,

NOTE Confidence: 0.876628236470588

00:10:57.940 --> 00:11:00.946 and I think many of us had continued to

NOTE Confidence: 0.876628236470588

00:11:00.946 --> 00:11:04.310 use anthracite playing for very high risk.

NOTE Confidence: 0.876628236470588

00:11:04.310 --> 00:11:06.818 Her two positive disease and inflammatory

NOTE Confidence: 0.876628236470588

00:11:06.818 --> 00:11:09.340 breast cancer and said that the

NOTE Confidence: 0.876628236470588

00:11:09.340 --> 00:11:11.300 after cycling news has persisted.

NOTE Confidence: 0.876628236470588

00:11:11.300 --> 00:11:13.407 But just in the last month the

NOTE Confidence: 0.876628236470588

00:11:13.407 --> 00:11:15.265 results of the perspective train

NOTE Confidence: 0.876628236470588

00:11:15.265 --> 00:11:17.465 two study were reported out.

NOTE Confidence: 0.876628236470588

00:11:17.470 --> 00:11:19.078 This was originally presented

NOTE Confidence: 0.876628236470588

00:11:19.078 --> 00:11:20.686 in the last ASKO,
NOTE Confidence: 0.876628236470588

00:11:20.690 --> 00:11:22.955 where a more modern regiment
NOTE Confidence: 0.876628236470588

00:11:22.955 --> 00:11:25.690 including for choosing map was used.
NOTE Confidence: 0.876628236470588

00:11:25.690 --> 00:11:27.140 And as you can see,
NOTE Confidence: 0.876628236470588

00:11:27.140 --> 00:11:28.560 there is absolutely no difference
NOTE Confidence: 0.876628236470588

00:11:28.560 --> 00:11:30.287 between the upper side pain and
NOTE Confidence: 0.876628236470588

00:11:30.287 --> 00:11:31.847 not after cycling group and no
NOTE Confidence: 0.876628236470588

00:11:31.847 --> 00:11:33.100 difference in overall survival.
NOTE Confidence: 0.876628236470588

00:11:33.100 --> 00:11:35.530 So I think additional reassuring
NOTE Confidence: 0.876628236470588

00:11:35.530 --> 00:11:38.447 data that answer cycling is can
NOTE Confidence: 0.876628236470588

00:11:38.447 --> 00:11:40.829 be deescalated and in the majority
NOTE Confidence: 0.876628236470588

00:11:40.829 --> 00:11:43.650 of our for two positive cases,
NOTE Confidence: 0.876628236470588

00:11:43.650 --> 00:11:45.594 what about staging won her two
NOTE Confidence: 0.876628236470588

00:11:45.594 --> 00:11:46.566 positive breast cancer?
NOTE Confidence: 0.876628236470588

00:11:46.570 --> 00:11:49.634 Obviously you know we used to use multi
NOTE Confidence: 0.876628236470588

00:11:49.634 --> 00:11:52.149 pomp chemotherapy for these tumors as well,

NOTE Confidence: 0.876628236470588
00:11:52.150 --> 00:11:55.480 But what if we use less than the APITI study,
NOTE Confidence: 0.876628236470588
00:11:55.480 --> 00:11:57.825 set the standard that using single agent
NOTE Confidence: 0.876628236470588
00:11:57.825 --> 00:12:00.170 taxing question has chosen not followed by.
NOTE Confidence: 0.876628236470588
00:12:00.170 --> 00:12:03.194 He requested to not lead to
NOTE Confidence: 0.876628236470588
00:12:03.194 --> 00:12:05.210 very highly effective outcomes,
NOTE Confidence: 0.876628236470588
00:12:05.210 --> 00:12:08.252 and it was certainly better tolerated
NOTE Confidence: 0.876628236470588
00:12:08.252 --> 00:12:11.399 than multi agent chemotherapy so so so
NOTE Confidence: 0.876628236470588
00:12:11.399 --> 00:12:13.835 it was a very reassuring results that
NOTE Confidence: 0.876628236470588
00:12:13.912 --> 00:12:17.088 continue to to persist as the data mature.
NOTE Confidence: 0.876628236470588
00:12:17.090 --> 00:12:19.256 Can we further deescalate this therapy
NOTE Confidence: 0.876628236470588
00:12:19.256 --> 00:12:21.920 and this was the attempt trial looking
NOTE Confidence: 0.876628236470588
00:12:21.920 --> 00:12:24.702 at what if we substituted the taxing
NOTE Confidence: 0.876628236470588
00:12:24.702 --> 00:12:28.110 percept in ARM with TDM one which tends
NOTE Confidence: 0.876628236470588
00:12:28.205 --> 00:12:31.614 to be better tolerated in some respects.
NOTE Confidence: 0.876628236470588
00:12:31.620 --> 00:12:33.664 I can have a little less neuropathy,
NOTE Confidence: 0.876628236470588

00:12:33.670 --> 00:12:34.573 not hair loss,
NOTE Confidence: 0.876628236470588

00:12:34.573 --> 00:12:37.084 and that time study showed that there was
NOTE Confidence: 0.876628236470588

00:12:37.084 --> 00:12:39.464 some similar efficacy between the two arms.
NOTE Confidence: 0.910635278

00:12:39.470 --> 00:12:42.398 However, to the surprise of some of the
NOTE Confidence: 0.910635278

00:12:42.398 --> 00:12:44.958 people who are looking at the data,
NOTE Confidence: 0.910635278

00:12:44.960 --> 00:12:46.790 it was not necessarily better
NOTE Confidence: 0.910635278

00:12:46.790 --> 00:12:49.012 tolerated and there was actually higher
NOTE Confidence: 0.910635278

00:12:49.012 --> 00:12:51.636 discontinuation rates in the TV on one arm.
NOTE Confidence: 0.910635278

00:12:51.640 --> 00:12:53.410 Which had led to the next,
NOTE Confidence: 0.910635278

00:12:53.410 --> 00:12:56.428 the escalation trial design account too,
NOTE Confidence: 0.910635278

00:12:56.430 --> 00:12:59.510 which is looking at a shorter to UTM one arm,
NOTE Confidence: 0.910635278

00:12:59.510 --> 00:13:01.174 not a whole year.
NOTE Confidence: 0.910635278

00:13:01.174 --> 00:13:03.670 And this is still in development,
NOTE Confidence: 0.910635278

00:13:03.670 --> 00:13:06.160 but certainly highlights for you another.
NOTE Confidence: 0.910635278

00:13:06.160 --> 00:13:08.760 Further attempt at Deescalating stage
NOTE Confidence: 0.910635278

00:13:08.760 --> 00:13:11.360 one her two positive chemotherapy.

NOTE Confidence: 0.910635278

00:13:11.360 --> 00:13:13.208 Many of you are familiar with the

NOTE Confidence: 0.910635278

00:13:13.208 --> 00:13:15.137 Compass study and I would like to

NOTE Confidence: 0.910635278

00:13:15.137 --> 00:13:16.487 just highlight that it's it's.

NOTE Confidence: 0.910635278

00:13:16.490 --> 00:13:18.398 It's a nice combination of both

NOTE Confidence: 0.910635278

00:13:18.398 --> 00:13:19.034 the escalation,

NOTE Confidence: 0.910635278

00:13:19.040 --> 00:13:21.495 an escalation of therapy where

NOTE Confidence: 0.910635278

00:13:21.495 --> 00:13:23.459 D escalating carboplatinum and.

NOTE Confidence: 0.910635278

00:13:23.460 --> 00:13:26.267 After cycling, but at the same time,

NOTE Confidence: 0.910635278

00:13:26.270 --> 00:13:28.926 given that we know that her two positive

NOTE Confidence: 0.910635278

00:13:28.926 --> 00:13:31.486 disease is at higher risk of CNS

NOTE Confidence: 0.910635278

00:13:31.486 --> 00:13:33.900 relapse for patients with residual disease,

NOTE Confidence: 0.910635278

00:13:33.900 --> 00:13:35.846 there is an opportunity to build on

NOTE Confidence: 0.910635278

00:13:35.846 --> 00:13:38.309 the data of the Katherine study and

NOTE Confidence: 0.910635278

00:13:38.309 --> 00:13:40.264 essentially add a small molecule

NOTE Confidence: 0.910635278

00:13:40.264 --> 00:13:42.135 inhibitor to catch them which has

NOTE Confidence: 0.910635278

00:13:42.135 --> 00:13:44.308 been shown to have great CNS activity

NOTE Confidence: 0.910635278

00:13:44.308 --> 00:13:46.926 that will show in a little bit.

NOTE Confidence: 0.910635278

00:13:46.930 --> 00:13:48.570 And we always need chemotherapy

NOTE Confidence: 0.910635278

00:13:48.570 --> 00:13:50.210 for her two positive disease.

NOTE Confidence: 0.910635278

00:13:50.210 --> 00:13:52.535 This area is rapidly changing

NOTE Confidence: 0.910635278

00:13:52.535 --> 00:13:53.930 and very exciting.

NOTE Confidence: 0.910635278

00:13:53.930 --> 00:13:56.625 I think there is an opportunity to

NOTE Confidence: 0.910635278

00:13:56.625 --> 00:13:58.759 potentially look at imaging biomarkers

NOTE Confidence: 0.910635278

00:13:58.759 --> 00:14:01.459 to identify patients who who are

NOTE Confidence: 0.910635278

00:14:01.459 --> 00:14:04.030 more likely to achieve PCR without

NOTE Confidence: 0.910635278

00:14:04.030 --> 00:14:06.906 chemotherapy with just the use of dual.

NOTE Confidence: 0.910635278

00:14:06.906 --> 00:14:08.810 Her two targeted therapy.

NOTE Confidence: 0.910635278

00:14:08.810 --> 00:14:11.345 So this was recently reported

NOTE Confidence: 0.910635278

00:14:11.345 --> 00:14:14.091 by Rosen Connelly and this this

NOTE Confidence: 0.910635278

00:14:14.091 --> 00:14:17.200 approach using PET imaging as a as a.

NOTE Confidence: 0.910635278

00:14:17.200 --> 00:14:19.165 Biomarker for picking the patients

NOTE Confidence: 0.910635278

00:14:19.165 --> 00:14:21.602 that can have a deescalated approach

NOTE Confidence: 0.910635278

00:14:21.602 --> 00:14:24.002 is actually going to be prospectively

NOTE Confidence: 0.910635278

00:14:24.002 --> 00:14:26.004 evaluated in any thoughts that

NOTE Confidence: 0.910635278

00:14:26.004 --> 00:14:27.108 they coming up.

NOTE Confidence: 0.910635278

00:14:27.110 --> 00:14:29.903 Keep an eye out on another presentation

NOTE Confidence: 0.910635278

00:14:29.903 --> 00:14:32.200 from Nadia hard working Group.

NOTE Confidence: 0.910635278

00:14:32.200 --> 00:14:35.455 Looking also at chemotherapy for you edge

NOTE Confidence: 0.910635278

00:14:35.455 --> 00:14:38.740 events coming up in the upcoming ASCO.

NOTE Confidence: 0.910635278

00:14:38.740 --> 00:14:41.309 Moving on to triple negative breast cancer.

NOTE Confidence: 0.910635278

00:14:41.310 --> 00:14:41.699 Certainly,

NOTE Confidence: 0.910635278

00:14:41.699 --> 00:14:43.644 given the more aggressive phenotype

NOTE Confidence: 0.910635278

00:14:43.644 --> 00:14:45.200 of triple negative disease,

NOTE Confidence: 0.910635278

00:14:45.200 --> 00:14:46.825 we've been much more cautious

NOTE Confidence: 0.910635278

00:14:46.825 --> 00:14:48.450 about the escalating therapies in

NOTE Confidence: 0.910635278

00:14:48.509 --> 00:14:50.057 triple negative breast cancer,

NOTE Confidence: 0.910635278

00:14:50.060 --> 00:14:51.900 but I would be remiss if I didn't
NOTE Confidence: 0.910635278

00:14:51.900 --> 00:14:53.386 mention that there's a body of
NOTE Confidence: 0.910635278

00:14:53.386 --> 00:14:54.606 work with tumor in simple,
NOTE Confidence: 0.910635278

00:14:54.610 --> 00:14:56.982 implicating lymphocytes as a
NOTE Confidence: 0.910635278

00:14:56.982 --> 00:14:59.354 measure of good prognosis,
NOTE Confidence: 0.910635278

00:14:59.360 --> 00:15:00.900 and this is something that
NOTE Confidence: 0.910635278

00:15:00.900 --> 00:15:02.440 can lead to potentially DFD.
NOTE Confidence: 0.910635278

00:15:02.440 --> 00:15:04.816 Escalated immunotherapy based treatments,
NOTE Confidence: 0.910635278

00:15:04.816 --> 00:15:07.786 or even elimination or chemotherapy.
NOTE Confidence: 0.910635278

00:15:07.790 --> 00:15:10.256 I will highlight one such study.
NOTE Confidence: 0.910635278

00:15:10.260 --> 00:15:11.769 Where stage one,
NOTE Confidence: 0.910635278

00:15:11.769 --> 00:15:14.284 triple negative breast cancers with
NOTE Confidence: 0.910635278

00:15:14.284 --> 00:15:17.541 high tells actually did did just as
NOTE Confidence: 0.910635278

00:15:17.541 --> 00:15:19.476 well with or without chemotherapy.
NOTE Confidence: 0.910635278

00:15:19.480 --> 00:15:20.900 Certainly a lot of ongoing,
NOTE Confidence: 0.910635278

00:15:20.900 --> 00:15:21.250 exciting,

NOTE Confidence: 0.910635278

00:15:21.250 --> 00:15:23.000 effective efforts are going on

NOTE Confidence: 0.910635278

00:15:23.000 --> 00:15:25.661 in the till space before we can

NOTE Confidence: 0.910635278

00:15:25.661 --> 00:15:27.253 safely deescalate therapy and

NOTE Confidence: 0.910635278

00:15:27.253 --> 00:15:28.940 triple negative breast cancer.

NOTE Confidence: 0.910635278

00:15:28.940 --> 00:15:31.300 But they are coming.

NOTE Confidence: 0.910635278

00:15:31.300 --> 00:15:33.215 An exciting abstract and presentation

NOTE Confidence: 0.910635278

00:15:33.215 --> 00:15:36.053 will be presented in this year's ASCO

NOTE Confidence: 0.910635278

00:15:36.053 --> 00:15:38.639 looking at part inhibitor alone as

NOTE Confidence: 0.910635278

00:15:38.639 --> 00:15:39.924 preoperative neoadjuvant chemotherapy

NOTE Confidence: 0.910635278

00:15:39.924 --> 00:15:42.060 and BRCA one and two tumors.

NOTE Confidence: 0.910635278

00:15:42.060 --> 00:15:45.090 This is without any chemotherapy

NOTE Confidence: 0.910635278

00:15:45.090 --> 00:15:47.190 patients with these types of tumors

NOTE Confidence: 0.910635278

00:15:47.190 --> 00:15:49.410 actually had pretty high on PCR rates,

NOTE Confidence: 0.910635278

00:15:49.410 --> 00:15:52.248 so these are exciting data that

NOTE Confidence: 0.910635278

00:15:52.248 --> 00:15:54.612 will be further represented in

NOTE Confidence: 0.910635278

00:15:54.612 --> 00:15:56.946 this coming as still coming up.
NOTE Confidence: 0.847098561428571

00:15:56.950 --> 00:15:59.036 So we talked a lot about Deescalation,
NOTE Confidence: 0.847098561428571

00:15:59.040 --> 00:15:59.694 but obviously.
NOTE Confidence: 0.847098561428571

00:15:59.694 --> 00:16:02.310 We need to just kind of touch on
NOTE Confidence: 0.847098561428571

00:16:02.382 --> 00:16:04.747 some of the escalation approaches.
NOTE Confidence: 0.847098561428571

00:16:04.750 --> 00:16:07.165 Certainly we've made a lot of progress,
NOTE Confidence: 0.847098561428571

00:16:07.170 --> 00:16:09.606 but we still have over 40,000
NOTE Confidence: 0.847098561428571

00:16:09.606 --> 00:16:11.230 individuals with breast cancer
NOTE Confidence: 0.847098561428571

00:16:11.305 --> 00:16:13.610 dying from advanced breast cancer,
NOTE Confidence: 0.847098561428571

00:16:13.610 --> 00:16:17.010 so it goes without saying that our current
NOTE Confidence: 0.847098561428571

00:16:17.010 --> 00:16:19.518 strip strategies have significant gaps.
NOTE Confidence: 0.847098561428571

00:16:19.520 --> 00:16:22.640 So one of the great successes of escalation,
NOTE Confidence: 0.847098561428571

00:16:22.640 --> 00:16:23.852 in my opinion,
NOTE Confidence: 0.847098561428571

00:16:23.852 --> 00:16:26.796 has been the the introduction of the CD.
NOTE Confidence: 0.847098561428571

00:16:26.800 --> 00:16:30.940 46 inhibitors 222 minus static breast cancer.
NOTE Confidence: 0.847098561428571

00:16:30.940 --> 00:16:33.586 That's, ER, positive that they have led

NOTE Confidence: 0.847098561428571

00:16:33.586 --> 00:16:35.620 to improved progression free survival.

NOTE Confidence: 0.847098561428571

00:16:35.620 --> 00:16:38.230 Anne continued more and more overall

NOTE Confidence: 0.847098561428571

00:16:38.230 --> 00:16:40.772 survival data are maturing and will

NOTE Confidence: 0.847098561428571

00:16:40.772 --> 00:16:42.950 be presented in this year's ASCO,

NOTE Confidence: 0.847098561428571

00:16:42.950 --> 00:16:46.072 so you can look at it as

NOTE Confidence: 0.847098561428571

00:16:46.072 --> 00:16:47.410 an escalation approach,

NOTE Confidence: 0.847098561428571

00:16:47.410 --> 00:16:50.250 but also deescalation approach because.

NOTE Confidence: 0.847098561428571

00:16:50.250 --> 00:16:53.010 What the data to show also is at work for

NOTE Confidence: 0.847098561428571

00:16:53.083 --> 00:16:55.820 a long time to initiation of chemotherapy

NOTE Confidence: 0.847098561428571

00:16:55.820 --> 00:16:58.749 in patients with metastatic breast cancer.

NOTE Confidence: 0.847098561428571

00:16:58.750 --> 00:17:00.222 What about escalating argument

NOTE Confidence: 0.847098561428571

00:17:00.222 --> 00:17:02.062 underground therapy in early stage?

NOTE Confidence: 0.847098561428571

00:17:02.070 --> 00:17:03.160 Breast cancer.

NOTE Confidence: 0.847098561428571

00:17:03.160 --> 00:17:06.430 Three studies have been reported out,

NOTE Confidence: 0.847098561428571

00:17:06.430 --> 00:17:09.762 but only monarchy with Emoci club has

NOTE Confidence: 0.847098561428571

00:17:09.762 --> 00:17:13.427 been shown to to to improve outcomes.
NOTE Confidence: 0.847098561428571

00:17:13.430 --> 00:17:16.986 I think the data are still maturing
NOTE Confidence: 0.847098561428571

00:17:16.990 --> 00:17:20.166 and I would say we are not ready
NOTE Confidence: 0.847098561428571

00:17:20.166 --> 00:17:22.250 too too too too too.
NOTE Confidence: 0.847098561428571

00:17:22.250 --> 00:17:23.738 Add city 46 inhibitors.
NOTE Confidence: 0.847098561428571

00:17:23.738 --> 00:17:24.854 Agile and therapy.
NOTE Confidence: 0.847098561428571

00:17:24.860 --> 00:17:27.550 At this point in time.
NOTE Confidence: 0.847098561428571

00:17:27.550 --> 00:17:30.644 And when you further inspect the data,
NOTE Confidence: 0.847098561428571

00:17:30.650 --> 00:17:32.210 that question has been why?
NOTE Confidence: 0.847098561428571

00:17:32.210 --> 00:17:34.826 Why has Monarch even the only positive study,
NOTE Confidence: 0.847098561428571

00:17:34.830 --> 00:17:39.238 while Penelope B and Palace were not an?
NOTE Confidence: 0.847098561428571

00:17:39.240 --> 00:17:40.956 There's a very nice presentation coming
NOTE Confidence: 0.847098561428571

00:17:40.956 --> 00:17:43.619 up in the next ***** looking at the
NOTE Confidence: 0.847098561428571

00:17:43.619 --> 00:17:45.434 composition of tumors that actually
NOTE Confidence: 0.847098561428571

00:17:45.434 --> 00:17:47.266 derive benefit and Penelope and they
NOTE Confidence: 0.847098561428571

00:17:47.266 --> 00:17:49.570 tend to be of the luminal before iety,

NOTE Confidence: 0.847098561428571
00:17:49.570 --> 00:17:51.614 so I think kind of the biology
NOTE Confidence: 0.847098561428571
00:17:51.614 --> 00:17:52.490 of these chambers.
NOTE Confidence: 0.847098561428571
00:17:52.490 --> 00:17:53.990 Whether we can kind of phenotype,
NOTE Confidence: 0.847098561428571
00:17:53.990 --> 00:17:56.020 the tumors that are more likely to
NOTE Confidence: 0.847098561428571
00:17:56.020 --> 00:17:57.929 benefit from agile and taxi for 1600.
NOTE Confidence: 0.847098561428571
00:17:57.930 --> 00:18:00.730 Happy, I think it's the next step.
NOTE Confidence: 0.847098561428571
00:18:00.730 --> 00:18:03.130 Brain metastases are huge gap and
NOTE Confidence: 0.847098561428571
00:18:03.130 --> 00:18:06.130 we need to do better to catnap
NOTE Confidence: 0.847098561428571
00:18:06.130 --> 00:18:08.130 inverted climb with an important
NOTE Confidence: 0.847098561428571
00:18:08.130 --> 00:18:10.883 study and as the basis of adjutant
NOTE Confidence: 0.847098561428571
00:18:10.883 --> 00:18:13.548 to catnip that I mentioned in the
NOTE Confidence: 0.847098561428571
00:18:13.548 --> 00:18:15.726 in the compass study coming up.
NOTE Confidence: 0.847098561428571
00:18:15.730 --> 00:18:21.018 And I will wrap up with escalation of
NOTE Confidence: 0.847098561428571
00:18:21.018 --> 00:18:23.694 our preoperative chemotherapy regiments
NOTE Confidence: 0.847098561428571
00:18:23.694 --> 00:18:27.050 in triple negative breast cancer.
NOTE Confidence: 0.847098561428571

00:18:27.050 --> 00:18:29.180 Certainly we have approval for
NOTE Confidence: 0.847098561428571

00:18:29.180 --> 00:18:30.884 two checkpoint inhibitors in
NOTE Confidence: 0.847098561428571

00:18:30.884 --> 00:18:32.669 the metastatic setting,
NOTE Confidence: 0.847098561428571

00:18:32.670 --> 00:18:34.510 but what about in the pre operative setting?
NOTE Confidence: 0.847098561428571

00:18:34.510 --> 00:18:34.926 Again,
NOTE Confidence: 0.847098561428571

00:18:34.926 --> 00:18:37.422 Keynote 522 has been in the
NOTE Confidence: 0.847098561428571

00:18:37.422 --> 00:18:39.909 news quite a bit recently.
NOTE Confidence: 0.847098561428571

00:18:39.910 --> 00:18:42.804 The patients and in the intervention arm
NOTE Confidence: 0.847098561428571

00:18:42.804 --> 00:18:44.340 essentially got everything they had,
NOTE Confidence: 0.847098561428571

00:18:44.340 --> 00:18:44.712 carbo,
NOTE Confidence: 0.847098561428571

00:18:44.712 --> 00:18:47.316 they attacks all they got after cycling
NOTE Confidence: 0.847098561428571

00:18:47.316 --> 00:18:49.726 symbolism as well as a year of her
NOTE Confidence: 0.847098561428571

00:18:49.726 --> 00:18:52.051 Pember Lizum app after after surgery.
NOTE Confidence: 0.847098561428571

00:18:52.051 --> 00:18:55.600 So the kitchen sink was given and
NOTE Confidence: 0.847098561428571

00:18:55.701 --> 00:18:59.193 improved PCR rates in the intervention
NOTE Confidence: 0.847098561428571

00:18:59.193 --> 00:19:02.470 arm improved event free survival.

NOTE Confidence: 0.847098561428571
00:19:02.470 --> 00:19:03.829 With these data,
NOTE Confidence: 0.847098561428571
00:19:03.829 --> 00:19:08.451 Merck went to FDA ODAC an ask for approval
NOTE Confidence: 0.847098561428571
00:19:08.451 --> 00:19:11.826 of pembrolizumab for pre operative.
NOTE Confidence: 0.847098561428571
00:19:11.830 --> 00:19:14.670 Want to get chemotherapy and it was denied.
NOTE Confidence: 0.847098561428571
00:19:14.670 --> 00:19:17.118 Why was it denied?
NOTE Confidence: 0.847098561428571
00:19:17.118 --> 00:19:17.730 Really?
NOTE Confidence: 0.847098561428571
00:19:17.730 --> 00:19:20.772 The the Act committee wanted to
NOTE Confidence: 0.847098561428571
00:19:20.772 --> 00:19:24.526 see results of analysis for an even
NOTE Confidence: 0.847098561428571
00:19:24.526 --> 00:19:27.236 potentially the the final analysis.
NOTE Confidence: 0.847098561428571
00:19:27.240 --> 00:19:28.828 Analysis For results actually
NOTE Confidence: 0.847098561428571
00:19:28.828 --> 00:19:30.416 became available in May,
NOTE Confidence: 0.875422415833334
00:19:30.420 --> 00:19:32.835 and they were positive whether they're going
NOTE Confidence: 0.875422415833334
00:19:32.835 --> 00:19:36.097 to go back in after time .4 or wait until
NOTE Confidence: 0.875422415833334
00:19:36.097 --> 00:19:38.277 the final analysis remains to be seen.
NOTE Confidence: 0.875422415833334
00:19:38.280 --> 00:19:41.976 But generally I think most of us think
NOTE Confidence: 0.875422415833334

00:19:41.976 --> 00:19:45.260 that potential approval is getting close.
NOTE Confidence: 0.875422415833334

00:19:45.260 --> 00:19:47.384 I wanted to highlight an important
NOTE Confidence: 0.875422415833334

00:19:47.384 --> 00:19:49.444 abstract that you will hear about
NOTE Confidence: 0.875422415833334

00:19:49.444 --> 00:19:51.732 in the next ASCO coming up with our
NOTE Confidence: 0.875422415833334

00:19:51.798 --> 00:19:54.038 rule of Mob that Jeffrey Nova study,
NOTE Confidence: 0.875422415833334

00:19:54.040 --> 00:19:56.098 which did not throw the kitchen
NOTE Confidence: 0.875422415833334

00:19:56.098 --> 00:19:56.784 sink applications.
NOTE Confidence: 0.875422415833334

00:19:56.790 --> 00:19:58.330 There was no carbo.
NOTE Confidence: 0.875422415833334

00:19:58.330 --> 00:20:00.640 There wasn't a year of immunotherapy
NOTE Confidence: 0.875422415833334

00:20:00.717 --> 00:20:03.678 and they still had very remarkable results.
NOTE Confidence: 0.875422415833334

00:20:03.680 --> 00:20:06.627 So I think data are mounting that
NOTE Confidence: 0.875422415833334

00:20:06.627 --> 00:20:07.469 for appropriate.
NOTE Confidence: 0.875422415833334

00:20:07.470 --> 00:20:09.600 We can select the patients most
NOTE Confidence: 0.875422415833334

00:20:09.600 --> 00:20:12.010 likely to benefit from immunotherapy.
NOTE Confidence: 0.875422415833334

00:20:12.010 --> 00:20:14.515 This is something that potentially
NOTE Confidence: 0.875422415833334

00:20:14.515 --> 00:20:16.538 could help. Our patients.

NOTE Confidence: 0.875422415833334

00:20:16.538 --> 00:20:20.913 I'm gonna wrap up with a saying that won't

NOTE Confidence: 0.875422415833334

00:20:20.913 --> 00:20:23.034 have time to discuss in great length.

NOTE Confidence: 0.875422415833334

00:20:23.040 --> 00:20:24.800 Our escalation strategies and

NOTE Confidence: 0.875422415833334

00:20:24.800 --> 00:20:26.120 metastatic breast cancer,

NOTE Confidence: 0.875422415833334

00:20:26.120 --> 00:20:28.360 but a lot of exciting work is going

NOTE Confidence: 0.875422415833334

00:20:28.360 --> 00:20:30.855 on in this area and it will be a

NOTE Confidence: 0.875422415833334

00:20:30.855 --> 00:20:33.030 focus of our future discussions.

NOTE Confidence: 0.875422415833334

00:20:33.030 --> 00:20:34.004 So in conclusion,

NOTE Confidence: 0.875422415833334

00:20:34.004 --> 00:20:36.386 it's it's about right side therapy,

NOTE Confidence: 0.875422415833334

00:20:36.390 --> 00:20:38.520 not D, escalation or escalation.

NOTE Confidence: 0.875422415833334

00:20:38.520 --> 00:20:40.302 We have a way to go to achieve this

NOTE Confidence: 0.875422415833334

00:20:40.302 --> 00:20:41.751 for every individual diagnosed

NOTE Confidence: 0.875422415833334

00:20:41.751 --> 00:20:43.347 with breast Cancer Research,

NOTE Confidence: 0.875422415833334

00:20:43.350 --> 00:20:44.238 patient engagement,

NOTE Confidence: 0.875422415833334

00:20:44.238 --> 00:20:46.014 team science and collaborations

NOTE Confidence: 0.875422415833334

00:20:46.014 --> 00:20:47.790 are the path forward.
NOTE Confidence: 0.875422415833334

00:20:47.790 --> 00:20:49.218 Thank you so much for your attention.
NOTE Confidence: 0.856699082307692

00:20:50.720 --> 00:20:53.114 Thank you Doctor Lustberg that was
NOTE Confidence: 0.856699082307692

00:20:53.114 --> 00:20:55.683 really fantastic and I know I have
NOTE Confidence: 0.856699082307692

00:20:55.683 --> 00:20:58.268 a bunch of questions for you at the
NOTE Confidence: 0.856699082307692

00:20:58.268 --> 00:21:00.308 end and hopefully our audience,
NOTE Confidence: 0.856699082307692

00:21:00.310 --> 00:21:02.640 whether they're locally here in
NOTE Confidence: 0.856699082307692

00:21:02.640 --> 00:21:04.038 Connecticut or internationally,
NOTE Confidence: 0.856699082307692

00:21:04.040 --> 00:21:06.416 will put some questions in the
NOTE Confidence: 0.856699082307692

00:21:06.416 --> 00:21:09.407 question to answer a chat box for you.
NOTE Confidence: 0.856699082307692

00:21:09.410 --> 00:21:11.036 Next, we're going to move on
NOTE Confidence: 0.856699082307692

00:21:11.036 --> 00:21:12.120 to Doctor Michael D.
NOTE Confidence: 0.856699082307692

00:21:12.120 --> 00:21:14.980 Geovanna and discussing recent advances
NOTE Confidence: 0.856699082307692

00:21:14.980 --> 00:21:20.000 of systemic therapy for breast cancer.
NOTE Confidence: 0.856699082307692

00:21:20.000 --> 00:21:21.788 Thank you doctor Cubana.
NOTE Confidence: 0.892945618

00:21:56.780 --> 00:21:58.980 Sorry for the technical problems,

NOTE Confidence: 0.892945618

00:21:58.980 --> 00:22:01.446 thank you for having me and for all of

NOTE Confidence: 0.892945618

00:22:01.446 --> 00:22:04.020 the attendees being on the conference.

NOTE Confidence: 0.892945618

00:22:04.020 --> 00:22:06.449 I will hit some highlights and advances

NOTE Confidence: 0.892945618

00:22:06.449 --> 00:22:09.136 in therapy for each of the types of

NOTE Confidence: 0.892945618

00:22:09.136 --> 00:22:11.466 breast cancer and I'll start with her

NOTE Confidence: 0.892945618

00:22:11.466 --> 00:22:13.867 two positive breast cancer we now have.

NOTE Confidence: 0.892945618

00:22:13.870 --> 00:22:15.960 Eight different targeted drugs for

NOTE Confidence: 0.892945618

00:22:15.960 --> 00:22:18.550 treating her two positive breast cancer,

NOTE Confidence: 0.892945618

00:22:18.550 --> 00:22:20.075 so it's been wonderful progress

NOTE Confidence: 0.892945618

00:22:20.075 --> 00:22:22.369 in this field and of these eight,

NOTE Confidence: 0.892945618

00:22:22.370 --> 00:22:24.578 there's actually been five new FDA

NOTE Confidence: 0.892945618

00:22:24.578 --> 00:22:27.109 approvals in just the last two years.

NOTE Confidence: 0.892945618

00:22:27.110 --> 00:22:28.790 Those are the ones that I've

NOTE Confidence: 0.892945618

00:22:28.790 --> 00:22:29.910 highlighted in red here,

NOTE Confidence: 0.892945618

00:22:29.910 --> 00:22:32.381 and that does not even include FDA

NOTE Confidence: 0.892945618

00:22:32.381 --> 00:22:34.397 approvals for a biosimilars or
NOTE Confidence: 0.892945618

00:22:34.397 --> 00:22:37.043 subq preparations of some of these.
NOTE Confidence: 0.892945618

00:22:37.050 --> 00:22:39.577 So the first drug I'll mention is
NOTE Confidence: 0.892945618

00:22:39.577 --> 00:22:42.639 TDM one or trastuzumab in fanzine.
NOTE Confidence: 0.892945618

00:22:42.640 --> 00:22:44.272 This was first approved a number
NOTE Confidence: 0.892945618

00:22:44.272 --> 00:22:45.088 of years ago,
NOTE Confidence: 0.892945618

00:22:45.090 --> 00:22:47.130 as per the Amelia trial,
NOTE Confidence: 0.892945618

00:22:47.130 --> 00:22:49.278 showing that in second line therapy
NOTE Confidence: 0.892945618

00:22:49.278 --> 00:22:52.248 for her two positive metastatic disease TDM,
NOTE Confidence: 0.892945618

00:22:52.250 --> 00:22:54.754 one was superior to what was then most
NOTE Confidence: 0.892945618

00:22:54.754 --> 00:22:56.850 commonly used second line therapy of
NOTE Confidence: 0.892945618

00:22:56.850 --> 00:22:59.505 lapetina been capeside of been with improved
NOTE Confidence: 0.892945618

00:22:59.505 --> 00:23:01.970 progression free survival response rate,
NOTE Confidence: 0.892945618

00:23:01.970 --> 00:23:03.110 and overall survival,
NOTE Confidence: 0.892945618

00:23:03.110 --> 00:23:05.010 as well as less toxicity,
NOTE Confidence: 0.892945618

00:23:05.010 --> 00:23:07.544 and this became the standard second line.

NOTE Confidence: 0.892945618

00:23:07.550 --> 00:23:09.720 B for metastatic disease at that time,

NOTE Confidence: 0.892945618

00:23:09.720 --> 00:23:11.230 bumping the patent Open Cape,

NOTE Confidence: 0.892945618

00:23:11.230 --> 00:23:13.900 cited being to third line and

NOTE Confidence: 0.892945618

00:23:13.900 --> 00:23:16.050 then the other really important.

NOTE Confidence: 0.892945618

00:23:16.050 --> 00:23:18.650 Recent results using this drug

NOTE Confidence: 0.892945618

00:23:18.650 --> 00:23:20.594 were the results of the Catherine

NOTE Confidence: 0.892945618

00:23:20.594 --> 00:23:23.003 trial that looked at this drug in

NOTE Confidence: 0.892945618

00:23:23.003 --> 00:23:24.803 the post neoadjuvant setting in

NOTE Confidence: 0.892945618

00:23:24.803 --> 00:23:27.161 patients who had been treated in

NOTE Confidence: 0.892945618

00:23:27.161 --> 00:23:29.101 the neoadjuvant setting with trust

NOTE Confidence: 0.892945618

00:23:29.101 --> 00:23:31.177 using map based therapy and those

NOTE Confidence: 0.892945618

00:23:31.177 --> 00:23:33.857 who did not achieve a pathological

NOTE Confidence: 0.892945618

00:23:33.857 --> 00:23:36.252 complete response were randomized to

NOTE Confidence: 0.892945618

00:23:36.252 --> 00:23:38.048 standard of care which was to complete

NOTE Confidence: 0.892945618

00:23:38.048 --> 00:23:39.840 a year of the trustees and map.

NOTE Confidence: 0.892945618

00:23:39.840 --> 00:23:43.386 Or switching to TDM one instead,
NOTE Confidence: 0.892945618

00:23:43.390 --> 00:23:45.622 and there was quite remarkable results
NOTE Confidence: 0.892945618

00:23:45.622 --> 00:23:47.964 in terms of switching with almost a
NOTE Confidence: 0.892945618

00:23:47.964 --> 00:23:50.595 50% decrease in disease free survival
NOTE Confidence: 0.892945618

00:23:50.595 --> 00:23:53.505 and freedom from distant response and
NOTE Confidence: 0.892945618

00:23:53.505 --> 00:23:56.349 overall survival looking promising as well.
NOTE Confidence: 0.892945618

00:23:56.350 --> 00:23:58.330 Just in the past month,
NOTE Confidence: 0.892945618

00:23:58.330 --> 00:24:01.734 published online is an update of
NOTE Confidence: 0.892945618

00:24:01.734 --> 00:24:03.764 the Catherine trial with subgroup
NOTE Confidence: 0.892945618

00:24:03.764 --> 00:24:06.138 analysis and I'll just mention a
NOTE Confidence: 0.892945618

00:24:06.138 --> 00:24:08.560 couple of the important follow line
NOTE Confidence: 0.892945618

00:24:08.560 --> 00:24:10.835 subgroup analysis from this trial.
NOTE Confidence: 0.892945618

00:24:10.840 --> 00:24:13.018 One is that the improvement with
NOTE Confidence: 0.892945618

00:24:13.018 --> 00:24:15.622 the switch to TDM one came both in
NOTE Confidence: 0.892945618

00:24:15.622 --> 00:24:17.610 patients who were treated with an for
NOTE Confidence: 0.892945618

00:24:17.669 --> 00:24:19.657 cycling as well as those who were

NOTE Confidence: 0.892945618

00:24:19.657 --> 00:24:21.420 not treated with anthracyclines.

NOTE Confidence: 0.892945618

00:24:21.420 --> 00:24:24.171 It came even in patients with the

NOTE Confidence: 0.892945618

00:24:24.171 --> 00:24:26.900 very highest risk disease categories.

NOTE Confidence: 0.892945618

00:24:26.900 --> 00:24:29.120 The improvement was seen regardless

NOTE Confidence: 0.892945618

00:24:29.120 --> 00:24:30.896 of hormone receptor status,

NOTE Confidence: 0.892945618

00:24:30.900 --> 00:24:32.706 positive or negative,

NOTE Confidence: 0.892945618

00:24:32.706 --> 00:24:35.114 and in this trial,

NOTE Confidence: 0.892945618

00:24:35.120 --> 00:24:38.975 about 70 patients entered initially

NOTE Confidence: 0.892945618

00:24:38.975 --> 00:24:42.830 having clinical stage one disease

NOTE Confidence: 0.892945618

00:24:42.830 --> 00:24:44.274 and getting neoadjuvant therapy.

NOTE Confidence: 0.892945618

00:24:44.274 --> 00:24:46.870 An of those who entered the trial

NOTE Confidence: 0.892945618

00:24:46.870 --> 00:24:48.675 with clinical stage one disease

NOTE Confidence: 0.892945618

00:24:48.675 --> 00:24:50.670 and still had residual disease.

NOTE Confidence: 0.892945618

00:24:50.670 --> 00:24:52.566 Those who got switched to TDM

NOTE Confidence: 0.892945618

00:24:52.566 --> 00:24:54.559 one seemed to have a benefit,

NOTE Confidence: 0.892945618

00:24:54.560 --> 00:24:56.444 although it's small numbers and so
NOTE Confidence: 0.892945618

00:24:56.444 --> 00:24:58.390 we can't really pull statistics.
NOTE Confidence: 0.892945618

00:24:58.390 --> 00:25:01.547 But there were six disease free survival
NOTE Confidence: 0.892945618

00:25:01.547 --> 00:25:05.159 events in those that continued trastuzumab,
NOTE Confidence: 0.892945618

00:25:05.160 --> 00:25:08.430 and none in the arm that was switched to TDM.
NOTE Confidence: 0.892945618

00:25:08.430 --> 00:25:10.650 One and of these events,
NOTE Confidence: 0.892945618

00:25:10.650 --> 00:25:12.996 three of them were non CNS
NOTE Confidence: 0.892945618

00:25:12.996 --> 00:25:13.778 distant recurrences,
NOTE Confidence: 0.836663429090909

00:25:13.780 --> 00:25:15.180 two or CNS recurrences,
NOTE Confidence: 0.836663429090909

00:25:15.180 --> 00:25:17.770 and one was a contralateral breast cancer.
NOTE Confidence: 0.836663429090909

00:25:17.770 --> 00:25:19.972 So although small numbers it gives
NOTE Confidence: 0.836663429090909

00:25:19.972 --> 00:25:22.769 us pause to think about even using
NOTE Confidence: 0.836663429090909

00:25:22.769 --> 00:25:25.271 this strategy in patients who present
NOTE Confidence: 0.836663429090909

00:25:25.271 --> 00:25:27.669 with clinical stage one disease,
NOTE Confidence: 0.836663429090909

00:25:27.670 --> 00:25:29.090 and that's a controversial area
NOTE Confidence: 0.836663429090909

00:25:29.090 --> 00:25:30.889 whether to use this strategy or not.

NOTE Confidence: 0.843883554

00:25:33.650 --> 00:25:35.396 But the Catherine trial did set

NOTE Confidence: 0.843883554

00:25:35.396 --> 00:25:37.016 a new paradigm for treating

NOTE Confidence: 0.843883554

00:25:37.016 --> 00:25:38.600 her two positive disease,

NOTE Confidence: 0.843883554

00:25:38.600 --> 00:25:41.030 which is in general we could

NOTE Confidence: 0.843883554

00:25:41.030 --> 00:25:42.650 debate stage one disease,

NOTE Confidence: 0.843883554

00:25:42.650 --> 00:25:43.950 but in general patients with

NOTE Confidence: 0.843883554

00:25:43.950 --> 00:25:44.990 her two positive disease,

NOTE Confidence: 0.843883554

00:25:44.990 --> 00:25:47.874 now we think should get neoadjuvant therapy,

NOTE Confidence: 0.843883554

00:25:47.880 --> 00:25:50.247 because if they get a non path CR we

NOTE Confidence: 0.843883554

00:25:50.247 --> 00:25:52.751 can improve their long term outcome by

NOTE Confidence: 0.843883554

00:25:52.751 --> 00:25:55.450 switching to TDM one and this paradigm.

NOTE Confidence: 0.843883554

00:25:55.450 --> 00:25:57.809 Now we also apply to the triple

NOTE Confidence: 0.843883554

00:25:57.809 --> 00:25:59.950 negative subset because the create X

NOTE Confidence: 0.843883554

00:25:59.950 --> 00:26:02.080 trial showed that in triple negative

NOTE Confidence: 0.843883554

00:26:02.080 --> 00:26:04.097 patients who get neoadjuvant chemo.

NOTE Confidence: 0.843883554

00:26:04.100 --> 00:26:04.361 Therapy.
NOTE Confidence: 0.843883554

00:26:04.361 --> 00:26:06.710 Those who do not get a path CR and
NOTE Confidence: 0.843883554

00:26:06.778 --> 00:26:08.906 we now have a worse outcome can
NOTE Confidence: 0.843883554

00:26:08.906 --> 00:26:10.683 have their outcome improved by the
NOTE Confidence: 0.843883554

00:26:10.683 --> 00:26:12.785 use of edge of in Cape cited mean.
NOTE Confidence: 0.843883554

00:26:12.785 --> 00:26:14.585 So I think for both her two positive
NOTE Confidence: 0.843883554

00:26:14.585 --> 00:26:16.631 and triple negative disease we should
NOTE Confidence: 0.843883554

00:26:16.631 --> 00:26:18.043 always think about neoadjuvant
NOTE Confidence: 0.843883554

00:26:18.043 --> 00:26:19.329 therapy For these reasons,
NOTE Confidence: 0.843883554

00:26:19.330 --> 00:26:21.040 because in the post neoadjuvant
NOTE Confidence: 0.843883554

00:26:21.040 --> 00:26:23.220 setting we can improve long term
NOTE Confidence: 0.843883554

00:26:23.220 --> 00:26:24.438 outcome by intervening.
NOTE Confidence: 0.843883554

00:26:24.440 --> 00:26:26.120 For those who don't get a path CR.
NOTE Confidence: 0.812819721818182

00:26:28.600 --> 00:26:29.644 The next drug I wanted to
NOTE Confidence: 0.812819721818182

00:26:29.644 --> 00:26:30.680 talk about is to cotton.
NOTE Confidence: 0.812819721818182

00:26:30.680 --> 00:26:33.816 If so, this is a her two

NOTE Confidence: 0.812819721818182
00:26:33.816 --> 00:26:35.160 tyrosine kinase inhibitor.
NOTE Confidence: 0.812819721818182
00:26:35.160 --> 00:26:36.728 We now have three.
NOTE Confidence: 0.812819721818182
00:26:36.728 --> 00:26:38.688 Her two tyrosine kinase inhibitors
NOTE Confidence: 0.812819721818182
00:26:38.688 --> 00:26:41.446 to choose from and low to captain.
NOTE Confidence: 0.812819721818182
00:26:41.446 --> 00:26:44.296 If unlike the other two is highly
NOTE Confidence: 0.812819721818182
00:26:44.296 --> 00:26:47.218 selective just for her two without
NOTE Confidence: 0.812819721818182
00:26:47.218 --> 00:26:49.679 hitting the other members of
NOTE Confidence: 0.812819721818182
00:26:49.679 --> 00:26:51.974 the her two receptor family,
NOTE Confidence: 0.812819721818182
00:26:51.980 --> 00:26:53.968 you can see here that there's no
NOTE Confidence: 0.812819721818182
00:26:53.968 --> 00:26:55.569 activity against the EGF receptor.
NOTE Confidence: 0.812819721818182
00:26:55.570 --> 00:26:58.150 Let Patton in has an Nurettin.
NOTE Confidence: 0.812819721818182
00:26:58.150 --> 00:27:00.200 They both have equivalent activity
NOTE Confidence: 0.812819721818182
00:27:00.200 --> 00:27:02.250 against the EGF receptor interaction.
NOTE Confidence: 0.812819721818182
00:27:02.250 --> 00:27:03.560 If actually inhibits all of
NOTE Confidence: 0.812819721818182
00:27:03.560 --> 00:27:04.870 the receptors in this family.
NOTE Confidence: 0.88725716

00:27:07.180 --> 00:27:11.052 So the her two climb trial looked
NOTE Confidence: 0.88725716

00:27:11.052 --> 00:27:13.815 at the introduction of Takata nib in
NOTE Confidence: 0.88725716

00:27:13.815 --> 00:27:15.815 the metastatic setting for patients
NOTE Confidence: 0.88725716

00:27:15.815 --> 00:27:18.972 who had prior first line therapy with
NOTE Confidence: 0.88725716

00:27:18.972 --> 00:27:21.252 trastuzumab and second line therapy
NOTE Confidence: 0.88725716

00:27:21.260 --> 00:27:23.829 with TDM one an the really important
NOTE Confidence: 0.88725716

00:27:23.829 --> 00:27:26.475 part of this trial as Merriam has
NOTE Confidence: 0.88725716

00:27:26.475 --> 00:27:29.248 shown you is that this trial welcomed
NOTE Confidence: 0.88725716

00:27:29.248 --> 00:27:31.718 patients with brain metastases and
NOTE Confidence: 0.88725716

00:27:31.718 --> 00:27:34.756 not only treated brain metastases but
NOTE Confidence: 0.88725716

00:27:34.756 --> 00:27:37.396 even untreated or progressing brain.
NOTE Confidence: 0.88725716

00:27:37.400 --> 00:27:39.600 Test icees because the earlier
NOTE Confidence: 0.88725716

00:27:39.600 --> 00:27:42.285 phase trials with this drug showed
NOTE Confidence: 0.88725716

00:27:42.285 --> 00:27:44.310 good activity in the CNS,
NOTE Confidence: 0.88725716

00:27:44.310 --> 00:27:47.488 and so patients in this trial were
NOTE Confidence: 0.88725716

00:27:47.488 --> 00:27:50.297 randomized to therapy with trastuzumab in

NOTE Confidence: 0.88725716

00:27:50.297 --> 00:27:54.210 capeside of being with or without to continu.

NOTE Confidence: 0.88725716

00:27:54.210 --> 00:27:56.142 And in this trial,

NOTE Confidence: 0.88725716

00:27:56.142 --> 00:27:59.040 almost half of the patients entered

NOTE Confidence: 0.88725716

00:27:59.139 --> 00:28:01.110 with brain metastases.

NOTE Confidence: 0.88725716

00:28:01.110 --> 00:28:03.100 About 60% of them were

NOTE Confidence: 0.88725716

00:28:03.100 --> 00:28:04.294 treated brain metastases,

NOTE Confidence: 0.88725716

00:28:04.300 --> 00:28:07.120 but the rest were untreated

NOTE Confidence: 0.88725716

00:28:07.120 --> 00:28:09.376 or treated but progressing.

NOTE Confidence: 0.88725716

00:28:09.380 --> 00:28:12.345 And the overall population showed

NOTE Confidence: 0.88725716

00:28:12.345 --> 00:28:14.717 an improvement in progression

NOTE Confidence: 0.88725716

00:28:14.717 --> 00:28:16.996 free survival of 2.2 months.

NOTE Confidence: 0.88725716

00:28:16.996 --> 00:28:18.586 An improvement in overall survival

NOTE Confidence: 0.88725716

00:28:18.586 --> 00:28:20.369 of four and a half months.

NOTE Confidence: 0.88725716

00:28:20.370 --> 00:28:22.603 So this was an important trial showing

NOTE Confidence: 0.88725716

00:28:22.603 --> 00:28:24.589 an improvement in overall survival.

NOTE Confidence: 0.88725716

00:28:24.590 --> 00:28:26.980 And the response rate nearly
NOTE Confidence: 0.88725716

00:28:26.980 --> 00:28:29.302 doubled from 23% to 41%.
NOTE Confidence: 0.88725716

00:28:29.302 --> 00:28:31.572 An in patients with brain
NOTE Confidence: 0.88725716

00:28:31.572 --> 00:28:34.148 metastases who entered the trial,
NOTE Confidence: 0.88725716

00:28:34.150 --> 00:28:36.660 they achieved the same benefit
NOTE Confidence: 0.88725716

00:28:36.660 --> 00:28:38.930 of a 2.2% month improvement
NOTE Confidence: 0.88725716

00:28:38.930 --> 00:28:40.610 in progression free survival.
NOTE Confidence: 0.854608315789474

00:28:43.110 --> 00:28:45.762 Interestingly, the objective response
NOTE Confidence: 0.854608315789474

00:28:45.762 --> 00:28:49.740 in the brain metastases of patients
NOTE Confidence: 0.854608315789474

00:28:49.833 --> 00:28:53.163 who had active brain metastases by
NOTE Confidence: 0.854608315789474

00:28:53.163 --> 00:28:55.814 resist criteria were 47% versus 20%
NOTE Confidence: 0.854608315789474

00:28:55.814 --> 00:28:58.110 because we know Cape cited being also
NOTE Confidence: 0.854608315789474

00:28:58.173 --> 00:29:00.375 does cross the blood brain barrier.
NOTE Confidence: 0.854608315789474

00:29:00.380 --> 00:29:03.080 So remarkably, almost half of patients
NOTE Confidence: 0.854608315789474

00:29:03.080 --> 00:29:05.403 had objective response by recist
NOTE Confidence: 0.854608315789474

00:29:05.403 --> 00:29:07.653 criteria in their brain metastases

NOTE Confidence: 0.854608315789474
00:29:07.653 --> 00:29:10.300 that were active brain metastases.
NOTE Confidence: 0.854608315789474
00:29:10.300 --> 00:29:12.298 So this drug is quite active.
NOTE Confidence: 0.854608315789474
00:29:12.300 --> 00:29:15.387 In the CNS and this slide shows
NOTE Confidence: 0.854608315789474
00:29:15.387 --> 00:29:16.710 the CNS progression,
NOTE Confidence: 0.854608315789474
00:29:16.710 --> 00:29:18.995 free survival of the patients
NOTE Confidence: 0.854608315789474
00:29:18.995 --> 00:29:20.366 with brain metastases,
NOTE Confidence: 0.854608315789474
00:29:20.370 --> 00:29:22.848 and it improved by nearly six
NOTE Confidence: 0.854608315789474
00:29:22.848 --> 00:29:24.654 months from 4.2 months.
NOTE Confidence: 0.854608315789474
00:29:24.654 --> 00:29:27.089 Median progression free survival to
NOTE Confidence: 0.854608315789474
00:29:27.089 --> 00:29:30.070 almost 10 months and at one year 40%
NOTE Confidence: 0.854608315789474
00:29:30.070 --> 00:29:32.170 of the patients had not had brain
NOTE Confidence: 0.854608315789474
00:29:32.170 --> 00:29:34.040 progression in the experimental arm,
NOTE Confidence: 0.854608315789474
00:29:34.040 --> 00:29:37.246 whereas none of the patients in the
NOTE Confidence: 0.854608315789474
00:29:37.246 --> 00:29:40.749 standard arm still are without progression.
NOTE Confidence: 0.854608315789474
00:29:40.750 --> 00:29:42.364 And this show is in the
NOTE Confidence: 0.854608315789474

00:29:42.364 --> 00:29:43.440 patients with brain metastases.
NOTE Confidence: 0.854608315789474

00:29:43.440 --> 00:29:44.820 The overall survival,
NOTE Confidence: 0.854608315789474

00:29:44.820 --> 00:29:47.580 which was improved by six months
NOTE Confidence: 0.854608315789474

00:29:47.580 --> 00:29:49.919 from 12 months to 18 months,
NOTE Confidence: 0.854608315789474

00:29:49.920 --> 00:29:52.440 so really important results in the CNS.
NOTE Confidence: 0.854608315789474

00:29:52.440 --> 00:29:54.862 And because this is such a active
NOTE Confidence: 0.854608315789474

00:29:54.862 --> 00:29:57.380 drug and with these good results,
NOTE Confidence: 0.854608315789474

00:29:57.380 --> 00:30:00.152 it's now being tested in the second
NOTE Confidence: 0.854608315789474

00:30:00.152 --> 00:30:03.485 line in the her two climb 02 trial
NOTE Confidence: 0.854608315789474

00:30:03.485 --> 00:30:06.160 which is looking at second line T
NOTE Confidence: 0.854608315789474

00:30:06.160 --> 00:30:08.680 DM one versus T DM 1 + 2 cotton.
NOTE Confidence: 0.819517523

00:30:11.060 --> 00:30:12.674 The next drug I want to
NOTE Confidence: 0.819517523

00:30:12.674 --> 00:30:13.750 talk about is trastuzumab.
NOTE Confidence: 0.819517523

00:30:13.750 --> 00:30:16.276 Dear XD can this is another
NOTE Confidence: 0.819517523

00:30:16.276 --> 00:30:18.380 antibody drug conjugate like TDM
NOTE Confidence: 0.819517523

00:30:18.380 --> 00:30:20.795 one and the table on the right

NOTE Confidence: 0.819517523

00:30:20.795 --> 00:30:22.705 compares it to TDM one TDM.

NOTE Confidence: 0.819517523

00:30:22.705 --> 00:30:24.630 One has the payload being

NOTE Confidence: 0.819517523

00:30:24.630 --> 00:30:25.785 a tubulin inhibitor.

NOTE Confidence: 0.819517523

00:30:25.790 --> 00:30:27.890 This drug has a topoisomerase

NOTE Confidence: 0.819517523

00:30:27.890 --> 00:30:30.453 one inhibitor and this drug also

NOTE Confidence: 0.819517523

00:30:30.453 --> 00:30:33.134 has what's called a stand by a

NOTE Confidence: 0.819517523

00:30:33.134 --> 00:30:35.264 bystander effect because when the

NOTE Confidence: 0.819517523

00:30:35.264 --> 00:30:37.404 targeted drug when the payload

NOTE Confidence: 0.819517523

00:30:37.404 --> 00:30:39.565 is cleared from the antibody,

NOTE Confidence: 0.819517523

00:30:39.565 --> 00:30:41.305 it actually can diffuse.

NOTE Confidence: 0.819517523

00:30:41.310 --> 00:30:43.638 Through the membrane of the cell.

NOTE Confidence: 0.819517523

00:30:43.640 --> 00:30:45.722 So if there is heterogeneity of

NOTE Confidence: 0.819517523

00:30:45.722 --> 00:30:47.890 the her two expression in a tumor,

NOTE Confidence: 0.819517523

00:30:47.890 --> 00:30:49.920 you can get killing of cells that

NOTE Confidence: 0.819517523

00:30:49.920 --> 00:30:51.850 perhaps have lower levels of her two.

NOTE Confidence: 0.819517523

00:30:51.850 --> 00:30:55.590 By this bystander effect.
NOTE Confidence: 0.819517523

00:30:55.590 --> 00:30:57.510 And in phase one trials,
NOTE Confidence: 0.819517523

00:30:57.510 --> 00:30:59.742 this drug was extremely active in
NOTE Confidence: 0.819517523

00:30:59.742 --> 00:31:01.986 her two positive breast cancer and
NOTE Confidence: 0.819517523

00:31:01.986 --> 00:31:03.711 her two positive gastric cancer
NOTE Confidence: 0.819517523

00:31:03.711 --> 00:31:05.856 as well as even breast cancers
NOTE Confidence: 0.819517523

00:31:05.856 --> 00:31:08.271 that had lower levels of her two.
NOTE Confidence: 0.819517523

00:31:08.280 --> 00:31:10.105 Perhaps because of this bystander
NOTE Confidence: 0.819517523

00:31:10.105 --> 00:31:12.374 effect in cells that had heterogeneous
NOTE Confidence: 0.819517523

00:31:12.374 --> 00:31:14.606 levels of her two expression and
NOTE Confidence: 0.819517523

00:31:14.606 --> 00:31:17.606 in phase one trials overall 86% of
NOTE Confidence: 0.819517523

00:31:17.606 --> 00:31:20.882 subjects had at least some tumor shrinkage.
NOTE Confidence: 0.819517523

00:31:20.890 --> 00:31:22.746 And so the trial that got this drug,
NOTE Confidence: 0.819517523

00:31:22.750 --> 00:31:25.590 FDA approved was the destiny of 1 trial,
NOTE Confidence: 0.819517523

00:31:25.590 --> 00:31:27.246 which was a single arm phase,
NOTE Confidence: 0.819517523

00:31:27.250 --> 00:31:29.680 two trial and patients in the

NOTE Confidence: 0.819517523

00:31:29.680 --> 00:31:32.116 metastatic setting had to have prior

NOTE Confidence: 0.819517523

00:31:32.116 --> 00:31:34.692 trastuzumab an prior TDM one and 2/3

NOTE Confidence: 0.819517523

00:31:34.692 --> 00:31:37.648 of them also had prior per Susan Mab.

NOTE Confidence: 0.819517523

00:31:37.650 --> 00:31:40.499 Almost all of them had visceral metastases,

NOTE Confidence: 0.819517523

00:31:40.500 --> 00:31:42.999 and this was a fairly late line

NOTE Confidence: 0.819517523

00:31:42.999 --> 00:31:45.398 trial with the median number of

NOTE Confidence: 0.819517523

00:31:45.398 --> 00:31:47.882 lines of prior therapy being 6.

NOTE Confidence: 0.819517523

00:31:47.890 --> 00:31:50.110 And despite this being a Lateline

NOTE Confidence: 0.819517523

00:31:50.110 --> 00:31:51.220 trial once again,

NOTE Confidence: 0.819517523

00:31:51.220 --> 00:31:53.660 the activity was really dramatic

NOTE Confidence: 0.819517523

00:31:53.660 --> 00:31:56.100 with almost all patients having

NOTE Confidence: 0.819517523

00:31:56.177 --> 00:31:58.829 at least some shrinkage of their

NOTE Confidence: 0.819517523

00:31:58.829 --> 00:32:00.597 tumor by recist criteria,

NOTE Confidence: 0.819517523

00:32:00.600 --> 00:32:04.248 a 60% confirmed objective response rate,

NOTE Confidence: 0.819517523

00:32:04.250 --> 00:32:07.496 a Disease Control rate of 97%,

NOTE Confidence: 0.819517523

00:32:07.496 --> 00:32:11.328 an 11 out of 168 patients with complete

NOTE Confidence: 0.819517523

00:32:11.328 --> 00:32:13.438 responses in their metastatic disease.

NOTE Confidence: 0.819517523

00:32:13.440 --> 00:32:15.420 So an amazingly active drug,

NOTE Confidence: 0.819517523

00:32:15.420 --> 00:32:18.668 even in a very late line setting.

NOTE Confidence: 0.819517523

00:32:18.670 --> 00:32:20.848 Excuse me and and despite this

NOTE Confidence: 0.819517523

00:32:20.848 --> 00:32:22.300 being a Lateline setting,

NOTE Confidence: 0.819517523

00:32:22.300 --> 00:32:24.740 these were really durable responses

NOTE Confidence: 0.819517523

00:32:24.740 --> 00:32:27.752 as well with their median duration

NOTE Confidence: 0.819517523

00:32:27.752 --> 00:32:30.680 of response of almost 15 months

NOTE Confidence: 0.819517523

00:32:30.680 --> 00:32:33.332 and overall survival at one year

NOTE Confidence: 0.819517523

00:32:33.332 --> 00:32:35.741 still being 86% despite being

NOTE Confidence: 0.819517523

00:32:35.741 --> 00:32:38.526 six line therapy on average.

NOTE Confidence: 0.819517523

00:32:38.530 --> 00:32:40.791 The one huge caveat with this drug

NOTE Confidence: 0.819517523

00:32:40.791 --> 00:32:43.909 is to watch out for the side effect

NOTE Confidence: 0.819517523

00:32:43.909 --> 00:32:45.565 of interstitial lung disease,

NOTE Confidence: 0.819517523

00:32:45.570 --> 00:32:46.970 or pneumonitis,

NOTE Confidence: 0.819517523

00:32:46.970 --> 00:32:50.524 which occur in almost 1415% of

NOTE Confidence: 0.819517523

00:32:50.524 --> 00:32:53.654 patients and in two point 2% of patients.

NOTE Confidence: 0.819517523

00:32:53.654 --> 00:32:55.814 It was actually a fatal,

NOTE Confidence: 0.819517523

00:32:55.820 --> 00:32:57.626 so the one caveat with this drug

NOTE Confidence: 0.819517523

00:32:57.626 --> 00:32:59.801 is to be highly vision vigilant

NOTE Confidence: 0.819517523

00:32:59.801 --> 00:33:02.031 for any respiratory symptoms that

NOTE Confidence: 0.819517523

00:33:02.031 --> 00:33:03.750 could indicate pneumonitis.

NOTE Confidence: 0.819517523

00:33:03.750 --> 00:33:06.039 And because this drug is so active,

NOTE Confidence: 0.819517523

00:33:06.040 --> 00:33:08.746 it's being tested in a number

NOTE Confidence: 0.819517523

00:33:08.746 --> 00:33:10.550 of other settings now.

NOTE Confidence: 0.819517523

00:33:10.550 --> 00:33:12.410 We have accelerated approval based

NOTE Confidence: 0.819517523

00:33:12.410 --> 00:33:14.926 on the single ARM trial that I

NOTE Confidence: 0.819517523

00:33:14.926 --> 00:33:16.696 just showed you the destiny O2

NOTE Confidence: 0.819517523

00:33:16.696 --> 00:33:18.699 trial is the definitive trial.

NOTE Confidence: 0.819517523

00:33:18.700 --> 00:33:20.392 Comparing this drug to treatment of

NOTE Confidence: 0.819517523

00:33:20.392 --> 00:33:22.550 physicians choice in a phase three setting.

NOTE Confidence: 0.819517523

00:33:22.550 --> 00:33:24.140 With these options,

NOTE Confidence: 0.819517523

00:33:24.140 --> 00:33:26.790 the Destiny 03 is comparing

NOTE Confidence: 0.819517523

00:33:26.790 --> 00:33:29.404 this after first line therapy

NOTE Confidence: 0.819517523

00:33:29.404 --> 00:33:32.326 head to head against TDM one.

NOTE Confidence: 0.819517523

00:33:32.330 --> 00:33:33.845 So it's just using web

NOTE Confidence: 0.819517523

00:33:33.845 --> 00:33:35.057 touristy can versus TDM.

NOTE Confidence: 0.8611110825

00:33:35.060 --> 00:33:36.308 One in second line.

NOTE Confidence: 0.8611110825

00:33:36.308 --> 00:33:38.573 The Destiny 04 trial is looking at

NOTE Confidence: 0.8611110825

00:33:38.573 --> 00:33:40.553 her two low breast cancer patients

NOTE Confidence: 0.8611110825

00:33:40.553 --> 00:33:42.649 because I showed you in phase one.

NOTE Confidence: 0.8611110825

00:33:42.650 --> 00:33:44.830 Trials responses in those patients.

NOTE Confidence: 0.8611110825

00:33:44.830 --> 00:33:48.286 So this is just using map touristy can

NOTE Confidence: 0.8611110825

00:33:48.286 --> 00:33:50.799 versus chemotherapy of physicians choice,

NOTE Confidence: 0.8611110825

00:33:50.800 --> 00:33:52.900 and in Destiny 05 it's actually

NOTE Confidence: 0.8611110825

00:33:52.900 --> 00:33:55.433 being compared to TDM one in the

NOTE Confidence: 0.8611110825

00:33:55.433 --> 00:33:57.208 in the post neoadjuvant setting.

NOTE Confidence: 0.8611110825

00:33:57.210 --> 00:33:58.884 As per the Catherine trial where

NOTE Confidence: 0.8611110825

00:33:58.884 --> 00:34:00.397 patients who get into management

NOTE Confidence: 0.8611110825

00:34:00.397 --> 00:34:02.102 therapy and have residual disease

NOTE Confidence: 0.8611110825

00:34:02.102 --> 00:34:04.026 will be randomized to TDM one

NOTE Confidence: 0.8611110825

00:34:04.026 --> 00:34:05.538 or try D'souza Mabdi rixty cat.

NOTE Confidence: 0.8611110825

00:34:05.540 --> 00:34:08.504 So being tested in all of

NOTE Confidence: 0.8611110825

00:34:08.504 --> 00:34:09.986 these different settings.

NOTE Confidence: 0.8611110825

00:34:09.990 --> 00:34:13.161 Another her two targeting drug that was

NOTE Confidence: 0.8611110825

00:34:13.161 --> 00:34:15.769 just recently approved is margetuximab,

NOTE Confidence: 0.8611110825

00:34:15.770 --> 00:34:19.417 and this is actually a derivative of

NOTE Confidence: 0.8611110825

00:34:19.417 --> 00:34:23.134 her of trastuzumab that has the FC

NOTE Confidence: 0.8611110825

00:34:23.134 --> 00:34:25.584 Gamma portion replaced by another

NOTE Confidence: 0.8611110825

00:34:25.584 --> 00:34:28.296 FC Gamma alteration that has a

NOTE Confidence: 0.8611110825

00:34:28.296 --> 00:34:30.644 higher affinity for activating FC

NOTE Confidence: 0.8611110825

00:34:30.644 --> 00:34:33.356 Gamma receptor and a lower affinity
NOTE Confidence: 0.8611110825

00:34:33.356 --> 00:34:36.200 for inhibitory FC Gamma receptor.
NOTE Confidence: 0.8611110825

00:34:36.200 --> 00:34:38.224 And this is based on the fact that
NOTE Confidence: 0.8611110825

00:34:38.224 --> 00:34:40.397 we know that trastuzumab is not
NOTE Confidence: 0.8611110825

00:34:40.397 --> 00:34:42.402 only a targeted signal transduction.
NOTE Confidence: 0.8611110825

00:34:42.410 --> 00:34:45.250 Drug, but it is that immunotherapy as well.
NOTE Confidence: 0.8611110825

00:34:45.250 --> 00:34:47.146 That does recruit the immune system,
NOTE Confidence: 0.8611110825

00:34:47.150 --> 00:34:49.642 and so it was thought by making
NOTE Confidence: 0.8611110825

00:34:49.642 --> 00:34:51.625 transducer maps more able to
NOTE Confidence: 0.8611110825

00:34:51.625 --> 00:34:53.730 actively recruit the immune system.
NOTE Confidence: 0.8611110825

00:34:53.730 --> 00:34:56.238 It may give it enhanced activity,
NOTE Confidence: 0.8611110825

00:34:56.240 --> 00:34:59.597 and so this was tested in the Sophia trial,
NOTE Confidence: 0.8611110825

00:34:59.600 --> 00:35:02.407 which was a phase three trial of
NOTE Confidence: 0.8611110825

00:35:02.407 --> 00:35:04.185 transducer Med chemotherapy versus
NOTE Confidence: 0.8611110825

00:35:04.185 --> 00:35:05.691 margetuximab plus chemotherapy
NOTE Confidence: 0.8611110825

00:35:05.691 --> 00:35:07.699 in later line therapy,

NOTE Confidence: 0.8611110825

00:35:07.700 --> 00:35:10.684 and there was a fairly small positive result.

NOTE Confidence: 0.8611110825

00:35:10.690 --> 00:35:12.608 As you can see here in progression.

NOTE Confidence: 0.8611110825

00:35:12.610 --> 00:35:16.068 Free survival improving by about two months,

NOTE Confidence: 0.8611110825

00:35:16.070 --> 00:35:17.550 so not a huge result,

NOTE Confidence: 0.8611110825

00:35:17.550 --> 00:35:20.110 but enough to get this drug FDA approved.

NOTE Confidence: 0.8611110825

00:35:20.110 --> 00:35:22.945 So it's now part of our armamentarium

NOTE Confidence: 0.8611110825

00:35:22.950 --> 00:35:24.792 and the final her two targeting

NOTE Confidence: 0.8611110825

00:35:24.792 --> 00:35:26.620 drug recently approved is narrative,

NOTE Confidence: 0.8611110825

00:35:26.620 --> 00:35:29.076 which was tested in the Nala trial and

NOTE Confidence: 0.8611110825

00:35:29.076 --> 00:35:31.989 this was a trial of Neurontin and Capeside,

NOTE Confidence: 0.8611110825

00:35:31.990 --> 00:35:33.958 it being versus LA patented capeside

NOTE Confidence: 0.8611110825

00:35:33.958 --> 00:35:36.312 of being in patients who had at

NOTE Confidence: 0.8611110825

00:35:36.312 --> 00:35:38.280 least two prior therapies for their

NOTE Confidence: 0.8611110825

00:35:38.280 --> 00:35:39.929 metastatic her two positive disease

NOTE Confidence: 0.8611110825

00:35:39.929 --> 00:35:42.092 and the new rotten if compared to

NOTE Confidence: 0.8611110825

00:35:42.092 --> 00:35:43.926 La Pata nib did have an improved
NOTE Confidence: 0.8611110825

00:35:43.926 --> 00:35:44.960 progression free survival.
NOTE Confidence: 0.8611110825

00:35:44.960 --> 00:35:45.762 Overall response,
NOTE Confidence: 0.8611110825

00:35:45.762 --> 00:35:48.970 and perhaps a little bit in overall survival.
NOTE Confidence: 0.8611110825

00:35:48.970 --> 00:35:52.226 None of these patients had prior to continu,
NOTE Confidence: 0.8611110825

00:35:52.230 --> 00:35:54.606 and so in the era now of using
NOTE Confidence: 0.8611110825

00:35:54.606 --> 00:35:55.200 two continents,
NOTE Confidence: 0.8611110825

00:35:55.200 --> 00:35:57.576 it will be difficult to know if there really
NOTE Confidence: 0.8611110825

00:35:57.576 --> 00:35:59.978 is a place for new ratine in metastatic.
NOTE Confidence: 0.8611110825

00:35:59.980 --> 00:36:03.148 Her two positive disease.
NOTE Confidence: 0.8611110825

00:36:03.150 --> 00:36:03.630 And so,
NOTE Confidence: 0.8611110825

00:36:03.630 --> 00:36:04.590 as I showed you,
NOTE Confidence: 0.8611110825

00:36:04.590 --> 00:36:07.390 we now have many drugs to choose from.
NOTE Confidence: 0.8611110825

00:36:07.390 --> 00:36:09.770 An I oppose this as a reasonable
NOTE Confidence: 0.8611110825

00:36:09.770 --> 00:36:11.613 order sequence of therapy that
NOTE Confidence: 0.8611110825

00:36:11.613 --> 00:36:14.231 we can use for her two positive

NOTE Confidence: 0.8611110825

00:36:14.231 --> 00:36:15.840 metastatic disease patients.

NOTE Confidence: 0.8611110825

00:36:15.840 --> 00:36:17.140 In the first line,

NOTE Confidence: 0.8611110825

00:36:17.140 --> 00:36:18.440 therapy should have pertuzumab,

NOTE Confidence: 0.8611110825

00:36:18.440 --> 00:36:18.950 trastuzumab,

NOTE Confidence: 0.8611110825

00:36:18.950 --> 00:36:22.010 and taxane because of the remarkable

NOTE Confidence: 0.8611110825

00:36:22.010 --> 00:36:23.980 overall survival benefit seen

NOTE Confidence: 0.8611110825

00:36:23.980 --> 00:36:25.815 in the Cleopatra trial TDM,

NOTE Confidence: 0.8611110825

00:36:25.820 --> 00:36:28.039 one is still considered the second line

NOTE Confidence: 0.8611110825

00:36:28.039 --> 00:36:30.173 therapy as per the Amelia trial and

NOTE Confidence: 0.8611110825

00:36:30.173 --> 00:36:32.689 we now can consider a third line therapy.

NOTE Confidence: 0.8611110825

00:36:32.690 --> 00:36:34.622 Being just do some AB capeside it

NOTE Confidence: 0.8611110825

00:36:34.622 --> 00:36:36.716 being into cotton if since we have

NOTE Confidence: 0.8611110825

00:36:36.716 --> 00:36:38.231 seen an improvement in overall

NOTE Confidence: 0.8611110825

00:36:38.231 --> 00:36:39.913 survival in the her two climb

NOTE Confidence: 0.8611110825

00:36:39.913 --> 00:36:41.238 study and this is especially

NOTE Confidence: 0.837415576470588

00:36:41.240 --> 00:36:43.196 of course attractive for patients who
NOTE Confidence: 0.837415576470588

00:36:43.196 --> 00:36:45.280 may already have brain metastases from
NOTE Confidence: 0.837415576470588

00:36:45.280 --> 00:36:47.430 their her two positive disease and
NOTE Confidence: 0.837415576470588

00:36:47.430 --> 00:36:49.230 then perhaps enforced line therapy,
NOTE Confidence: 0.837415576470588

00:36:49.230 --> 00:36:50.490 we could use a trust.
NOTE Confidence: 0.837415576470588

00:36:50.490 --> 00:36:52.094 Susan abjure Exede can,
NOTE Confidence: 0.837415576470588

00:36:52.094 --> 00:36:54.500 although this may ultimately compete with
NOTE Confidence: 0.837415576470588

00:36:54.568 --> 00:36:57.136 the her two climb regimen for third line
NOTE Confidence: 0.837415576470588

00:36:57.136 --> 00:36:59.448 therapy and then in late line therapy,
NOTE Confidence: 0.837415576470588

00:36:59.450 --> 00:37:01.613 perhaps we might want to use margetuximab
NOTE Confidence: 0.837415576470588

00:37:01.613 --> 00:37:03.869 for the slight edge it might have over
NOTE Confidence: 0.837415576470588

00:37:03.869 --> 00:37:06.189 trust using map in the Wave line therapy.
NOTE Confidence: 0.837415576470588

00:37:06.190 --> 00:37:09.746 Moving on to triple negative breast cancer.
NOTE Confidence: 0.837415576470588

00:37:09.750 --> 00:37:12.249 We now have five or six targeted
NOTE Confidence: 0.837415576470588

00:37:12.249 --> 00:37:14.490 drugs that are approved for
NOTE Confidence: 0.837415576470588

00:37:14.490 --> 00:37:16.670 triple negative breast cancer.

NOTE Confidence: 0.837415576470588

00:37:16.670 --> 00:37:19.928 We have two park inhibitors are lab rib and

NOTE Confidence: 0.837415576470588

00:37:19.928 --> 00:37:23.448 no tell is operated as Merriam showed you,

NOTE Confidence: 0.837415576470588

00:37:23.450 --> 00:37:26.126 we now have two checkpoint inhibitors,

NOTE Confidence: 0.837415576470588

00:37:26.130 --> 00:37:27.954 anti PDL, one drugs at Season

NOTE Confidence: 0.837415576470588

00:37:27.954 --> 00:37:29.759 11 map and Pember Lism AB.

NOTE Confidence: 0.837415576470588

00:37:29.760 --> 00:37:31.440 We have an antibody drug conjugate

NOTE Confidence: 0.837415576470588

00:37:31.440 --> 00:37:33.418 and I kind of include carboplatin

NOTE Confidence: 0.837415576470588

00:37:33.418 --> 00:37:35.800 as a targeted therapy for triple

NOTE Confidence: 0.837415576470588

00:37:35.800 --> 00:37:37.629 negative breast cancer because if

NOTE Confidence: 0.837415576470588

00:37:37.629 --> 00:37:39.573 you remember from the TNT trial,

NOTE Confidence: 0.837415576470588

00:37:39.580 --> 00:37:42.928 particularly patients who had germline BRCA.

NOTE Confidence: 0.837415576470588

00:37:42.930 --> 00:37:43.328 Mutations.

NOTE Confidence: 0.837415576470588

00:37:43.328 --> 00:37:45.716 They had a remarkable high response

NOTE Confidence: 0.837415576470588

00:37:45.716 --> 00:37:47.733 rate to single agent carboplatin

NOTE Confidence: 0.837415576470588

00:37:47.733 --> 00:37:50.790 about a 60% response rate for germline

NOTE Confidence: 0.837415576470588

00:37:50.790 --> 00:37:53.955 carriers and that is applies to not
NOTE Confidence: 0.837415576470588

00:37:53.955 --> 00:37:56.445 only triple negative disease but any
NOTE Confidence: 0.837415576470588

00:37:56.445 --> 00:37:59.017 germ line BRCA mutation carriers.
NOTE Confidence: 0.837415576470588

00:37:59.020 --> 00:38:01.990 So in terms of immunotherapy,
NOTE Confidence: 0.837415576470588

00:38:01.990 --> 00:38:04.630 we have two positive results in
NOTE Confidence: 0.837415576470588

00:38:04.630 --> 00:38:05.950 the metastatic setting.
NOTE Confidence: 0.837415576470588

00:38:05.950 --> 00:38:08.092 I think the results aren't as
NOTE Confidence: 0.837415576470588

00:38:08.092 --> 00:38:09.882 enormously impressive as they are
NOTE Confidence: 0.837415576470588

00:38:09.882 --> 00:38:11.646 in some other types of cancer,
NOTE Confidence: 0.837415576470588

00:38:11.650 --> 00:38:14.630 like Melanoma or lung cancer,
NOTE Confidence: 0.837415576470588

00:38:14.630 --> 00:38:16.430 but they are positive results,
NOTE Confidence: 0.837415576470588

00:38:16.430 --> 00:38:18.902 and so we now have these that we
NOTE Confidence: 0.837415576470588

00:38:18.902 --> 00:38:21.955 can use in the IMPASSION 130 trial
NOTE Confidence: 0.837415576470588

00:38:21.955 --> 00:38:24.976 atisa lism AB versus placebo was
NOTE Confidence: 0.837415576470588

00:38:24.976 --> 00:38:26.960 added to nab paclitaxel,
NOTE Confidence: 0.837415576470588

00:38:26.960 --> 00:38:30.019 an in the PDL 1 positive patients.

NOTE Confidence: 0.837415576470588
00:38:30.020 --> 00:38:32.085 There was a two to three month
NOTE Confidence: 0.837415576470588
00:38:32.085 --> 00:38:33.749 improvement in progression Free Survival,
NOTE Confidence: 0.837415576470588
00:38:33.750 --> 00:38:36.198 a significant improvement in response rate,
NOTE Confidence: 0.837415576470588
00:38:36.200 --> 00:38:37.540 and if this holds up,
NOTE Confidence: 0.837415576470588
00:38:37.540 --> 00:38:40.255 but perhaps an impressive improvement
NOTE Confidence: 0.837415576470588
00:38:40.255 --> 00:38:41.884 in overall survival,
NOTE Confidence: 0.837415576470588
00:38:41.890 --> 00:38:44.614 the Keynote 355 was a similar
NOTE Confidence: 0.837415576470588
00:38:44.614 --> 00:38:46.860 trial using Pember Lizum app,
NOTE Confidence: 0.837415576470588
00:38:46.860 --> 00:38:48.655 and the chemotherapy might have
NOTE Confidence: 0.837415576470588
00:38:48.655 --> 00:38:51.125 been nap after taxol or path that
NOTE Confidence: 0.837415576470588
00:38:51.125 --> 00:38:53.253 axle or gem carbo in first line.
NOTE Confidence: 0.837415576470588
00:38:53.260 --> 00:38:55.336 Setting again and in those with
NOTE Confidence: 0.837415576470588
00:38:55.336 --> 00:38:57.379 the CPS score greater than 10%,
NOTE Confidence: 0.837415576470588
00:38:57.380 --> 00:38:59.535 an improvement in progression free
NOTE Confidence: 0.837415576470588
00:38:59.535 --> 00:39:01.690 survival of almost four months.
NOTE Confidence: 0.837415576470588

00:39:01.690 --> 00:39:04.178 And so we now have either of these
NOTE Confidence: 0.837415576470588

00:39:04.178 --> 00:39:06.090 drugs atisa lism AB or embolism
NOTE Confidence: 0.837415576470588

00:39:06.090 --> 00:39:08.397 AB for approval for PD L1 positive
NOTE Confidence: 0.837415576470588

00:39:08.397 --> 00:39:10.833 patients by the appropriate assay I
NOTE Confidence: 0.837415576470588

00:39:10.833 --> 00:39:13.875 might add in the first line setting
NOTE Confidence: 0.837415576470588

00:39:13.875 --> 00:39:15.655 with these chemotherapy agents
NOTE Confidence: 0.837415576470588

00:39:15.655 --> 00:39:17.825 there was another trial looking at
NOTE Confidence: 0.837415576470588

00:39:17.825 --> 00:39:20.699 a teasel is a map with paclitaxel,
NOTE Confidence: 0.837415576470588

00:39:20.700 --> 00:39:23.886 the impassioned 131 and interesting Lee.
NOTE Confidence: 0.837415576470588

00:39:23.890 --> 00:39:25.927 This was a flat out negative trial
NOTE Confidence: 0.837415576470588

00:39:25.927 --> 00:39:27.670 with no improvement in progression.
NOTE Confidence: 0.837415576470588

00:39:27.670 --> 00:39:28.482 Free survival,
NOTE Confidence: 0.837415576470588

00:39:28.482 --> 00:39:30.512 minimal improvement in response rate
NOTE Confidence: 0.837415576470588

00:39:30.512 --> 00:39:32.958 and no improvement in overall survival.
NOTE Confidence: 0.837415576470588

00:39:32.960 --> 00:39:35.402 And the only difference between this
NOTE Confidence: 0.837415576470588

00:39:35.402 --> 00:39:38.416 and the 130 child was a nap attack,

NOTE Confidence: 0.837415576470588
00:39:38.420 --> 00:39:39.701 slow versus paclitaxel.
NOTE Confidence: 0.837415576470588
00:39:39.701 --> 00:39:42.263 So we don't really understand why
NOTE Confidence: 0.837415576470588
00:39:42.263 --> 00:39:44.048 is this one negative?
NOTE Confidence: 0.837415576470588
00:39:44.050 --> 00:39:46.416 Is there a difference in the patient
NOTE Confidence: 0.837415576470588
00:39:46.416 --> 00:39:48.040 population that was enrolled?
NOTE Confidence: 0.837415576470588
00:39:48.040 --> 00:39:49.391 It's hard to see that on the
NOTE Confidence: 0.837415576470588
00:39:49.391 --> 00:39:50.520 surface it was first line.
NOTE Confidence: 0.837415576470588
00:39:50.520 --> 00:39:51.888 Triple negative patients.
NOTE Confidence: 0.837415576470588
00:39:51.888 --> 00:39:53.712 Is there truly some
NOTE Confidence: 0.837415576470588
00:39:53.712 --> 00:39:55.080 magical difference between
NOTE Confidence: 0.76114745375
00:39:55.148 --> 00:39:57.050 Napa Taxol and path that axle?
NOTE Confidence: 0.76114745375
00:39:57.050 --> 00:39:58.286 I suspect nabbed paclitaxel
NOTE Confidence: 0.76114745375
00:39:58.286 --> 00:40:00.140 does have an edge on Paxil,
NOTE Confidence: 0.76114745375
00:40:00.140 --> 00:40:01.814 but is it really so much of an edge
NOTE Confidence: 0.76114745375
00:40:01.814 --> 00:40:03.446 that it would make this difference?
NOTE Confidence: 0.76114745375

00:40:03.450 --> 00:40:06.474 Or is it just chance because the
NOTE Confidence: 0.76114745375

00:40:06.474 --> 00:40:08.432 results with immunotherapy are
NOTE Confidence: 0.76114745375

00:40:08.432 --> 00:40:10.190 not tremendously impressive?
NOTE Confidence: 0.76114745375

00:40:10.190 --> 00:40:11.666 And is it possible that some
NOTE Confidence: 0.76114745375

00:40:11.666 --> 00:40:13.110 private trials might look positive?
NOTE Confidence: 0.76114745375

00:40:13.110 --> 00:40:15.100 Some might look at negative?
NOTE Confidence: 0.76114745375

00:40:15.100 --> 00:40:16.880 We don't know the answer,
NOTE Confidence: 0.76114745375

00:40:16.880 --> 00:40:19.666 but for now, if we use atezolizumab,
NOTE Confidence: 0.76114745375

00:40:19.670 --> 00:40:21.044 we should use it with nab
NOTE Confidence: 0.76114745375

00:40:21.044 --> 00:40:22.590 Papa Taxol and not paclitaxel.
NOTE Confidence: 0.895919262857143

00:40:26.260 --> 00:40:29.396 What about the use of immunotherapy in early
NOTE Confidence: 0.895919262857143

00:40:29.396 --> 00:40:32.428 stages of triple negative breast cancer?
NOTE Confidence: 0.895919262857143

00:40:32.430 --> 00:40:34.602 Miriam mentioned this child,
NOTE Confidence: 0.895919262857143

00:40:34.602 --> 00:40:37.435 the keynote 522 trial and the first
NOTE Confidence: 0.895919262857143

00:40:37.435 --> 00:40:38.831 interim analysis was published
NOTE Confidence: 0.895919262857143

00:40:38.831 --> 00:40:40.720 in the New England Journal,

NOTE Confidence: 0.895919262857143

00:40:40.720 --> 00:40:42.526 at which point 600 patients were

NOTE Confidence: 0.895919262857143

00:40:42.526 --> 00:40:44.567 enrolled and it showed an impressive

NOTE Confidence: 0.895919262857143

00:40:44.567 --> 00:40:46.123 difference in pathological complete

NOTE Confidence: 0.895919262857143

00:40:46.123 --> 00:40:48.306 response rate for the addition of

NOTE Confidence: 0.895919262857143

00:40:48.306 --> 00:40:50.308 Pember Lism AB to the kitchen sink,

NOTE Confidence: 0.895919262857143

00:40:50.310 --> 00:40:53.834 as Merriam explained with a 14% improvement

NOTE Confidence: 0.895919262857143

00:40:53.834 --> 00:40:55.994 in pathologic complete response rate.

NOTE Confidence: 0.895919262857143

00:40:56.000 --> 00:40:58.704 And we do know in this disease that

NOTE Confidence: 0.895919262857143

00:40:58.704 --> 00:41:00.844 pathologic complete response is a very

NOTE Confidence: 0.895919262857143

00:41:00.844 --> 00:41:02.944 strong predictor of long term outcome.

NOTE Confidence: 0.895919262857143

00:41:02.950 --> 00:41:04.630 And we know that the FDA in the

NOTE Confidence: 0.895919262857143

00:41:04.630 --> 00:41:06.466 past has said that they would

NOTE Confidence: 0.895919262857143

00:41:06.466 --> 00:41:08.171 consider drug approvals based on

NOTE Confidence: 0.895919262857143

00:41:08.171 --> 00:41:09.563 improvement in pathologic complete

NOTE Confidence: 0.895919262857143

00:41:09.563 --> 00:41:11.555 response for this type of disease.

NOTE Confidence: 0.922421592

00:41:15.620 --> 00:41:17.400 This is not yet approved,
NOTE Confidence: 0.922421592

00:41:17.400 --> 00:41:21.570 and as Marion mentioned in February,
NOTE Confidence: 0.922421592

00:41:21.570 --> 00:41:23.458 the pharmaceutical company actually
NOTE Confidence: 0.922421592

00:41:23.458 --> 00:41:26.290 asked the FDA to consider accelerated
NOTE Confidence: 0.922421592

00:41:26.360 --> 00:41:28.820 approval based on these early results.
NOTE Confidence: 0.922421592

00:41:28.820 --> 00:41:30.140 As she mentioned,
NOTE Confidence: 0.922421592

00:41:30.140 --> 00:41:33.220 there was an ODAC meeting in February
NOTE Confidence: 0.922421592

00:41:33.300 --> 00:41:36.464 and the Odacon the FDA decided at that
NOTE Confidence: 0.922421592

00:41:36.464 --> 00:41:39.740 time not yet to grant accelerated approval.
NOTE Confidence: 0.922421592

00:41:39.740 --> 00:41:42.236 Wanting further follow up and more
NOTE Confidence: 0.922421592

00:41:42.236 --> 00:41:44.670 endpoints that were still premature.
NOTE Confidence: 0.922421592

00:41:44.670 --> 00:41:46.662 In terms of event free survival
NOTE Confidence: 0.922421592

00:41:46.662 --> 00:41:47.658 and overall survival,
NOTE Confidence: 0.922421592

00:41:47.660 --> 00:41:50.060 and in fact at the time of this
NOTE Confidence: 0.922421592

00:41:50.060 --> 00:41:52.377 meeting the trial was up to over
NOTE Confidence: 0.922421592

00:41:52.377 --> 00:41:54.763 1100 patients and the path CR rate

NOTE Confidence: 0.922421592

00:41:54.763 --> 00:41:57.108 delta was a little bit different than

NOTE Confidence: 0.922421592

00:41:57.108 --> 00:41:59.286 it was with the 1st 600 patients.

NOTE Confidence: 0.922421592

00:41:59.290 --> 00:42:02.578 There was a 7% difference at that time.

NOTE Confidence: 0.922421592

00:42:02.580 --> 00:42:05.450 The P value was still quite good,

NOTE Confidence: 0.922421592

00:42:05.450 --> 00:42:07.880 but be 'cause the statistics

NOTE Confidence: 0.922421592

00:42:07.880 --> 00:42:09.824 were allowing multiple analysis.

NOTE Confidence: 0.922421592

00:42:09.830 --> 00:42:11.846 Then in order to have a

NOTE Confidence: 0.922421592

00:42:11.846 --> 00:42:12.854 statistical significance though,

NOTE Confidence: 0.922421592

00:42:12.860 --> 00:42:14.165 there was very high stringency

NOTE Confidence: 0.922421592

00:42:14.165 --> 00:42:16.237 for what the P value would need to

NOTE Confidence: 0.922421592

00:42:16.237 --> 00:42:17.889 be an it actually didn't hit it.

NOTE Confidence: 0.922421592

00:42:17.890 --> 00:42:19.222 Yet at this point,

NOTE Confidence: 0.922421592

00:42:19.222 --> 00:42:21.220 and Merriam showed you that there

NOTE Confidence: 0.922421592

00:42:21.288 --> 00:42:23.364 is ongoing analysis and we might

NOTE Confidence: 0.922421592

00:42:23.364 --> 00:42:24.748 hear about this soon.

NOTE Confidence: 0.922421592

00:42:24.750 --> 00:42:26.406 But meanwhile we have to decide
NOTE Confidence: 0.922421592

00:42:26.406 --> 00:42:29.082 to do what to do with our triple
NOTE Confidence: 0.922421592

00:42:29.082 --> 00:42:30.586 negative patients who present,
NOTE Confidence: 0.922421592

00:42:30.590 --> 00:42:33.380 especially if there are high risk
NOTE Confidence: 0.922421592

00:42:33.380 --> 00:42:35.780 patients and I will tell you
NOTE Confidence: 0.922421592

00:42:35.780 --> 00:42:37.324 that for some young,
NOTE Confidence: 0.922421592

00:42:37.330 --> 00:42:39.544 very high risk multiple node positive
NOTE Confidence: 0.922421592

00:42:39.544 --> 00:42:42.248 patients who I have encountered a since
NOTE Confidence: 0.922421592

00:42:42.248 --> 00:42:44.576 the publication of the first data.
NOTE Confidence: 0.922421592

00:42:44.580 --> 00:42:46.470 I have used this regimen even though
NOTE Confidence: 0.922421592

00:42:46.470 --> 00:42:48.807 it is not FDA approved and we still
NOTE Confidence: 0.922421592

00:42:48.807 --> 00:42:50.810 don't know the long term outcome.
NOTE Confidence: 0.922421592

00:42:50.810 --> 00:42:52.658 I've had insurance companies
NOTE Confidence: 0.922421592

00:42:52.658 --> 00:42:54.968 agree to improve this approved.
NOTE Confidence: 0.922421592

00:42:54.970 --> 00:42:57.545 The immunotherapy on the basis
NOTE Confidence: 0.922421592

00:42:57.545 --> 00:43:01.036 of what data we have so far.

NOTE Confidence: 0.922421592

00:43:01.040 --> 00:43:02.727 It's not clear that we should all

NOTE Confidence: 0.922421592

00:43:02.727 --> 00:43:04.429 be doing this for every patient,

NOTE Confidence: 0.922421592

00:43:04.430 --> 00:43:06.368 but we have to discuss with

NOTE Confidence: 0.922421592

00:43:06.368 --> 00:43:07.900 the patient sitting before us.

NOTE Confidence: 0.922421592

00:43:07.900 --> 00:43:08.968 Whether we do this or not.

NOTE Confidence: 0.922421592

00:43:08.970 --> 00:43:10.146 And I will say that I've done it

NOTE Confidence: 0.922421592

00:43:10.146 --> 00:43:11.650 with a couple of patients so far.

NOTE Confidence: 0.864887442857143

00:43:13.700 --> 00:43:15.578 We now have an antibody drug

NOTE Confidence: 0.864887442857143

00:43:15.578 --> 00:43:16.830 conjugate for treating metastatic

NOTE Confidence: 0.864887442857143

00:43:16.884 --> 00:43:18.400 triple negative breast cancer.

NOTE Confidence: 0.864887442857143

00:43:18.400 --> 00:43:20.368 That's quite a good active drug.

NOTE Confidence: 0.864887442857143

00:43:20.370 --> 00:43:22.110 It's sacituzumab gobatti can

NOTE Confidence: 0.864887442857143

00:43:22.110 --> 00:43:24.285 the antigen is trope too,

NOTE Confidence: 0.864887442857143

00:43:24.290 --> 00:43:27.618 which is present on many breast cancers and

NOTE Confidence: 0.864887442857143

00:43:27.618 --> 00:43:30.918 the active moiety is a topa one inhibitor.

NOTE Confidence: 0.864887442857143

00:43:30.920 --> 00:43:32.860 It's actually SN 38,
NOTE Confidence: 0.864887442857143

00:43:32.860 --> 00:43:35.285 which is the business molecule,
NOTE Confidence: 0.864887442857143

00:43:35.290 --> 00:43:38.176 the active metabolite of Irene Attican.
NOTE Confidence: 0.864887442857143

00:43:38.180 --> 00:43:40.400 Ann, this was tested in the
NOTE Confidence: 0.864887442857143

00:43:40.400 --> 00:43:42.427 ascent trial versus treatment of
NOTE Confidence: 0.864887442857143

00:43:42.427 --> 00:43:44.347 chemotherapy of physicians choice,
NOTE Confidence: 0.864887442857143

00:43:44.350 --> 00:43:46.010 and this antibody, drug conjugate,
NOTE Confidence: 0.864887442857143

00:43:46.010 --> 00:43:47.972 was quite active with an improvement
NOTE Confidence: 0.864887442857143

00:43:47.972 --> 00:43:49.280 in progression free survival.
NOTE Confidence: 0.864887442857143

00:43:49.280 --> 00:43:51.356 A six month improvement in overall
NOTE Confidence: 0.864887442857143

00:43:51.356 --> 00:43:52.740 survival and of substantial
NOTE Confidence: 0.864887442857143

00:43:52.804 --> 00:43:54.649 improvement in the response rate.
NOTE Confidence: 0.864887442857143

00:43:54.650 --> 00:43:56.426 So this was approved for triple
NOTE Confidence: 0.864887442857143

00:43:56.426 --> 00:43:57.610 negative metastatic breast cancer.
NOTE Confidence: 0.864887442857143

00:43:57.610 --> 00:43:59.878 After two or more prior chemotherapies,
NOTE Confidence: 0.864887442857143

00:43:59.880 --> 00:44:01.590 and it's actually now being tested

NOTE Confidence: 0.864887442857143

00:44:01.590 --> 00:44:03.696 in hormone receptor positive as well.

NOTE Confidence: 0.864887442857143

00:44:03.696 --> 00:44:05.112 We are participating in that trial

NOTE Confidence: 0.864887442857143

00:44:05.112 --> 00:44:06.767 and I've had patients with hormone

NOTE Confidence: 0.864887442857143

00:44:06.767 --> 00:44:08.573 receptor positive disease in the trial.

NOTE Confidence: 0.864887442857143

00:44:08.580 --> 00:44:10.940 Had good responses as well.

NOTE Confidence: 0.864887442857143

00:44:10.940 --> 00:44:13.656 We often think of an antibody drug

NOTE Confidence: 0.864887442857143

00:44:13.656 --> 00:44:16.511 conjugate as a much more tolerable

NOTE Confidence: 0.864887442857143

00:44:16.511 --> 00:44:19.186 therapy than a naked chemotherapy,

NOTE Confidence: 0.864887442857143

00:44:19.190 --> 00:44:21.766 but actually I have to say this

NOTE Confidence: 0.864887442857143

00:44:21.766 --> 00:44:23.825 particular drug does have toxicities

NOTE Confidence: 0.864887442857143

00:44:23.825 --> 00:44:26.477 that are on par with chemotherapy,

NOTE Confidence: 0.864887442857143

00:44:26.480 --> 00:44:27.492 including neutropenia,

NOTE Confidence: 0.864887442857143

00:44:27.492 --> 00:44:29.010 nausea and vomiting,

NOTE Confidence: 0.864887442857143

00:44:29.010 --> 00:44:31.404 diarrhea, abdominal symptoms,

NOTE Confidence: 0.864887442857143

00:44:31.404 --> 00:44:34.812 complete alopecia, low blood counts,

NOTE Confidence: 0.864887442857143

00:44:34.812 --> 00:44:36.648 decreased appetite, and rash.
NOTE Confidence: 0.864887442857143

00:44:36.648 --> 00:44:38.218 So although it's a very
NOTE Confidence: 0.864887442857143

00:44:38.218 --> 00:44:40.019 active drug in a good drug,
NOTE Confidence: 0.864887442857143

00:44:40.020 --> 00:44:42.029 it doesn't seem in terms of toxicity.
NOTE Confidence: 0.864887442857143

00:44:42.030 --> 00:44:44.570 Would be a free ride
NOTE Confidence: 0.864887442857143

00:44:44.570 --> 00:44:46.094 compared to chemotherapy.
NOTE Confidence: 0.864887442857143

00:44:46.100 --> 00:44:46.949 And then finally,
NOTE Confidence: 0.864887442857143

00:44:46.949 --> 00:44:48.647 in the last few minutes I'll
NOTE Confidence: 0.864887442857143

00:44:48.647 --> 00:44:50.800 just a few words about hormone
NOTE Confidence: 0.864887442857143

00:44:50.800 --> 00:44:51.883 receptor positive disease.
NOTE Confidence: 0.864887442857143

00:44:51.890 --> 00:44:54.890 We now have five biological agents that we
NOTE Confidence: 0.864887442857143

00:44:54.890 --> 00:44:57.730 can combine with our endocrine therapies.
NOTE Confidence: 0.864887442857143

00:44:57.730 --> 00:45:00.555 The three CDK 46 inhibitors
NOTE Confidence: 0.864887442857143

00:45:00.555 --> 00:45:03.380 everolimus and alkalis sub alkalis,
NOTE Confidence: 0.864887442857143

00:45:03.380 --> 00:45:05.552 is active only in those tumors
NOTE Confidence: 0.864887442857143

00:45:05.552 --> 00:45:08.528 that have a PR 3 kinase mutation,

NOTE Confidence: 0.864887442857143
00:45:08.530 --> 00:45:10.798 which is about 40% of metastatic
NOTE Confidence: 0.864887442857143
00:45:10.798 --> 00:45:12.310 hormone receptor positive breast
NOTE Confidence: 0.864887442857143
00:45:12.377 --> 00:45:14.937 cancer in the solar one trial that was
NOTE Confidence: 0.864887442857143
00:45:14.937 --> 00:45:16.689 published almost two years ago now,
NOTE Confidence: 0.864887442857143
00:45:16.690 --> 00:45:18.090 which was a randomized phase
NOTE Confidence: 0.864887442857143
00:45:18.090 --> 00:45:19.490 three looking at full strength,
NOTE Confidence: 0.864887442857143
00:45:19.490 --> 00:45:20.866 with or without alkalis.
NOTE Confidence: 0.864887442857143
00:45:20.866 --> 00:45:22.930 If there was a significant improvement,
NOTE Confidence: 0.864887442857143
00:45:22.930 --> 00:45:25.600 progression free survival and response rate.
NOTE Confidence: 0.864887442857143
00:45:25.600 --> 00:45:27.802 So this is now considered standard
NOTE Confidence: 0.864887442857143
00:45:27.802 --> 00:45:29.673 therapy for patients in combination
NOTE Confidence: 0.864887442857143
00:45:29.673 --> 00:45:31.348 with focus strength to have
NOTE Confidence: 0.864887442857143
00:45:31.348 --> 00:45:33.330 a PR 3 kinase mutation.
NOTE Confidence: 0.864887442857143
00:45:33.330 --> 00:45:35.165 This can have some substantial
NOTE Confidence: 0.864887442857143
00:45:35.165 --> 00:45:37.630 toxicity as well, including diarrhea.
NOTE Confidence: 0.864887442857143

00:45:37.630 --> 00:45:39.670 Hyperglycemia that requires
NOTE Confidence: 0.864887442857143

00:45:39.670 --> 00:45:41.030 aggressive management,
NOTE Confidence: 0.864887442857143

00:45:41.030 --> 00:45:43.802 an erracht as well that can be
NOTE Confidence: 0.864887442857143

00:45:43.802 --> 00:45:46.449 prevented by using an antihistamine.
NOTE Confidence: 0.864887442857143

00:45:46.450 --> 00:45:49.964 We have the three CDK 46 inhibitors
NOTE Confidence: 0.864887442857143

00:45:49.964 --> 00:45:53.360 which have remarkable activity in the
NOTE Confidence: 0.864887442857143

00:45:53.360 --> 00:45:55.544 metastatic setting in first line,
NOTE Confidence: 0.864887442857143

00:45:55.544 --> 00:45:57.840 and says the second line nearly doubling
NOTE Confidence: 0.864887442857143

00:45:57.901 --> 00:45:59.866 response rate and nearly doubling
NOTE Confidence: 0.864887442857143

00:45:59.866 --> 00:46:02.245 progression free survival and in the
NOTE Confidence: 0.864887442857143

00:46:02.245 --> 00:46:03.975 metastatic setting they really all
NOTE Confidence: 0.864887442857143

00:46:03.975 --> 00:46:06.202 seem to have nearly identical activity.
NOTE Confidence: 0.864887442857143

00:46:06.202 --> 00:46:08.728 There's maybe a slight edge for
NOTE Confidence: 0.864887442857143

00:46:08.728 --> 00:46:11.233 abemaciclib in that it has a little
NOTE Confidence: 0.864887442857143

00:46:11.233 --> 00:46:12.828 bit of single agent activity,
NOTE Confidence: 0.864887442857143

00:46:12.830 --> 00:46:14.818 which the other two seem not to,

NOTE Confidence: 0.864887442857143
00:46:14.820 --> 00:46:17.876 and perhaps some potential to cross the CNS.
NOTE Confidence: 0.864887442857143
00:46:17.880 --> 00:46:20.554 Blood brain barrier and some CNS activity.
NOTE Confidence: 0.864887442857143
00:46:20.560 --> 00:46:22.975 But for the most part in the
NOTE Confidence: 0.864887442857143
00:46:22.975 --> 00:46:25.249 metastatic setting they seem to be
NOTE Confidence: 0.864887442857143
00:46:25.249 --> 00:46:27.199 extremely active and equally active.
NOTE Confidence: 0.864887442857143
00:46:27.200 --> 00:46:28.664 So as Miriam mentioned,
NOTE Confidence: 0.864887442857143
00:46:28.664 --> 00:46:30.860 the big question is will these
NOTE Confidence: 0.888861496206897
00:46:30.932 --> 00:46:33.532 be able to be moved into the early
NOTE Confidence: 0.888861496206897
00:46:33.532 --> 00:46:35.388 stage setting and she mentioned
NOTE Confidence: 0.888861496206897
00:46:35.388 --> 00:46:37.650 that we have one positive trial,
NOTE Confidence: 0.888861496206897
00:46:37.650 --> 00:46:38.775 the monarchy trial,
NOTE Confidence: 0.888861496206897
00:46:38.775 --> 00:46:41.400 which looked at very high risk patients
NOTE Confidence: 0.888861496206897
00:46:41.467 --> 00:46:43.602 with four or more nodes positive or
NOTE Confidence: 0.888861496206897
00:46:43.602 --> 00:46:46.192 one to three nodes positive and other
NOTE Confidence: 0.888861496206897
00:46:46.192 --> 00:46:48.202 high risk features and enrolled.
NOTE Confidence: 0.888861496206897

00:46:48.210 --> 00:46:50.478 Over 5000 patients and looked at
NOTE Confidence: 0.888861496206897

00:46:50.478 --> 00:46:52.752 the use of abemaciclib for two
NOTE Confidence: 0.888861496206897

00:46:52.752 --> 00:46:55.160 years with the edge of an enderman
NOTE Confidence: 0.888861496206897

00:46:55.160 --> 00:46:57.499 therapy versus not an this at early.
NOTE Confidence: 0.888861496206897

00:46:57.500 --> 00:47:00.080 At about a year and a half follow up as
NOTE Confidence: 0.888861496206897

00:47:00.150 --> 00:47:02.769 seems to be a positive trial so far in
NOTE Confidence: 0.888861496206897

00:47:02.769 --> 00:47:05.250 terms of reduction in distant relapse.
NOTE Confidence: 0.888861496206897

00:47:05.250 --> 00:47:07.640 Free survival.
NOTE Confidence: 0.888861496206897

00:47:07.640 --> 00:47:10.136 But as far as Marion mentioned,
NOTE Confidence: 0.888861496206897

00:47:10.140 --> 00:47:12.660 what we have looking at us in the face
NOTE Confidence: 0.888861496206897

00:47:12.660 --> 00:47:15.469 is two other early stage trials with
NOTE Confidence: 0.888861496206897

00:47:15.469 --> 00:47:17.839 palbociclib that seemed to be negative
NOTE Confidence: 0.888861496206897

00:47:17.839 --> 00:47:20.240 and so is there really a difference
NOTE Confidence: 0.888861496206897

00:47:20.240 --> 00:47:21.940 between abemaciclib in pabulum?
NOTE Confidence: 0.888861496206897

00:47:21.940 --> 00:47:23.215 Albo psych lab?
NOTE Confidence: 0.888861496206897

00:47:23.220 --> 00:47:24.870 Is there a difference in the

NOTE Confidence: 0.888861496206897
00:47:24.870 --> 00:47:25.420 patient population?
NOTE Confidence: 0.888861496206897
00:47:25.420 --> 00:47:26.975 Is there some other explanation
NOTE Confidence: 0.888861496206897
00:47:26.975 --> 00:47:29.389 and we have an ongoing trial with
NOTE Confidence: 0.888861496206897
00:47:29.389 --> 00:47:31.369 Ribociclib which hasn't reported yet.
NOTE Confidence: 0.888861496206897
00:47:31.370 --> 00:47:33.250 Now the interesting thing is,
NOTE Confidence: 0.888861496206897
00:47:33.250 --> 00:47:35.025 these results are reported at
NOTE Confidence: 0.888861496206897
00:47:35.025 --> 00:47:36.800 different time points and there
NOTE Confidence: 0.888861496206897
00:47:36.868 --> 00:47:38.908 were different treatment durations.
NOTE Confidence: 0.888861496206897
00:47:38.910 --> 00:47:41.796 So in the Penelope B trial,
NOTE Confidence: 0.888861496206897
00:47:41.800 --> 00:47:44.884 which looked at patients who had
NOTE Confidence: 0.888861496206897
00:47:44.884 --> 00:47:47.640 residual disease after neoadjuvant therapy,
NOTE Confidence: 0.888861496206897
00:47:47.640 --> 00:47:51.100 this analysis is out at 43 months.
NOTE Confidence: 0.888861496206897
00:47:51.100 --> 00:47:54.430 And if you looked at the two year mark,
NOTE Confidence: 0.888861496206897
00:47:54.430 --> 00:47:57.232 there was a 4% difference in
NOTE Confidence: 0.888861496206897
00:47:57.232 --> 00:47:59.100 favor of the palbociclib,
NOTE Confidence: 0.888861496206897

00:47:59.100 --> 00:48:01.634 but that went down at three years,
NOTE Confidence: 0.888861496206897

00:48:01.640 --> 00:48:03.915 and at the four year follow-up Timepoint,
NOTE Confidence: 0.888861496206897

00:48:03.920 --> 00:48:06.176 essentially no difference between the arms.
NOTE Confidence: 0.888861496206897

00:48:06.180 --> 00:48:07.932 When we look at the monarchy
NOTE Confidence: 0.888861496206897

00:48:07.932 --> 00:48:08.516 with abemaciclib,
NOTE Confidence: 0.888861496206897

00:48:08.520 --> 00:48:11.400 which appears to be a positive trial so far.
NOTE Confidence: 0.888861496206897

00:48:11.400 --> 00:48:13.260 The treatment duration is 2 years,
NOTE Confidence: 0.888861496206897

00:48:13.260 --> 00:48:15.402 but the follow up so far is
NOTE Confidence: 0.888861496206897

00:48:15.402 --> 00:48:17.847 only 19 months and so it may be
NOTE Confidence: 0.888861496206897

00:48:17.847 --> 00:48:20.089 that we see some effect of these
NOTE Confidence: 0.888861496206897

00:48:20.089 --> 00:48:22.219 while the therapy is going on.
NOTE Confidence: 0.888861496206897

00:48:22.220 --> 00:48:25.180 But once the therapy is completed over time,
NOTE Confidence: 0.888861496206897

00:48:25.180 --> 00:48:26.424 the difference between the
NOTE Confidence: 0.888861496206897

00:48:26.424 --> 00:48:27.979 two arms might go away.
NOTE Confidence: 0.888861496206897

00:48:27.980 --> 00:48:29.950 So we need more study,
NOTE Confidence: 0.888861496206897

00:48:29.950 --> 00:48:31.931 more follow up and we need to

NOTE Confidence: 0.888861496206897
00:48:31.931 --> 00:48:33.870 see the results of the Natalie
NOTE Confidence: 0.888861496206897
00:48:33.870 --> 00:48:35.910 trial which is using recycled for
NOTE Confidence: 0.888861496206897
00:48:35.910 --> 00:48:38.018 three years in high risk disease.
NOTE Confidence: 0.888861496206897
00:48:38.020 --> 00:48:39.680 That's my last slide.
NOTE Confidence: 0.89656174
00:48:40.850 --> 00:48:41.898 One thing I wanted
NOTE Confidence: 0.877980285789474
00:48:41.910 --> 00:48:43.688 to say once again getting back to
NOTE Confidence: 0.877980285789474
00:48:43.688 --> 00:48:45.351 dealing with the person to sitting
NOTE Confidence: 0.877980285789474
00:48:45.351 --> 00:48:47.043 in front of you question arises.
NOTE Confidence: 0.877980285789474
00:48:47.050 --> 00:48:49.794 Should we act on this data with abemaciclib?
NOTE Confidence: 0.877980285789474
00:48:49.800 --> 00:48:51.172 It's not FDA approved.
NOTE Confidence: 0.877980285789474
00:48:51.172 --> 00:48:53.576 We really don't know if this is
NOTE Confidence: 0.877980285789474
00:48:53.576 --> 00:48:55.784 going to hold up in the long term,
NOTE Confidence: 0.877980285789474
00:48:55.790 --> 00:48:57.914 but I will tell you that I have brought
NOTE Confidence: 0.877980285789474
00:48:57.914 --> 00:48:59.657 this up sometimes with patients.
NOTE Confidence: 0.877980285789474
00:48:59.660 --> 00:49:02.748 So I recently had a patient who had
NOTE Confidence: 0.877980285789474

00:49:02.748 --> 00:49:05.512 12 nodes positive and was starting her
NOTE Confidence: 0.877980285789474

00:49:05.512 --> 00:49:07.216 regimen therapy and I discussed with
NOTE Confidence: 0.877980285789474

00:49:07.216 --> 00:49:09.319 her whether to add emoci clip because
NOTE Confidence: 0.877980285789474

00:49:09.319 --> 00:49:10.949 it's enormously high risk to have.
NOTE Confidence: 0.877980285789474

00:49:10.950 --> 00:49:13.365 Well, no, it's positive and I prescribed
NOTE Confidence: 0.877980285789474

00:49:13.365 --> 00:49:15.389 with Emoci clip for this woman.
NOTE Confidence: 0.877980285789474

00:49:15.390 --> 00:49:17.838 It would be covered by her insurance company.
NOTE Confidence: 0.877980285789474

00:49:17.840 --> 00:49:19.456 Again, we don't know if we should be
NOTE Confidence: 0.877980285789474

00:49:19.456 --> 00:49:21.124 doing this. We sometimes act early.
NOTE Confidence: 0.877980285789474

00:49:21.124 --> 00:49:23.706 We may be giving therapy that has toxicity
NOTE Confidence: 0.877980285789474

00:49:23.706 --> 00:49:25.883 that in the long run doesn't help,
NOTE Confidence: 0.877980285789474

00:49:25.890 --> 00:49:28.172 but I consider it in very high
NOTE Confidence: 0.877980285789474

00:49:28.172 --> 00:49:30.530 risk patients based on this data.
NOTE Confidence: 0.877980285789474

00:49:30.530 --> 00:49:33.241 So I stuck my neck out in a
NOTE Confidence: 0.877980285789474

00:49:33.241 --> 00:49:34.680 couple of areas there,
NOTE Confidence: 0.877980285789474

00:49:34.680 --> 00:49:36.451 but that's my last slide and I'll

NOTE Confidence: 0.877980285789474
00:49:36.451 --> 00:49:38.189 be happy to take any questions
NOTE Confidence: 0.877980285789474
00:49:38.189 --> 00:49:40.025 now or at the discussion time.
NOTE Confidence: 0.8365242304
00:49:42.090 --> 00:49:43.746 Thank you Doctor Digiovanni,
NOTE Confidence: 0.8365242304
00:49:43.746 --> 00:49:46.653 that was fantastic and there are questions
NOTE Confidence: 0.8365242304
00:49:46.653 --> 00:49:49.124 that are trickling in and they both
NOTE Confidence: 0.8365242304
00:49:49.124 --> 00:49:51.799 in the chat in question and answer.
NOTE Confidence: 0.8365242304
00:49:51.800 --> 00:49:54.690 Certainly not last and least,
NOTE Confidence: 0.8365242304
00:49:54.690 --> 00:49:57.576 but we have Professor Andreas Silvers.
NOTE Confidence: 0.8365242304
00:49:57.580 --> 00:49:59.620 Gonna really give us a exciting
NOTE Confidence: 0.8365242304
00:49:59.620 --> 00:50:00.980 update on breast cancer
NOTE Confidence: 0.8365242304
00:50:01.044 --> 00:50:02.900 epidemiology for risk factors,
NOTE Confidence: 0.8365242304
00:50:02.900 --> 00:50:06.200 especially in our vulnerable populations so.
NOTE Confidence: 0.8365242304
00:50:06.200 --> 00:50:07.169 Thank you, Andrea.
NOTE Confidence: 0.77995725
00:50:14.970 --> 00:50:16.218 You're on mute still.
NOTE Confidence: 0.916978778571429
00:50:19.170 --> 00:50:19.960 Good afternoon,
NOTE Confidence: 0.916978778571429

00:50:19.960 --> 00:50:21.935 thank you for that introduction.
NOTE Confidence: 0.916978778571429

00:50:21.940 --> 00:50:24.478 It's my pleasure to present today
NOTE Confidence: 0.916978778571429

00:50:24.478 --> 00:50:27.725 and I will start out by describing
NOTE Confidence: 0.916978778571429

00:50:27.725 --> 00:50:30.170 the topography of breast cancer
NOTE Confidence: 0.916978778571429

00:50:30.170 --> 00:50:32.695 in 2021 and I reviewed current
NOTE Confidence: 0.916978778571429

00:50:32.695 --> 00:50:35.180 epidemiology and how we got here.
NOTE Confidence: 0.631061254

00:50:44.820 --> 00:50:47.630 Sure, but it's not advancing.
NOTE Confidence: 0.803014352

00:50:58.350 --> 00:51:01.510 It's my conflict of interest.
NOTE Confidence: 0.803014352

00:51:01.510 --> 00:51:04.230 And as you can see on this slide,
NOTE Confidence: 0.803014352

00:51:04.230 --> 00:51:06.565 breast cancer in the United
NOTE Confidence: 0.803014352

00:51:06.565 --> 00:51:08.433 States is extremely common.
NOTE Confidence: 0.803014352

00:51:08.440 --> 00:51:12.176 It's the most common cancer one season women.
NOTE Confidence: 0.803014352

00:51:12.180 --> 00:51:14.595 But it is not the most common
NOTE Confidence: 0.803014352

00:51:14.595 --> 00:51:17.279 cause of death that is lung cancer.
NOTE Confidence: 0.803014352

00:51:17.280 --> 00:51:20.526 You can compare the results of
NOTE Confidence: 0.803014352

00:51:20.526 --> 00:51:23.281 deaths that are anticipated in 2021

NOTE Confidence: 0.803014352

00:51:23.281 --> 00:51:25.458 for lung cancer, which is 100 and

NOTE Confidence: 0.867313785555556

00:51:27.490 --> 00:51:30.670 16,660. It's a very common

NOTE Confidence: 0.867313785555556

00:51:30.670 --> 00:51:33.214 tumor in elderly women.

NOTE Confidence: 0.867313785555556

00:51:33.220 --> 00:51:36.514 7% of all breast cancers will

NOTE Confidence: 0.867313785555556

00:51:36.514 --> 00:51:40.358 appear in women over the age of 70.

NOTE Confidence: 0.853695164

00:51:43.450 --> 00:51:45.496 Just want to highlight a little

NOTE Confidence: 0.853695164

00:51:45.496 --> 00:51:47.373 bit that breast cancer is

NOTE Confidence: 0.853695164

00:51:47.373 --> 00:51:49.613 heterogeneous and there are multiple

NOTE Confidence: 0.853695164

00:51:49.613 --> 00:51:51.405 different tumor subtypes there.

NOTE Confidence: 0.853695164

00:51:51.410 --> 00:51:53.054 Subtypes within the subtypes

NOTE Confidence: 0.853695164

00:51:53.054 --> 00:51:55.740 such as Luminal A and luminal B.

NOTE Confidence: 0.853695164

00:51:55.740 --> 00:51:58.440 The significance of this is going

NOTE Confidence: 0.853695164

00:51:58.440 --> 00:52:02.166 to be come clear when we talk about

NOTE Confidence: 0.853695164

00:52:02.166 --> 00:52:05.092 etiology and prevention and also keep

NOTE Confidence: 0.853695164

00:52:05.092 --> 00:52:07.966 in mind that breast cancer subtypes

NOTE Confidence: 0.853695164

00:52:07.966 --> 00:52:10.871 actually can change in up to 25%
NOTE Confidence: 0.853695164

00:52:10.871 --> 00:52:13.976 of patients when they metastasize.
NOTE Confidence: 0.853695164

00:52:13.980 --> 00:52:16.195 Their breast cancer has changed
NOTE Confidence: 0.853695164

00:52:16.195 --> 00:52:18.892 subtype and the most common change
NOTE Confidence: 0.853695164

00:52:18.892 --> 00:52:21.713 that one sees is going from luminal,
NOTE Confidence: 0.853695164

00:52:21.720 --> 00:52:23.500 a two triple negative.
NOTE Confidence: 0.870443961111111

00:52:25.880 --> 00:52:28.245 And here's the breakdown of
NOTE Confidence: 0.870443961111111

00:52:28.245 --> 00:52:30.137 breast cancer by subtype,
NOTE Confidence: 0.870443961111111

00:52:30.140 --> 00:52:34.388 and you can see that luminal a specifically,
NOTE Confidence: 0.870443961111111

00:52:34.390 --> 00:52:37.828 but hormone receptor positive breast cancer,
NOTE Confidence: 0.870443961111111

00:52:37.830 --> 00:52:39.910 is the most common type,
NOTE Confidence: 0.870443961111111

00:52:39.910 --> 00:52:42.900 regardless of age or race,
NOTE Confidence: 0.870443961111111

00:52:42.900 --> 00:52:45.784 and it's six times more common than
NOTE Confidence: 0.870443961111111

00:52:45.784 --> 00:52:48.150 the triple negative breast cancer.
NOTE Confidence: 0.87256719625

00:52:50.320 --> 00:52:53.448 Let's move ahead and talk about risk factors.
NOTE Confidence: 0.87256719625

00:52:53.450 --> 00:52:56.360 I think from my previous slide,

NOTE Confidence: 0.87256719625

00:52:56.360 --> 00:52:59.897 you can tell one of the risk factors is

NOTE Confidence: 0.87256719625

00:52:59.897 --> 00:53:03.349 being female and another is being older,

NOTE Confidence: 0.87256719625

00:53:03.350 --> 00:53:07.109 but those are non modifiable risk factors.

NOTE Confidence: 0.87256719625

00:53:07.110 --> 00:53:10.362 Personal history of invasive or non

NOTE Confidence: 0.87256719625

00:53:10.362 --> 00:53:13.849 invasive breast cancer predisposes to both

NOTE Confidence: 0.87256719625

00:53:13.849 --> 00:53:16.325 contralateral and ipsilateral primaries.

NOTE Confidence: 0.87256719625

00:53:16.330 --> 00:53:19.940 Benign breast disease with atypia.

NOTE Confidence: 0.87256719625

00:53:19.940 --> 00:53:22.364 Family history and this is regardless

NOTE Confidence: 0.87256719625

00:53:22.364 --> 00:53:24.511 of whether there's a mutation

NOTE Confidence: 0.87256719625

00:53:24.511 --> 00:53:26.776 for women with family history.

NOTE Confidence: 0.87256719625

00:53:26.780 --> 00:53:32.107 Only 5 to 6% have identifiable mutations,

NOTE Confidence: 0.87256719625

00:53:32.110 --> 00:53:34.840 and when you look at known

NOTE Confidence: 0.87256719625

00:53:34.840 --> 00:53:37.074 mutations that comprises less than

NOTE Confidence: 0.87256719625

00:53:37.074 --> 00:53:39.100 10% of all breast cancers.

NOTE Confidence: 0.87256719625

00:53:39.100 --> 00:53:42.103 Breast density I will get into that

NOTE Confidence: 0.87256719625

00:53:42.103 --> 00:53:44.700 a little more later in the talk,
NOTE Confidence: 0.87256719625

00:53:44.700 --> 00:53:48.102 but let's talk about increased exposure to
NOTE Confidence: 0.87256719625

00:53:48.102 --> 00:53:50.820 estrogen throughout the female lifetime,
NOTE Confidence: 0.87256719625

00:53:50.820 --> 00:53:52.668 early menses.
NOTE Confidence: 0.87256719625

00:53:52.668 --> 00:53:56.535 Menses now starts below the age
NOTE Confidence: 0.87256719625

00:53:56.535 --> 00:53:58.725 of 11 in the United States.
NOTE Confidence: 0.87256719625

00:53:58.730 --> 00:54:00.638 This was not true.
NOTE Confidence: 0.87256719625

00:54:00.638 --> 00:54:03.462 A generation ago, delayed childbearing
NOTE Confidence: 0.87256719625

00:54:03.462 --> 00:54:06.600 or no lipperhey late menopause.
NOTE Confidence: 0.87256719625

00:54:06.600 --> 00:54:09.976 Menopause is occurring later now, it said.
NOTE Confidence: 0.87256719625

00:54:09.976 --> 00:54:11.468 Between 50 and 51,
NOTE Confidence: 0.87256719625

00:54:11.470 --> 00:54:12.970 that was not true.
NOTE Confidence: 0.87256719625

00:54:12.970 --> 00:54:14.095 A generation ago,
NOTE Confidence: 0.87256719625

00:54:14.100 --> 00:54:16.445 exogenous estrogen that has been
NOTE Confidence: 0.87256719625

00:54:16.445 --> 00:54:19.817 given to women to help them through
NOTE Confidence: 0.87256719625

00:54:19.817 --> 00:54:22.631 the menopause and that estrogen is

NOTE Confidence: 0.87256719625

00:54:22.631 --> 00:54:26.304 more of a risk when it's combined

NOTE Confidence: 0.87256719625

00:54:26.304 --> 00:54:28.949 with progestin and previous studies,

NOTE Confidence: 0.87256719625

00:54:28.950 --> 00:54:31.380 it looks like the estrogen that's

NOTE Confidence: 0.87256719625

00:54:31.380 --> 00:54:34.324 given as a single agent to women

NOTE Confidence: 0.87256719625

00:54:34.324 --> 00:54:36.802 who have had hysterectomies is not

NOTE Confidence: 0.87256719625

00:54:36.802 --> 00:54:40.260 as risky as transgender women.

NOTE Confidence: 0.87256719625

00:54:40.260 --> 00:54:44.820 Due to increased exposure of estrogen.

NOTE Confidence: 0.87256719625

00:54:44.820 --> 00:54:46.900 Moving along to radiation,

NOTE Confidence: 0.87256719625

00:54:46.900 --> 00:54:48.460 that's radiation therapy,

NOTE Confidence: 0.87256719625

00:54:48.460 --> 00:54:52.114 which is given to children or mantle

NOTE Confidence: 0.87256719625

00:54:52.114 --> 00:54:54.470 radiation for Hodgkin's disease.

NOTE Confidence: 0.87256719625

00:54:54.470 --> 00:54:57.164 Radiation therapy is the highest risk

NOTE Confidence: 0.87256719625

00:54:57.164 --> 00:54:59.940 when it's given during adolescence,

NOTE Confidence: 0.87256719625

00:54:59.940 --> 00:55:01.672 between age 10 to.

NOTE Confidence: 0.87256719625

00:55:01.672 --> 00:55:04.270 14 When the breast is most

NOTE Confidence: 0.87256719625

00:55:04.373 --> 00:55:06.589 actively proliferating,
NOTE Confidence: 0.87256719625

00:55:06.590 --> 00:55:09.010 but there's also an increased
NOTE Confidence: 0.87256719625

00:55:09.010 --> 00:55:10.946 risk from radiation exposure,
NOTE Confidence: 0.87256719625

00:55:10.950 --> 00:55:12.342 either accidental,
NOTE Confidence: 0.87256719625

00:55:12.342 --> 00:55:14.430 such as Chernobyl,
NOTE Confidence: 0.87256719625

00:55:14.430 --> 00:55:18.080 or intentional such as warfare,
NOTE Confidence: 0.87256719625

00:55:18.080 --> 00:55:21.181 and this also was shown to be
NOTE Confidence: 0.87256719625

00:55:21.181 --> 00:55:23.538 most active for the adolescent
NOTE Confidence: 0.87256719625

00:55:23.538 --> 00:55:27.242 girls and wasn't as seen to be a
NOTE Confidence: 0.87256719625

00:55:27.341 --> 00:55:30.761 risk factor after the age of 45.
NOTE Confidence: 0.87256719625

00:55:30.761 --> 00:55:32.083 Drinking alcohol.
NOTE Confidence: 0.87256719625

00:55:32.083 --> 00:55:36.049 As little as one alcoholic beverage
NOTE Confidence: 0.87256719625

00:55:36.049 --> 00:55:39.969 per day in several studies has
NOTE Confidence: 0.87256719625

00:55:39.969 --> 00:55:43.837 shown a slightly increased risk of
NOTE Confidence: 0.87256719625

00:55:43.837 --> 00:55:46.907 breast cancer and then obesity.
NOTE Confidence: 0.87256719625

00:55:46.910 --> 00:55:50.018 Just wanted to highlight breast density.

NOTE Confidence: 0.87256719625

00:55:50.020 --> 00:55:54.432 You can see here that there are some

NOTE Confidence: 0.87256719625

00:55:54.432 --> 00:55:57.156 women who have extremely dense breasts,

NOTE Confidence: 0.87256719625

00:55:57.160 --> 00:56:01.544 and for those women at level 4 that

NOTE Confidence: 0.87256719625

00:56:01.544 --> 00:56:04.768 increases the odds ratio 6 fold.

NOTE Confidence: 0.87256719625

00:56:04.770 --> 00:56:10.004 So that's a very very important risk factor.

NOTE Confidence: 0.87256719625

00:56:10.004 --> 00:56:13.352 So much so that the Christmas

NOTE Confidence: 0.87256719625

00:56:13.352 --> 00:56:16.417 study that comes out of Sweden.

NOTE Confidence: 0.87256719625

00:56:16.420 --> 00:56:19.255 Actually use breast density to

NOTE Confidence: 0.87256719625

00:56:19.255 --> 00:56:22.090 enroll women in their chemoprevention

NOTE Confidence: 0.87256719625

00:56:22.183 --> 00:56:24.019 trial using tamoxifen.

NOTE Confidence: 0.770337186666667

00:56:26.980 --> 00:56:30.730 An risk factors vary by subtype.

NOTE Confidence: 0.770337186666667

00:56:30.730 --> 00:56:32.346 Greater parity was associated

NOTE Confidence: 0.770337186666667

00:56:32.346 --> 00:56:34.770 with a lower risk of hormone

NOTE Confidence: 0.770337186666667

00:56:34.841 --> 00:56:37.069 receptor positive breast cancer,

NOTE Confidence: 0.770337186666667

00:56:37.070 --> 00:56:40.094 but it is an increased risk for

NOTE Confidence: 0.770337186666667

00:56:40.094 --> 00:56:42.040 triple negative breast cancer.
NOTE Confidence: 0.770337186666667

00:56:42.040 --> 00:56:44.656 Breastfeeding can cut the risk for
NOTE Confidence: 0.770337186666667

00:56:44.656 --> 00:56:47.170 triple negative breast cancer by 50%.
NOTE Confidence: 0.770337186666667

00:56:47.170 --> 00:56:49.970 Well, that's not true for
NOTE Confidence: 0.770337186666667

00:56:49.970 --> 00:56:52.210 receptor positive breast cancer.
NOTE Confidence: 0.872638806363636

00:56:54.720 --> 00:56:57.534 So these two women on the cover
NOTE Confidence: 0.872638806363636

00:56:57.534 --> 00:56:59.210 of Good Housekeeping show.
NOTE Confidence: 0.872638806363636

00:56:59.210 --> 00:57:02.594 How are modern women are more likely to
NOTE Confidence: 0.872638806363636

00:57:02.594 --> 00:57:06.155 have risk factors for hormone receptor
NOTE Confidence: 0.872638806363636

00:57:06.155 --> 00:57:09.435 positive breast cancer by delaying
NOTE Confidence: 0.872638806363636

00:57:09.435 --> 00:57:11.825 childbearing having fewer children
NOTE Confidence: 0.872638806363636

00:57:11.825 --> 00:57:15.107 and those things increase the risk.
NOTE Confidence: 0.872638806363636

00:57:15.110 --> 00:57:16.730 As a matter of fact,
NOTE Confidence: 0.872638806363636

00:57:16.730 --> 00:57:20.498 breast cancer is more common in
NOTE Confidence: 0.872638806363636

00:57:20.498 --> 00:57:23.522 areas like the I-95 corridor,
NOTE Confidence: 0.872638806363636

00:57:23.522 --> 00:57:25.786 an in Marin County,

NOTE Confidence: 0.872638806363636

00:57:25.790 --> 00:57:27.278 not due to environment,

NOTE Confidence: 0.872638806363636

00:57:27.278 --> 00:57:30.643 but due to cluster of risk factor for the

NOTE Confidence: 0.872638806363636

00:57:30.643 --> 00:57:33.620 type of women that live in these areas,

NOTE Confidence: 0.872638806363636

00:57:33.620 --> 00:57:36.360 and modern women are taller.

NOTE Confidence: 0.872638806363636

00:57:36.360 --> 00:57:38.355 Bigger also are more likely

NOTE Confidence: 0.872638806363636

00:57:38.355 --> 00:57:41.090 to be diverse in this country,

NOTE Confidence: 0.872638806363636

00:57:41.090 --> 00:57:44.384 and these are reasons to increase

NOTE Confidence: 0.872638806363636

00:57:44.384 --> 00:57:47.410 the risk for breast cancer.

NOTE Confidence: 0.872638806363636

00:57:47.410 --> 00:57:48.855 Let's move ahead to looking

NOTE Confidence: 0.872638806363636

00:57:48.855 --> 00:57:50.750 at the rest of the world.

NOTE Confidence: 0.872638806363636

00:57:50.750 --> 00:57:55.578 Global incidence is increasing.

NOTE Confidence: 0.872638806363636

00:57:55.580 --> 00:57:58.204 And you can see that breast cancer is

NOTE Confidence: 0.872638806363636

00:57:58.204 --> 00:58:00.837 different in different types of countries.

NOTE Confidence: 0.872638806363636

00:58:00.840 --> 00:58:02.484 In highly developed countries,

NOTE Confidence: 0.872638806363636

00:58:02.484 --> 00:58:05.477 most women get breast cancer when they're

NOTE Confidence: 0.872638806363636

00:58:05.477 --> 00:58:07.777 older and less developed countries.
NOTE Confidence: 0.872638806363636

00:58:07.780 --> 00:58:08.797 That's the reverse,
NOTE Confidence: 0.872638806363636

00:58:08.797 --> 00:58:11.170 and it's thought to have to do
NOTE Confidence: 0.872638806363636

00:58:11.240 --> 00:58:13.048 with the wealthier countries
NOTE Confidence: 0.872638806363636

00:58:13.048 --> 00:58:15.308 having higher rates of obesity.
NOTE Confidence: 0.872638806363636

00:58:15.310 --> 00:58:16.960 But as you can imagine,
NOTE Confidence: 0.872638806363636

00:58:16.960 --> 00:58:20.014 the case fatality rate is lowest
NOTE Confidence: 0.872638806363636

00:58:20.014 --> 00:58:22.050 in highly developed countries,
NOTE Confidence: 0.872638806363636

00:58:22.050 --> 00:58:25.587 and this is even true in our own country.
NOTE Confidence: 0.872638806363636

00:58:25.590 --> 00:58:27.599 When you look at the case fatality
NOTE Confidence: 0.872638806363636

00:58:27.599 --> 00:58:30.028 rate in a state like Connecticut,
NOTE Confidence: 0.872638806363636

00:58:30.030 --> 00:58:32.150 which has the second highest
NOTE Confidence: 0.872638806363636

00:58:32.150 --> 00:58:33.846 rate of breast cancer,
NOTE Confidence: 0.872638806363636

00:58:33.850 --> 00:58:38.506 the case fatality rate is the lowest Ann.
NOTE Confidence: 0.872638806363636

00:58:38.510 --> 00:58:42.398 You compare that to some of our Southern
NOTE Confidence: 0.872638806363636

00:58:42.398 --> 00:58:45.789 states that may have lower incidence

NOTE Confidence: 0.872638806363636
00:58:45.789 --> 00:58:48.694 but higher case fatality rates,
NOTE Confidence: 0.872638806363636
00:58:48.700 --> 00:58:52.420 and this may have to do with insurance
NOTE Confidence: 0.872638806363636
00:58:52.420 --> 00:58:56.427 in these various states in our country.
NOTE Confidence: 0.872638806363636
00:58:56.430 --> 00:58:58.843 When we look at the nationality, the
NOTE Confidence: 0.872638806363636
00:58:58.843 --> 00:59:02.307 United States doesn't even make the top 15.
NOTE Confidence: 0.872638806363636
00:59:02.310 --> 00:59:06.310 Belgium is the number one.
NOTE Confidence: 0.872638806363636
00:59:06.310 --> 00:59:09.126 But when we look at Survival World wide,
NOTE Confidence: 0.872638806363636
00:59:09.130 --> 00:59:12.469 you can see a very different story.
NOTE Confidence: 0.872638806363636
00:59:12.470 --> 00:59:15.090 The five year survival in
NOTE Confidence: 0.872638806363636
00:59:15.090 --> 00:59:17.593 the United States is 95%.
NOTE Confidence: 0.872638806363636
00:59:17.593 --> 00:59:20.011 Compare that to what you see
NOTE Confidence: 0.872638806363636
00:59:20.011 --> 00:59:22.379 in South Africa and Mongolia.
NOTE Confidence: 0.848581026363636
00:59:24.590 --> 00:59:26.906 And survival rate in the United
NOTE Confidence: 0.848581026363636
00:59:26.906 --> 00:59:29.140 States does vary by subtype.
NOTE Confidence: 0.848581026363636
00:59:29.140 --> 00:59:33.466 The hormone receptor positive breast cancers.
NOTE Confidence: 0.848581026363636

00:59:33.470 --> 00:59:35.996 Looking at the most recent SEER
NOTE Confidence: 0.848581026363636

00:59:35.996 --> 00:59:38.200 data have an excellent prognosis
NOTE Confidence: 0.848581026363636

00:59:38.200 --> 00:59:41.259 and even the five year survival for
NOTE Confidence: 0.848581026363636

00:59:41.259 --> 00:59:44.143 the triple negatives when they are
NOTE Confidence: 0.848581026363636

00:59:44.143 --> 00:59:46.558 localized have a better prognosis
NOTE Confidence: 0.848581026363636

00:59:46.558 --> 00:59:49.360 than you see in other countries.
NOTE Confidence: 0.915700154444445

00:59:51.530 --> 00:59:53.466 But survival rates don't
NOTE Confidence: 0.915700154444445

00:59:53.466 --> 00:59:55.886 really tell the whole story.
NOTE Confidence: 0.915700154444445

00:59:55.890 --> 00:59:59.614 First of all, women being diagnosed with
NOTE Confidence: 0.915700154444445

00:59:59.614 --> 01:00:03.518 breast cancer today may have better outcomes.
NOTE Confidence: 0.915700154444445

01:00:03.520 --> 01:00:06.544 We'll see in the most recent SEER data,
NOTE Confidence: 0.915700154444445

01:00:06.550 --> 01:00:09.150 but diagnostics and treatments
NOTE Confidence: 0.915700154444445

01:00:09.150 --> 01:00:11.750 continue to improve overtime,
NOTE Confidence: 0.915700154444445

01:00:11.750 --> 01:00:14.683 and there's good access in highly developed
NOTE Confidence: 0.915700154444445

01:00:14.683 --> 01:00:17.129 countries and highly developed cities.
NOTE Confidence: 0.915700154444445

01:00:17.130 --> 01:00:20.046 When you look at some of the SEER data,

NOTE Confidence: 0.915700154444445
01:00:20.050 --> 01:00:22.425 but these numbers don't take
NOTE Confidence: 0.915700154444445
01:00:22.425 --> 01:00:23.850 everything into account.
NOTE Confidence: 0.915700154444445
01:00:23.850 --> 01:00:25.434 First of all,
NOTE Confidence: 0.915700154444445
01:00:25.434 --> 01:00:28.074 survival rates for hormone receptor
NOTE Confidence: 0.915700154444445
01:00:28.074 --> 01:00:29.790 positive breast cancer.
NOTE Confidence: 0.915700154444445
01:00:29.790 --> 01:00:32.710 50% of the patients that are going to
NOTE Confidence: 0.915700154444445
01:00:32.710 --> 01:00:35.338 relapse will relapse after five years.
NOTE Confidence: 0.915700154444445
01:00:35.340 --> 01:00:38.756 So the five year survival rate kind of
NOTE Confidence: 0.915700154444445
01:00:38.756 --> 01:00:42.286 skews things and some of the survival rates,
NOTE Confidence: 0.915700154444445
01:00:42.290 --> 01:00:45.188 although they may be due to stage,
NOTE Confidence: 0.915700154444445
01:00:45.190 --> 01:00:48.396 they may really have to do with
NOTE Confidence: 0.915700154444445
01:00:48.396 --> 01:00:49.770 overall health response,
NOTE Confidence: 0.915700154444445
01:00:49.770 --> 01:00:53.172 an access to treatment so different
NOTE Confidence: 0.915700154444445
01:00:53.172 --> 01:00:56.529 subtypes may predict timing of relapse.
NOTE Confidence: 0.915700154444445
01:00:56.530 --> 01:00:59.306 But there are so many other things I'm
NOTE Confidence: 0.915700154444445

01:00:59.306 --> 01:01:02.436 going to be a little controversial here
NOTE Confidence: 0.915700154444445

01:01:02.436 --> 01:01:05.470 and say geopolitics can determine outcome.
NOTE Confidence: 0.915700154444445

01:01:05.470 --> 01:01:08.851 Look at a situation in Puerto Rico
NOTE Confidence: 0.915700154444445

01:01:08.851 --> 01:01:11.503 during Hurricane Maria where it
NOTE Confidence: 0.915700154444445

01:01:11.503 --> 01:01:14.288 really decimated their health system.
NOTE Confidence: 0.915700154444445

01:01:14.290 --> 01:01:16.398 That does change screening.
NOTE Confidence: 0.915700154444445

01:01:16.398 --> 01:01:19.033 It does change treatment and
NOTE Confidence: 0.915700154444445

01:01:19.033 --> 01:01:21.438 it will change outcome.
NOTE Confidence: 0.915700154444445

01:01:21.440 --> 01:01:23.592 Let's take geopolitical changes
NOTE Confidence: 0.915700154444445

01:01:23.592 --> 01:01:25.744 in our own country.
NOTE Confidence: 0.915700154444445

01:01:25.750 --> 01:01:27.760 Let's look at the pandemic.
NOTE Confidence: 0.915700154444445

01:01:27.760 --> 01:01:30.682 For the pandemic may have changed
NOTE Confidence: 0.915700154444445

01:01:30.682 --> 01:01:33.090 patterns of screening change patterns
NOTE Confidence: 0.915700154444445

01:01:33.090 --> 01:01:36.106 of treatment and I hate to say it
NOTE Confidence: 0.915700154444445

01:01:36.106 --> 01:01:39.875 women have been known to increase their
NOTE Confidence: 0.915700154444445

01:01:39.875 --> 01:01:42.870 alcohol intake during the pandemic.

NOTE Confidence: 0.915700154444445
01:01:42.870 --> 01:01:47.294 Are we going to see changes in
NOTE Confidence: 0.915700154444445
01:01:47.294 --> 01:01:50.959 epidemiology due to the pandemic?
NOTE Confidence: 0.915700154444445
01:01:50.960 --> 01:01:53.738 So who are the most vulnerable
NOTE Confidence: 0.915700154444445
01:01:53.738 --> 01:01:55.590 that we see now?
NOTE Confidence: 0.915700154444445
01:01:55.590 --> 01:01:59.090 Black women, particularly younger women.
NOTE Confidence: 0.915700154444445
01:01:59.090 --> 01:02:02.324 They are more likely to be diagnosed
NOTE Confidence: 0.915700154444445
01:02:02.330 --> 01:02:04.315 with triple negative breast cancer
NOTE Confidence: 0.915700154444445
01:02:04.315 --> 01:02:07.090 and more likely to be diagnosed.
NOTE Confidence: 0.915700154444445
01:02:07.090 --> 01:02:10.100 Diagnosed at a younger age.
NOTE Confidence: 0.915700154444445
01:02:10.100 --> 01:02:12.452 Blacks are more likely to die
NOTE Confidence: 0.915700154444445
01:02:12.452 --> 01:02:14.749 of breast cancer at any age.
NOTE Confidence: 0.915700154444445
01:02:14.750 --> 01:02:17.090 They presented a later stage,
NOTE Confidence: 0.915700154444445
01:02:17.090 --> 01:02:20.420 but their insurance status is worse
NOTE Confidence: 0.915700154444445
01:02:20.420 --> 01:02:24.090 twice as likely to be uninsured.
NOTE Confidence: 0.915700154444445
01:02:24.090 --> 01:02:24.536 Well,
NOTE Confidence: 0.915700154444445

01:02:24.536 --> 01:02:26.320 immigrants from less developed
NOTE Confidence: 0.915700154444445

01:02:26.320 --> 01:02:28.955 nations we talked about what you
NOTE Confidence: 0.915700154444445

01:02:28.955 --> 01:02:30.635 see with global breast cancer
NOTE Confidence: 0.915700154444445

01:02:30.635 --> 01:02:33.312 and I'll talk a little bit about
NOTE Confidence: 0.915700154444445

01:02:33.312 --> 01:02:34.996 sexual minorities as well.
NOTE Confidence: 0.80241686

01:02:37.490 --> 01:02:40.570 The NCI talks about risks in terms
NOTE Confidence: 0.80241686

01:02:40.570 --> 01:02:43.020 of cancer health disparities,
NOTE Confidence: 0.80241686

01:02:43.020 --> 01:02:43.950 and you can see it.
NOTE Confidence: 0.80241686

01:02:43.950 --> 01:02:46.402 Top of this slide.
NOTE Confidence: 0.80241686

01:02:46.402 --> 01:02:50.794 Women who are African American have a
NOTE Confidence: 0.80241686

01:02:50.794 --> 01:02:54.966 higher risk of dying from breast cancer,
NOTE Confidence: 0.80241686

01:02:54.970 --> 01:02:57.406 but let's get into the various
NOTE Confidence: 0.80241686

01:02:57.406 --> 01:03:00.261 groups that are more likely to
NOTE Confidence: 0.80241686

01:03:00.261 --> 01:03:02.545 suffer cancer health disparities,
NOTE Confidence: 0.80241686

01:03:02.550 --> 01:03:05.448 and I think I'm going to describe for you
NOTE Confidence: 0.80241686

01:03:05.448 --> 01:03:08.494 how many of these apply to breast cancer.

NOTE Confidence: 0.80241686

01:03:08.500 --> 01:03:11.248 We already talked about women of

NOTE Confidence: 0.80241686

01:03:11.248 --> 01:03:13.820 color and breast cancer outcome,

NOTE Confidence: 0.80241686

01:03:13.820 --> 01:03:16.585 and women of different ancestry

NOTE Confidence: 0.80241686

01:03:16.585 --> 01:03:18.797 or recent immigrants made.

NOTE Confidence: 0.80241686

01:03:18.800 --> 01:03:22.895 We also have a higher risk of both getting

NOTE Confidence: 0.80241686

01:03:22.895 --> 01:03:26.978 breast cancer or particularly their outcomes.

NOTE Confidence: 0.80241686

01:03:26.980 --> 01:03:29.780 Individuals of lower socioeconomic

NOTE Confidence: 0.80241686

01:03:29.780 --> 01:03:31.880 status have decreased.

NOTE Confidence: 0.80241686

01:03:31.880 --> 01:03:33.791 Access to screening,

NOTE Confidence: 0.80241686

01:03:33.791 --> 01:03:36.339 decreased access to treatment.

NOTE Confidence: 0.80241686

01:03:36.340 --> 01:03:39.526 An also may have associated health

NOTE Confidence: 0.80241686

01:03:39.526 --> 01:03:42.750 problems that make treatment problematic.

NOTE Confidence: 0.80241686

01:03:42.750 --> 01:03:44.822 Well, individuals with disabilities

NOTE Confidence: 0.80241686

01:03:44.822 --> 01:03:47.930 are less likely to get screened,

NOTE Confidence: 0.80241686

01:03:47.930 --> 01:03:49.250 and that's been looked at.

NOTE Confidence: 0.80241686

01:03:49.250 --> 01:03:52.043 At Mammographic screening
NOTE Confidence: 0.80241686

01:03:52.043 --> 01:03:54.836 in wheelchair population.
NOTE Confidence: 0.80241686

01:03:54.840 --> 01:03:55.417 Again,
NOTE Confidence: 0.80241686

01:03:55.417 --> 01:03:57.725 individuals who have poor
NOTE Confidence: 0.80241686

01:03:57.725 --> 01:04:00.610 insurance coverage are less likely
NOTE Confidence: 0.80241686

01:04:00.696 --> 01:04:03.276 to get the best possible care.
NOTE Confidence: 0.80241686

01:04:03.280 --> 01:04:05.740 We talked about the rural areas
NOTE Confidence: 0.80241686

01:04:05.740 --> 01:04:08.930 in the United States in the South
NOTE Confidence: 0.80241686

01:04:08.930 --> 01:04:11.375 that those patients have worse
NOTE Confidence: 0.80241686

01:04:11.375 --> 01:04:13.567 insurance coverage and are less
NOTE Confidence: 0.80241686

01:04:13.567 --> 01:04:15.829 likely to have access to care.
NOTE Confidence: 0.80241686

01:04:15.830 --> 01:04:17.426 LGBT population.
NOTE Confidence: 0.80241686

01:04:17.426 --> 01:04:22.214 LGBT women are less likely to
NOTE Confidence: 0.80241686

01:04:22.214 --> 01:04:25.839 get screened and also have.
NOTE Confidence: 0.80241686

01:04:25.840 --> 01:04:29.816 Some of the estrogen during lifetime risk
NOTE Confidence: 0.80241686

01:04:29.816 --> 01:04:33.520 factors that would increase their risk.

NOTE Confidence: 0.80241686

01:04:33.520 --> 01:04:36.760 We talked about immigrants,

NOTE Confidence: 0.80241686

01:04:36.760 --> 01:04:37.570 refugees,

NOTE Confidence: 0.80241686

01:04:37.570 --> 01:04:41.188 and the elderly who are more

NOTE Confidence: 0.80241686

01:04:41.188 --> 01:04:44.590 likely to get breast cancer.

NOTE Confidence: 0.80241686

01:04:44.590 --> 01:04:46.996 So breast cancer rates are declining

NOTE Confidence: 0.80241686

01:04:46.996 --> 01:04:50.132 in our country and this is due to

NOTE Confidence: 0.80241686

01:04:50.132 --> 01:04:52.316 diagnostic advances and some of the

NOTE Confidence: 0.80241686

01:04:52.398 --> 01:04:55.387 things that Mariam and Mike talked about.

NOTE Confidence: 0.80241686

01:04:55.390 --> 01:04:58.435 But risk factors have been identified and

NOTE Confidence: 0.80241686

01:04:58.435 --> 01:05:01.687 they really vary depending on the subtype.

NOTE Confidence: 0.80241686

01:05:01.690 --> 01:05:03.909 There are certain regions in the world,

NOTE Confidence: 0.80241686

01:05:03.910 --> 01:05:06.070 but in our own country that

NOTE Confidence: 0.80241686

01:05:06.070 --> 01:05:08.176 are increased risk for adverse

NOTE Confidence: 0.80241686

01:05:08.176 --> 01:05:10.540 outcomes and special populations.

NOTE Confidence: 0.80241686

01:05:10.540 --> 01:05:14.194 In the United States are disproportionately

NOTE Confidence: 0.80241686

01:05:14.194 --> 01:05:16.630 vulnerable to adverse outcomes.
NOTE Confidence: 0.80241686

01:05:16.630 --> 01:05:19.780 It will require an enormous
NOTE Confidence: 0.80241686

01:05:19.780 --> 01:05:22.930 collaborative effort not only on
NOTE Confidence: 0.80241686

01:05:23.035 --> 01:05:25.282 the part of the medical community,
NOTE Confidence: 0.80241686

01:05:25.282 --> 01:05:28.286 but on the part of all citizens to
NOTE Confidence: 0.80241686

01:05:28.286 --> 01:05:30.596 transform cancer care for all people.
NOTE Confidence: 0.80241686

01:05:30.600 --> 01:05:33.272 Regardless of their race,
NOTE Confidence: 0.80241686

01:05:33.272 --> 01:05:35.664 ethnicity, immigration status,
NOTE Confidence: 0.80241686

01:05:35.664 --> 01:05:37.388 age, gender,
NOTE Confidence: 0.80241686

01:05:37.388 --> 01:05:41.698 sexual orientation or socioeconomic status,
NOTE Confidence: 0.80241686

01:05:41.700 --> 01:05:44.040 one of the biggest risk factors
NOTE Confidence: 0.80241686

01:05:44.040 --> 01:05:46.092 for breast cancer is the
NOTE Confidence: 0.80241686

01:05:46.092 --> 01:05:48.594 communities that people grew up in.
NOTE Confidence: 0.913730628333333

01:05:50.760 --> 01:05:52.638 And thank you for your attention,
NOTE Confidence: 0.913730628333333

01:05:52.640 --> 01:05:55.167 and I always like to mention those
NOTE Confidence: 0.913730628333333

01:05:55.167 --> 01:05:58.096 that I seen with breast cancer or

NOTE Confidence: 0.913730628333333

01:05:58.096 --> 01:06:00.736 have been affected by the disease.

NOTE Confidence: 0.82665481

01:06:03.880 --> 01:06:05.506 Thank you doctor.

NOTE Confidence: 0.82665481

01:06:05.506 --> 01:06:09.176 So that was fantastic and you know,

NOTE Confidence: 0.82665481

01:06:09.180 --> 01:06:10.614 thank you for all three of

NOTE Confidence: 0.82665481

01:06:10.614 --> 01:06:11.880 our speakers for you know,

NOTE Confidence: 0.82665481

01:06:11.880 --> 01:06:13.744 three really phenomenal presentations

NOTE Confidence: 0.82665481

01:06:13.744 --> 01:06:16.540 that you know show the breadth

NOTE Confidence: 0.82665481

01:06:16.613 --> 01:06:18.150 of the care and services that

NOTE Confidence: 0.82665481

01:06:18.150 --> 01:06:19.550 we provide here at Yale.

NOTE Confidence: 0.82665481

01:06:19.550 --> 01:06:20.765 But more importantly,

NOTE Confidence: 0.82665481

01:06:20.765 --> 01:06:23.195 you know the the options and

NOTE Confidence: 0.82665481

01:06:23.195 --> 01:06:25.135 therapies that are available to

NOTE Confidence: 0.82665481

01:06:25.135 --> 01:06:27.325 women and some of the challenges

NOTE Confidence: 0.82665481

01:06:27.394 --> 01:06:29.338 that we have moving forward in

NOTE Confidence: 0.82665481

01:06:29.338 --> 01:06:31.802 terms of not only screening but

NOTE Confidence: 0.82665481

01:06:31.802 --> 01:06:34.707 treatment of our more vulnerable.
NOTE Confidence: 0.82665481

01:06:34.710 --> 01:06:36.480 Populations there were a couple of
NOTE Confidence: 0.82665481

01:06:36.480 --> 01:06:38.554 questions in the chat box and hopefully
NOTE Confidence: 0.82665481

01:06:38.554 --> 01:06:40.507 others will come in in the question
NOTE Confidence: 0.82665481

01:06:40.566 --> 01:06:42.358 and answer until we get some more.
NOTE Confidence: 0.82665481

01:06:42.360 --> 01:06:44.866 I wanted to start with a question
NOTE Confidence: 0.82665481

01:06:44.866 --> 01:06:47.216 to for Doctor Lustberg and the
NOTE Confidence: 0.82665481

01:06:47.216 --> 01:06:49.434 others on D escalation of therapy,
NOTE Confidence: 0.82665481

01:06:49.434 --> 01:06:52.671 and I guess how do you approach that
NOTE Confidence: 0.82665481

01:06:52.671 --> 01:06:55.216 question to patients when you're,
NOTE Confidence: 0.82665481

01:06:55.220 --> 01:06:56.844 you know, trying to offer a trial?
NOTE Confidence: 0.82665481

01:06:56.850 --> 01:06:59.386 That's going to do less rather than more,
NOTE Confidence: 0.82665481

01:06:59.390 --> 01:07:00.878 especially for that anxious
NOTE Confidence: 0.82665481

01:07:00.878 --> 01:07:02.366 patient who's you know,
NOTE Confidence: 0.82665481

01:07:02.370 --> 01:07:05.359 main concern is living and survival and.
NOTE Confidence: 0.82665481

01:07:05.360 --> 01:07:08.446 I'm not necessarily trying to sell

NOTE Confidence: 0.82665481
01:07:08.446 --> 01:07:10.630 that trial to them on deescalation,
NOTE Confidence: 0.82665481
01:07:10.630 --> 01:07:11.686 but kind of.
NOTE Confidence: 0.82665481
01:07:11.686 --> 01:07:14.150 How do you make them feel comfortable
NOTE Confidence: 0.82665481
01:07:14.225 --> 01:07:16.410 moving forward down that route?
NOTE Confidence: 0.82665481
01:07:16.410 --> 01:07:16.620 Yeah,
NOTE Confidence: 0.71441351
01:07:16.630 --> 01:07:17.874 that's a great question.
NOTE Confidence: 0.71441351
01:07:17.874 --> 01:07:19.490 Doctor goes on, I think.
NOTE Confidence: 0.71441351
01:07:19.490 --> 01:07:23.520 I think it takes a lot of open communication,
NOTE Confidence: 0.71441351
01:07:23.520 --> 01:07:26.008 listening understanding their fears,
NOTE Confidence: 0.71441351
01:07:26.008 --> 01:07:29.623 goals of care, but also spending
NOTE Confidence: 0.71441351
01:07:29.623 --> 01:07:32.528 time laying out the rationale.
NOTE Confidence: 0.71441351
01:07:32.530 --> 01:07:35.258 I like to say these trials were conceived
NOTE Confidence: 0.71441351
01:07:35.258 --> 01:07:37.996 by the best minds in breast cancer,
NOTE Confidence: 0.71441351
01:07:38.000 --> 01:07:39.688 essentially synthesizing all the
NOTE Confidence: 0.71441351
01:07:39.688 --> 01:07:42.660 best data that we have to date.
NOTE Confidence: 0.71441351

01:07:42.660 --> 01:07:43.785 And here's why.
NOTE Confidence: 0.71441351

01:07:43.785 --> 01:07:46.041 We're thinking that more is not
NOTE Confidence: 0.71441351

01:07:46.041 --> 01:07:49.808 necessarily more so it does take more time.
NOTE Confidence: 0.71441351

01:07:49.810 --> 01:07:51.986 But I think I tend to use that
NOTE Confidence: 0.71441351

01:07:51.986 --> 01:07:54.430 as an educational opportunity,
NOTE Confidence: 0.71441351

01:07:54.430 --> 01:07:57.307 and certainly if they don't feel comfortable,
NOTE Confidence: 0.71441351

01:07:57.310 --> 01:07:58.834 that's their choice.
NOTE Confidence: 0.71441351

01:07:58.834 --> 01:08:00.866 But I think regardless,
NOTE Confidence: 0.71441351

01:08:00.870 --> 01:08:03.510 I think it opens up the dialogue for
NOTE Confidence: 0.71441351

01:08:03.510 --> 01:08:05.410 potentially an additional trials down
NOTE Confidence: 0.71441351

01:08:05.410 --> 01:08:08.133 the road just to get them comfortable
NOTE Confidence: 0.71441351

01:08:08.200 --> 01:08:10.340 about the clinical trial process,
NOTE Confidence: 0.71441351

01:08:10.340 --> 01:08:13.520 how these concepts are vetted so
NOTE Confidence: 0.71441351

01:08:13.520 --> 01:08:16.919 carefully and that we would never.
NOTE Confidence: 0.71441351

01:08:16.920 --> 01:08:18.264 Consciously give a therapy
NOTE Confidence: 0.71441351

01:08:18.264 --> 01:08:20.630 that is known to be so far.

NOTE Confidence: 0.56738253

01:08:22.430 --> 01:08:26.018 Angel yeah. In a safer,

NOTE Confidence: 0.56738253

01:08:26.018 --> 01:08:27.050 vulnerable population.

NOTE Confidence: 0.92762132875

01:08:27.050 --> 01:08:29.222 So many women have to work

NOTE Confidence: 0.92762132875

01:08:29.222 --> 01:08:32.450 and have to take care of their

NOTE Confidence: 0.92762132875

01:08:32.450 --> 01:08:34.136 families during treatment.

NOTE Confidence: 0.92762132875

01:08:34.140 --> 01:08:36.710 And it's not a choice.

NOTE Confidence: 0.92762132875

01:08:36.710 --> 01:08:39.769 And if we can deescalate it can

NOTE Confidence: 0.92762132875

01:08:39.769 --> 01:08:42.393 be the difference between being

NOTE Confidence: 0.92762132875

01:08:42.393 --> 01:08:45.428 unemployed and maybe losing housing

NOTE Confidence: 0.92762132875

01:08:45.428 --> 01:08:48.444 and losing ability to take care

NOTE Confidence: 0.92762132875

01:08:48.444 --> 01:08:51.006 of the rest of their life so

NOTE Confidence: 0.92762132875

01:08:51.010 --> 01:08:54.920 they can be attractive. Slowly.

NOTE Confidence: 0.850641555

01:08:56.990 --> 01:08:59.238 There is a question in the chat box

NOTE Confidence: 0.850641555

01:08:59.238 --> 01:09:01.389 from Carolyn Friedman and maybe Andrew.

NOTE Confidence: 0.850641555

01:09:01.390 --> 01:09:03.582 You want to tackle this first and then

NOTE Confidence: 0.850641555

01:09:03.582 --> 01:09:05.848 the other is why are dense breast
NOTE Confidence: 0.850641555

01:09:05.848 --> 01:09:07.503 dense breasted women still getting
NOTE Confidence: 0.850641555

01:09:07.568 --> 01:09:09.568 yearly mammograms and nothing else?
NOTE Confidence: 0.850641555

01:09:09.570 --> 01:09:11.388 And maybe a little bit about
NOTE Confidence: 0.850641555

01:09:11.388 --> 01:09:12.600 the difference between kinetic
NOTE Confidence: 0.850641555

01:09:12.659 --> 01:09:14.099 and maybe some other states.
NOTE Confidence: 0.874390768

01:09:15.240 --> 01:09:18.607 I'm, well, Connecticut was one of the
NOTE Confidence: 0.874390768

01:09:18.607 --> 01:09:22.283 first states to pass a wonderful law
NOTE Confidence: 0.874390768

01:09:22.283 --> 01:09:24.958 mandating that women are identified
NOTE Confidence: 0.874390768

01:09:24.958 --> 01:09:28.312 as having dense breasts and making
NOTE Confidence: 0.874390768

01:09:28.312 --> 01:09:31.032 sure that there is insurance
NOTE Confidence: 0.874390768

01:09:31.040 --> 01:09:34.224 coverage for additional testing
NOTE Confidence: 0.874390768

01:09:34.224 --> 01:09:39.000 either an ultrasound or an MRI.
NOTE Confidence: 0.874390768

01:09:39.000 --> 01:09:42.024 An Carolyn, you bring up a great point.
NOTE Confidence: 0.874390768

01:09:42.030 --> 01:09:45.229 Many states have signed on to this.
NOTE Confidence: 0.874390768

01:09:45.230 --> 01:09:50.536 But not all States and you ask a question.

NOTE Confidence: 0.874390768

01:09:50.536 --> 01:09:53.500 I think it's a matter of priorities.

NOTE Confidence: 0.874390768

01:09:53.500 --> 01:09:56.110 Connecticut has been very good

NOTE Confidence: 0.874390768

01:09:56.110 --> 01:09:58.198 in terms of advocacy,

NOTE Confidence: 0.874390768

01:09:58.200 --> 01:10:01.242 and there was a tremendous advocate

NOTE Confidence: 0.874390768

01:10:01.242 --> 01:10:05.132 who got this through after her own

NOTE Confidence: 0.874390768

01:10:05.132 --> 01:10:08.077 experience of having a mammographic

NOTE Confidence: 0.874390768

01:10:08.077 --> 01:10:09.890 le undetectable tumor.

NOTE Confidence: 0.874390768

01:10:09.890 --> 01:10:12.220 That was an advanced cancer.

NOTE Confidence: 0.788246111666667

01:10:14.620 --> 01:10:18.406 Thank you Andrea. A question for.

NOTE Confidence: 0.788246111666667

01:10:18.410 --> 01:10:21.650 Michael, I'm here Chesapeake early on,

NOTE Confidence: 0.788246111666667

01:10:21.650 --> 01:10:24.298 about two years ago it posed a question

NOTE Confidence: 0.788246111666667

01:10:24.298 --> 01:10:26.858 in an editorial where to platinum

NOTE Confidence: 0.788246111666667

01:10:26.858 --> 01:10:29.594 salts it in triple negative breast

NOTE Confidence: 0.788246111666667

01:10:29.669 --> 01:10:32.169 cancer in the neoadjuvant setting.

NOTE Confidence: 0.788246111666667

01:10:32.170 --> 01:10:33.500 You know, have things changed,

NOTE Confidence: 0.788246111666667

01:10:33.500 --> 01:10:36.650 or is it still something that were?
NOTE Confidence: 0.788246111666667

01:10:36.650 --> 01:10:39.422 You know struggling through case by
NOTE Confidence: 0.788246111666667

01:10:39.422 --> 01:10:41.868 case and differences maybe between
NOTE Confidence: 0.788246111666667

01:10:41.868 --> 01:10:45.800 bracca specific T NBC versus sporadic.
NOTE Confidence: 0.858326927333333

01:10:46.760 --> 01:10:48.713 It's a good question and we still
NOTE Confidence: 0.858326927333333

01:10:48.713 --> 01:10:50.560 do struggle with it an it's we it.
NOTE Confidence: 0.858326927333333

01:10:50.560 --> 01:10:53.038 I think it's fair to say it's
NOTE Confidence: 0.858326927333333

01:10:53.038 --> 01:10:54.769 still not standard of care.
NOTE Confidence: 0.858326927333333

01:10:54.770 --> 01:10:57.010 There are a number of trials that that
NOTE Confidence: 0.858326927333333

01:10:57.010 --> 01:10:59.266 have shown that when it's incorporated
NOTE Confidence: 0.858326927333333

01:10:59.266 --> 01:11:00.898 into the neoadjuvant setting,
NOTE Confidence: 0.858326927333333

01:11:00.900 --> 01:11:02.480 it improves the pathological
NOTE Confidence: 0.858326927333333

01:11:02.480 --> 01:11:03.665 complete response rate.
NOTE Confidence: 0.858326927333333

01:11:03.670 --> 01:11:06.160 So if you are of the mind that the goal
NOTE Confidence: 0.858326927333333

01:11:06.233 --> 01:11:08.501 of treating early stage triple negative
NOTE Confidence: 0.858326927333333

01:11:08.501 --> 01:11:11.359 breast cancer is to maximize the triple,

NOTE Confidence: 0.858326927333333
01:11:11.360 --> 01:11:12.192 the maximized,
NOTE Confidence: 0.858326927333333
01:11:12.192 --> 01:11:13.856 the pathological complete response
NOTE Confidence: 0.858326927333333
01:11:13.856 --> 01:11:16.182 rate because we know those patients
NOTE Confidence: 0.858326927333333
01:11:16.182 --> 01:11:17.964 are the best to be cured.
NOTE Confidence: 0.858326927333333
01:11:17.970 --> 01:11:19.934 Then it's reasonable to
NOTE Confidence: 0.858326927333333
01:11:19.934 --> 01:11:21.407 consider incorporating it.
NOTE Confidence: 0.858326927333333
01:11:21.410 --> 01:11:23.270 One might not think it's
NOTE Confidence: 0.858326927333333
01:11:23.270 --> 01:11:25.130 worth incorporating it in a
NOTE Confidence: 0.858326927333333
01:11:25.206 --> 01:11:27.570 relatively lower anatomical risk,
NOTE Confidence: 0.858326927333333
01:11:27.570 --> 01:11:31.399 so maybe a stage one patient or,
NOTE Confidence: 0.858326927333333
01:11:31.400 --> 01:11:32.952 and as you said,
NOTE Confidence: 0.858326927333333
01:11:32.952 --> 01:11:34.892 we know from the metastatic
NOTE Confidence: 0.858326927333333
01:11:34.892 --> 01:11:37.464 setting with the TNT trial that the
NOTE Confidence: 0.858326927333333
01:11:37.464 --> 01:11:39.349 response rate for BRCA germline
NOTE Confidence: 0.858326927333333
01:11:39.349 --> 01:11:41.229 mutation carriers is quite high,
NOTE Confidence: 0.858326927333333

01:11:41.230 --> 01:11:43.396 so it may be worth incorporating
NOTE Confidence: 0.858326927333333

01:11:43.396 --> 01:11:44.840 it in that standpoint,
NOTE Confidence: 0.858326927333333

01:11:44.840 --> 01:11:46.950 although there was an early
NOTE Confidence: 0.858326927333333

01:11:46.950 --> 01:11:48.638 stage trial that compared.
NOTE Confidence: 0.858326927333333

01:11:48.640 --> 01:11:48.975 Yes,
NOTE Confidence: 0.858326927333333

01:11:48.975 --> 01:11:50.650 this Platten to standard chemotherapy
NOTE Confidence: 0.858326927333333

01:11:50.650 --> 01:11:53.493 and it wasn't much of a difference in
NOTE Confidence: 0.858326927333333

01:11:53.493 --> 01:11:55.293 terms of pathological complete response.
NOTE Confidence: 0.858326927333333

01:11:55.300 --> 01:11:57.910 For just just that comparison.
NOTE Confidence: 0.858326927333333

01:11:57.910 --> 01:11:59.926 So it's still a question that's up
NOTE Confidence: 0.858326927333333

01:11:59.926 --> 01:12:01.986 in the air whether to incorporate
NOTE Confidence: 0.858326927333333

01:12:01.986 --> 01:12:03.866 it into the early stage.
NOTE Confidence: 0.7494846625

01:12:06.690 --> 01:12:08.748 There's a probably a question maybe
NOTE Confidence: 0.7494846625

01:12:08.748 --> 01:12:10.975 for Andrew, but also others in the
NOTE Confidence: 0.7494846625

01:12:10.975 --> 01:12:13.230 chat box from our fellow Angelique.
NOTE Confidence: 0.7494846625

01:12:13.230 --> 01:12:15.552 Has there been any reduction of

NOTE Confidence: 0.7494846625

01:12:15.552 --> 01:12:17.520 the disparities in outcomes between

NOTE Confidence: 0.7494846625

01:12:17.520 --> 01:12:19.644 minority races and white women in

NOTE Confidence: 0.7494846625

01:12:19.644 --> 01:12:21.888 the last two or three decades?

NOTE Confidence: 0.7494846625

01:12:21.890 --> 01:12:24.602 And maybe expanding on some of the exciting

NOTE Confidence: 0.7494846625

01:12:24.602 --> 01:12:27.048 work and research that you've been?

NOTE Confidence: 0.7494846625

01:12:27.050 --> 01:12:28.670 An advocacy that you've been

NOTE Confidence: 0.7494846625

01:12:28.670 --> 01:12:30.290 doing here here at home?

NOTE Confidence: 0.850145492142857

01:12:31.570 --> 01:12:35.010 I'm. We do a lot better in Connecticut

NOTE Confidence: 0.850145492142857

01:12:35.010 --> 01:12:37.840 than in rest of the country.

NOTE Confidence: 0.850145492142857

01:12:37.840 --> 01:12:42.776 Some of the disparities in terms of outcomes,

NOTE Confidence: 0.850145492142857

01:12:42.780 --> 01:12:44.700 certainly in terms of

NOTE Confidence: 0.850145492142857

01:12:44.700 --> 01:12:47.100 screening and access to care,

NOTE Confidence: 0.850145492142857

01:12:47.100 --> 01:12:50.468 are better in this state than many others,

NOTE Confidence: 0.850145492142857

01:12:50.470 --> 01:12:54.096 but there is still a huge disparity.

NOTE Confidence: 0.850145492142857

01:12:54.100 --> 01:12:58.040 Partially because white women are

NOTE Confidence: 0.850145492142857

01:12:58.040 --> 01:13:01.957 doing better, which it increases.
NOTE Confidence: 0.850145492142857

01:13:01.957 --> 01:13:08.360 But the difference between races and I think.
NOTE Confidence: 0.850145492142857

01:13:08.360 --> 01:13:10.628 You know, we've got a long way to go.
NOTE Confidence: 0.837891923076923

01:13:13.840 --> 01:13:17.128 There is a question in the chat box
NOTE Confidence: 0.837891923076923

01:13:17.128 --> 01:13:19.348 from Professor Rim and Merriam.
NOTE Confidence: 0.837891923076923

01:13:19.350 --> 01:13:21.870 Do you want to 'cause I can't even
NOTE Confidence: 0.837891923076923

01:13:21.870 --> 01:13:23.984 pronounce half the drugs that you guys
NOTE Confidence: 0.837891923076923

01:13:23.984 --> 01:13:26.290 can put out the transducer map I get,
NOTE Confidence: 0.837891923076923

01:13:26.290 --> 01:13:28.130 but the others are tougher.
NOTE Confidence: 0.872252413333333

01:13:29.390 --> 01:13:30.329 Yeah, it's great.
NOTE Confidence: 0.872252413333333

01:13:30.330 --> 01:13:32.486 Great question, so I think I
NOTE Confidence: 0.872252413333333

01:13:32.486 --> 01:13:34.130 think what you're pointing at is,
NOTE Confidence: 0.872252413333333

01:13:34.130 --> 01:13:37.140 I think our our poor man's definition
NOTE Confidence: 0.872252413333333

01:13:37.140 --> 01:13:39.430 of what's triple negative and
NOTE Confidence: 0.872252413333333

01:13:39.430 --> 01:13:41.710 what's to her two positive.
NOTE Confidence: 0.872252413333333

01:13:41.710 --> 01:13:43.342 I think it's going to change a lot

NOTE Confidence: 0.872252413333333

01:13:43.342 --> 01:13:45.576 in the coming years because of these

NOTE Confidence: 0.872252413333333

01:13:45.576 --> 01:13:46.992 antibody drug conjugate therapies.

NOTE Confidence: 0.8079124575

01:13:49.590 --> 01:13:52.551 Drugs like this have shown to have

NOTE Confidence: 0.8079124575

01:13:52.551 --> 01:13:55.080 remarkable activity even in what we would

NOTE Confidence: 0.8079124575

01:13:55.080 --> 01:13:56.616 consider normally hurting negative,

NOTE Confidence: 0.8079124575

01:13:56.616 --> 01:13:59.184 but just a little bit of

NOTE Confidence: 0.8079124575

01:13:59.184 --> 01:14:01.797 her to her too low signal.

NOTE Confidence: 0.8079124575

01:14:01.800 --> 01:14:04.253 Is associated with significant outcomes.

NOTE Confidence: 0.8079124575

01:14:04.253 --> 01:14:09.199 So I do agree with you Doctor Ram that I,

NOTE Confidence: 0.8079124575

01:14:09.200 --> 01:14:12.609 I suspect, as these trials are finalized,

NOTE Confidence: 0.8079124575

01:14:12.610 --> 01:14:14.542 I think we will be looking at

NOTE Confidence: 0.8079124575

01:14:14.542 --> 01:14:15.768 different standards or care

NOTE Confidence: 0.8079124575

01:14:15.768 --> 01:14:17.128 for this purchase subgroup.

NOTE Confidence: 0.86461306625

01:14:18.210 --> 01:14:20.394 And for those who couldn't see the question,

NOTE Confidence: 0.86461306625

01:14:20.400 --> 01:14:22.703 it will is will trousers some outdoor

NOTE Confidence: 0.86461306625

01:14:22.703 --> 01:14:24.880 teak sent he can make all low.
NOTE Confidence: 0.86461306625

01:14:24.880 --> 01:14:26.332 Her two patients targets
NOTE Confidence: 0.86461306625

01:14:26.332 --> 01:14:28.147 for this sort of therapy.
NOTE Confidence: 0.86461306625

01:14:28.150 --> 01:14:29.835 And will this change the
NOTE Confidence: 0.86461306625

01:14:29.835 --> 01:14:31.183 triple negative category so?
NOTE Confidence: 0.836180874

01:14:32.580 --> 01:14:34.950 So, so it's like, yeah, I think
NOTE Confidence: 0.836180874

01:14:34.950 --> 01:14:38.135 obviously we need to wait for additional.
NOTE Confidence: 0.836180874

01:14:38.140 --> 01:14:41.060 You know, phase three data for that category,
NOTE Confidence: 0.836180874

01:14:41.060 --> 01:14:44.399 but so far the results are very,
NOTE Confidence: 0.836180874

01:14:44.400 --> 01:14:48.144 very promising. I think there may
NOTE Confidence: 0.836180874

01:14:48.144 --> 01:14:52.069 be additional Adcs that maybe safer.
NOTE Confidence: 0.836180874

01:14:52.070 --> 01:14:53.870 But with this particular drug,
NOTE Confidence: 0.836180874

01:14:53.870 --> 01:14:56.198 the higher, higher risk of interstitial
NOTE Confidence: 0.836180874

01:14:56.198 --> 01:14:58.370 lung disease is a concern.
NOTE Confidence: 0.836180874

01:14:58.370 --> 01:15:00.442 But but, but I, I really think
NOTE Confidence: 0.836180874

01:15:00.442 --> 01:15:02.449 we're going to have a lot more.

NOTE Confidence: 0.836180874

01:15:02.450 --> 01:15:04.928 ABC's in the next few years,

NOTE Confidence: 0.836180874

01:15:04.930 --> 01:15:06.526 and they seem to be very

NOTE Confidence: 0.836180874

01:15:06.526 --> 01:15:07.590 effective class of drugs.

NOTE Confidence: 0.885659614444444

01:15:09.090 --> 01:15:12.735 So maybe a question for all three of you.

NOTE Confidence: 0.885659614444444

01:15:12.740 --> 01:15:14.700 You know, I guess, how do you you

NOTE Confidence: 0.885659614444444

01:15:14.700 --> 01:15:16.611 know in your leadership positions and

NOTE Confidence: 0.885659614444444

01:15:16.611 --> 01:15:19.077 when you go to advocate for these

NOTE Confidence: 0.885659614444444

01:15:19.077 --> 01:15:21.225 drug therapy trials to be developed,

NOTE Confidence: 0.885659614444444

01:15:21.230 --> 01:15:24.394 you know how do you convince drug

NOTE Confidence: 0.885659614444444

01:15:24.394 --> 01:15:26.176 companies and pharmaceuticals to

NOTE Confidence: 0.885659614444444

01:15:26.176 --> 01:15:28.633 deescalate when so much of their work

NOTE Confidence: 0.885659614444444

01:15:28.633 --> 01:15:31.437 is based on giving more so that they

NOTE Confidence: 0.885659614444444

01:15:31.437 --> 01:15:34.332 can make more money for themselves and

NOTE Confidence: 0.885659614444444

01:15:34.332 --> 01:15:37.930 their shareholders and that kind of that.

NOTE Confidence: 0.885659614444444

01:15:37.930 --> 01:15:40.927 Challenge that you know that we all we all

NOTE Confidence: 0.885659614444444

01:15:40.927 --> 01:15:43.808 face in in in this in these discussions.
NOTE Confidence: 0.87893873

01:15:47.570 --> 01:15:49.260 No simple answer, I'm sure. I
NOTE Confidence: 0.824169366666667

01:15:49.270 --> 01:15:52.348 think there is such a mark.
NOTE Confidence: 0.824169366666667

01:15:52.350 --> 01:15:53.988 I live in a market because
NOTE Confidence: 0.824169366666667

01:15:53.988 --> 01:15:55.080 these are human lives,
NOTE Confidence: 0.824169366666667

01:15:55.080 --> 01:15:58.496 but there there there is so much need.
NOTE Confidence: 0.824169366666667

01:15:58.500 --> 01:15:59.912 For additional therapeutic that
NOTE Confidence: 0.824169366666667

01:15:59.912 --> 01:16:02.451 sadly there is a market to have
NOTE Confidence: 0.824169366666667

01:16:02.451 --> 01:16:04.226 new drugs that address things.
NOTE Confidence: 0.824169366666667

01:16:04.230 --> 01:16:06.085 But one thing if we were talking
NOTE Confidence: 0.824169366666667

01:16:06.085 --> 01:16:07.782 about the business model of things
NOTE Confidence: 0.824169366666667

01:16:07.782 --> 01:16:09.480 is what happens in breast cancer?
NOTE Confidence: 0.824169366666667

01:16:09.480 --> 01:16:11.532 Is if an agent is shown to be effective
NOTE Confidence: 0.824169366666667

01:16:11.532 --> 01:16:13.536 in the metastatic setting then we move
NOTE Confidence: 0.824169366666667

01:16:13.536 --> 01:16:15.560 it forward to the earlier stages.
NOTE Confidence: 0.824169366666667

01:16:15.560 --> 01:16:17.380 Untested and early state setting.

NOTE Confidence: 0.824169366666667
01:16:17.380 --> 01:16:19.921 So just take the CD 46 inhibitors
NOTE Confidence: 0.824169366666667
01:16:19.921 --> 01:16:22.590 or even even some of these Adcs.
NOTE Confidence: 0.824169366666667
01:16:22.590 --> 01:16:24.438 I think the market will expand
NOTE Confidence: 0.824169366666667
01:16:24.438 --> 01:16:26.801 and they will be tested in these
NOTE Confidence: 0.824169366666667
01:16:26.801 --> 01:16:28.571 earlier stage cancers with the
NOTE Confidence: 0.824169366666667
01:16:28.571 --> 01:16:30.790 goal of improving outcomes so.
NOTE Confidence: 0.824169366666667
01:16:30.790 --> 01:16:32.617 I don't, I think they'll do fine.
NOTE Confidence: 0.824169366666667
01:16:32.620 --> 01:16:33.890 I think they'll be OK.
NOTE Confidence: 0.896390301666667
01:16:34.600 --> 01:16:36.556 And I guess I would add the drug
NOTE Confidence: 0.896390301666667
01:16:36.556 --> 01:16:38.340 looks the best when it has the best
NOTE Confidence: 0.896390301666667
01:16:38.396 --> 01:16:40.279 outcome and the drugs have the best
NOTE Confidence: 0.896390301666667
01:16:40.279 --> 01:16:42.156 outcome when they are used in the
NOTE Confidence: 0.896390301666667
01:16:42.156 --> 01:16:43.426 population for which they there
NOTE Confidence: 0.896390301666667
01:16:43.426 --> 01:16:44.930 is really the benefit for them.
NOTE Confidence: 0.7771661
01:16:46.970 --> 01:16:48.150 And I was going to say,
NOTE Confidence: 0.899846958

01:16:48.150 --> 01:16:50.618 with respect to disparities,
NOTE Confidence: 0.899846958

01:16:50.618 --> 01:16:55.072 that if more people who had chronic
NOTE Confidence: 0.899846958

01:16:55.072 --> 01:16:58.080 conditions from different backgrounds
NOTE Confidence: 0.899846958

01:16:58.080 --> 01:17:01.840 were in the clinical trials,
NOTE Confidence: 0.899846958

01:17:01.840 --> 01:17:04.717 they would better be able to evaluate
NOTE Confidence: 0.899846958

01:17:04.717 --> 01:17:07.060 is more better for everyone.
NOTE Confidence: 0.899846958

01:17:07.060 --> 01:17:10.154 What happens with the diabetic obese patient?
NOTE Confidence: 0.899846958

01:17:10.160 --> 01:17:12.746 Maybe more isn't better for them,
NOTE Confidence: 0.899846958

01:17:12.750 --> 01:17:15.726 and because so many of these
NOTE Confidence: 0.899846958

01:17:15.726 --> 01:17:18.440 patients are excluded from trials.
NOTE Confidence: 0.899846958

01:17:18.440 --> 01:17:20.140 We're able to say more,
NOTE Confidence: 0.899846958

01:17:20.140 --> 01:17:22.940 maybe better for the healthy,
NOTE Confidence: 0.899846958

01:17:22.940 --> 01:17:25.884 wealthy and wise patients,
NOTE Confidence: 0.899846958

01:17:25.884 --> 01:17:30.300 but not necessarily for other patients.
NOTE Confidence: 0.850890446666667

01:17:31.610 --> 01:17:33.150 And maybe that points to the kind
NOTE Confidence: 0.850890446666667

01:17:33.150 --> 01:17:34.810 of the low resource countries,

NOTE Confidence: 0.850890446666667
01:17:34.810 --> 01:17:36.664 because a lot of this has been focused on,
NOTE Confidence: 0.850890446666667
01:17:36.670 --> 01:17:37.513 you know, discussions,
NOTE Confidence: 0.850890446666667
01:17:37.513 --> 01:17:39.199 and what happens here in the
NOTE Confidence: 0.850890446666667
01:17:39.199 --> 01:17:40.510 United States and you know,
NOTE Confidence: 0.850890446666667
01:17:40.510 --> 01:17:42.904 many of the audience you know are
NOTE Confidence: 0.850890446666667
01:17:42.904 --> 01:17:44.896 what may be potentially calling
NOTE Confidence: 0.850890446666667
01:17:44.896 --> 01:17:47.101 in or watching from overseas
NOTE Confidence: 0.850890446666667
01:17:47.101 --> 01:17:49.879 and a low resource settings.
NOTE Confidence: 0.850890446666667
01:17:49.880 --> 01:17:52.071 And you know some of the challenges
NOTE Confidence: 0.850890446666667
01:17:52.071 --> 01:17:53.969 they may face not having the
NOTE Confidence: 0.850890446666667
01:17:53.970 --> 01:17:55.914 access of the same drug therapies
NOTE Confidence: 0.850890446666667
01:17:55.914 --> 01:17:57.938 that we do here in the US.
NOTE Confidence: 0.8874447
01:18:00.720 --> 01:18:03.185 Yeah, so the the World Health
NOTE Confidence: 0.8874447
01:18:03.185 --> 01:18:05.270 Organization has launched a new
NOTE Confidence: 0.825585508571429
01:18:05.351 --> 01:18:07.779 global Breast health initiative,
NOTE Confidence: 0.825585508571429

01:18:07.780 --> 01:18:10.115 and there are actually looking
NOTE Confidence: 0.825585508571429

01:18:10.115 --> 01:18:12.450 for interested members to apply
NOTE Confidence: 0.825585508571429

01:18:12.525 --> 01:18:14.859 to be part of these committees.
NOTE Confidence: 0.825585508571429

01:18:14.860 --> 01:18:17.268 Looking at different pillars
NOTE Confidence: 0.825585508571429

01:18:17.268 --> 01:18:19.676 and that includes diagnostics.
NOTE Confidence: 0.825585508571429

01:18:19.680 --> 01:18:22.472 That's one area where if you can't even
NOTE Confidence: 0.825585508571429

01:18:22.472 --> 01:18:24.620 determine her two results reliably,
NOTE Confidence: 0.825585508571429

01:18:24.620 --> 01:18:26.306 you know how can you even
NOTE Confidence: 0.825585508571429

01:18:26.306 --> 01:18:27.430 determined a good therapies.
NOTE Confidence: 0.825585508571429

01:18:27.430 --> 01:18:28.876 So there's a. There's a pillar.
NOTE Confidence: 0.825585508571429

01:18:28.880 --> 01:18:30.284 Focus on Diagnostics,
NOTE Confidence: 0.825585508571429

01:18:30.284 --> 01:18:32.156 an access to therapeutic.
NOTE Confidence: 0.825585508571429

01:18:32.160 --> 01:18:33.990 Supportive care and symptom management.
NOTE Confidence: 0.825585508571429

01:18:33.990 --> 01:18:37.203 So I think there are some exciting
NOTE Confidence: 0.825585508571429

01:18:37.203 --> 01:18:39.033 developments in diagnostics so
NOTE Confidence: 0.825585508571429

01:18:39.033 --> 01:18:42.049 that we can at least have a better

NOTE Confidence: 0.825585508571429

01:18:42.049 --> 01:18:44.357 understanding of the subtype of breast

NOTE Confidence: 0.825585508571429

01:18:44.357 --> 01:18:46.790 cancer and then further working with

NOTE Confidence: 0.825585508571429

01:18:46.790 --> 01:18:48.990 pharma companies to form collaboration.

NOTE Confidence: 0.825585508571429

01:18:48.990 --> 01:18:51.748 So so for those who are interested

NOTE Confidence: 0.825585508571429

01:18:51.750 --> 01:18:53.810 WHO is now accepting applications

NOTE Confidence: 0.825585508571429

01:18:53.810 --> 01:18:55.046 to these committees,

NOTE Confidence: 0.825585508571429

01:18:55.050 --> 01:18:57.270 and if you need if you want to be in touch,

NOTE Confidence: 0.825585508571429

01:18:57.270 --> 01:18:59.167 I'm happy to put you in touch.

NOTE Confidence: 0.839474755454545

01:19:00.060 --> 01:19:03.486 I'm also encouraged at Yale seeing

NOTE Confidence: 0.839474755454545

01:19:03.486 --> 01:19:06.340 younger physicians who are very,

NOTE Confidence: 0.839474755454545

01:19:06.340 --> 01:19:09.570 very interested in lower resource

NOTE Confidence: 0.839474755454545

01:19:09.570 --> 01:19:13.654 nations an in devoting their academic

NOTE Confidence: 0.839474755454545

01:19:13.654 --> 01:19:17.389 careers to finding some solutions.

NOTE Confidence: 0.750877056

01:19:20.420 --> 01:19:23.340 Excellent and any parting words.

NOTE Confidence: 0.750877056

01:19:23.340 --> 01:19:25.620 Merriam, Andrea, Michael.

NOTE Confidence: 0.91841394

01:19:28.390 --> 01:19:30.735 I just wanted to thank Doctor
NOTE Confidence: 0.91841394

01:19:30.735 --> 01:19:32.880 Gauchan for organizing the series
NOTE Confidence: 0.801163685625

01:19:32.950 --> 01:19:35.056 of best breast care is really,
NOTE Confidence: 0.801163685625

01:19:35.060 --> 01:19:39.608 truly multidisciplinary and I think Next
NOTE Confidence: 0.801163685625

01:19:39.608 --> 01:19:41.780 up will be radiation oncology, correct?
NOTE Confidence: 0.865352983684211

01:19:43.100 --> 01:19:44.820 And I'll say that you asked about the
NOTE Confidence: 0.865352983684211

01:19:44.820 --> 01:19:46.052 difficulty of getting patients on
NOTE Confidence: 0.865352983684211

01:19:46.052 --> 01:19:47.570 some of our other clinical trials,
NOTE Confidence: 0.865352983684211

01:19:47.570 --> 01:19:48.830 and I'll say clinical trials
NOTE Confidence: 0.865352983684211

01:19:48.830 --> 01:19:50.090 is also the best care.
NOTE Confidence: 0.93961334

01:19:51.540 --> 01:19:52.530 Absolutely.
NOTE Confidence: 0.905919320333333

01:19:53.660 --> 01:19:55.884 And I was just going to conclude by
NOTE Confidence: 0.905919320333333

01:19:55.884 --> 01:19:58.572 saying I'm lucky to be able to work with
NOTE Confidence: 0.905919320333333

01:19:58.572 --> 01:20:00.581 the colleagues that I can because we
NOTE Confidence: 0.905919320333333

01:20:00.581 --> 01:20:02.540 really do have a breadth of experience.
NOTE Confidence: 0.905919320333333

01:20:02.540 --> 01:20:05.780 And thank you very much for having me here.

NOTE Confidence: 0.865230198461538

01:20:06.530 --> 01:20:08.539 Thank you everyone and would like to

NOTE Confidence: 0.865230198461538

01:20:08.539 --> 01:20:10.730 thank all the participants you know,

NOTE Confidence: 0.865230198461538

01:20:10.730 --> 01:20:12.305 calling either from the office

NOTE Confidence: 0.865230198461538

01:20:12.305 --> 01:20:13.880 next door or from overseas.

NOTE Confidence: 0.865230198461538

01:20:13.880 --> 01:20:15.769 This is a lot of fun. Thanks so much.